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Human cytomegalovirus (CMV) was first isolated in cell culture in 1950 from the salivary 
gland and kidney of two infants who had died with enlarged or cytomegalic inclusion-
bearing cells.1 About 70 years before the identification of the causative agent, these 
cellular changes with a typical owl’s eye appearance observed in affected newborns 
had led to use of the term cytomegalic inclusion disease (CID)2. After initially being 
called “salivary gland virus”, the term “cytomegalovirus” was proposed by Weller et 
al in 1962.3
Cmv
Human CMV or human herpesvirus (HHV) 5 is a member of the family Herpesviridae, 
which also includes the human viruses herpes simplex virus 1 and 2, varicella-zoster 
virus, Epstein-Barr virus, and HHV 6, 7 and 8. CMV has been sub-classified as a 
betaherpesvirus, originally based on its growth characteristics in vitro, but nowadays 
based on genetic sequence homologies.4 Other beta-herpesviruses include HHV 6 
and 7, the agents associated with the childhood disease exanthema subitum (sudden 
rash) or roseola infantum (rose rash of infants). CMV is amongst the largest human 
viral pathogens, measuring about 200 nm in diameter. The CMV virion consists of 
a capsid containing a large linear double stranded DNA genome encoding more 
than 200 potential proteins, enclosed by a protein tegument and a lipid envelope.5 
The tegument contains key regulatory proteins, among which the immunomodulatory 
protein pp65 (UL83).4 This pp65 is the most abundant virion protein, accounting 
for about 15% of the total virion protein4, and is the antigen that is detected in 
the diagnostic antigenemia assay. The capsid exhibits icosahedral symmetry of 
triangulation number (T) 16, with 162 capsomere subunits.6 The envelope contains 
several glycoproteins with the most abundant ones being the gM (UL100)/gN (UL73) 
complex, gB (UL55), and the gH (UL75)/gL (UL115) /gO (UL74) complex.7 The 
envelope renders the virus susceptible to lipid solvents, low pH, heat, and ultraviolet 
light. Unlike herpes simplex and varicella-zoster viruses, CMV exhibits an exceptionally 
broad cellular tropism, rendering CMV capable of infecting most cell types including 
dendritic, endothelial, epithelial, fibroblast, and monocytes/ macrophages.5 A large 
number of cellular receptors for CMV have been proposed, mainly interacting 
with the CMV envelope glycoproteins gB, gH and gM.5 The association of specific 
CMV glycoprotein genotypes with severity of disease has been addressed, with 




and CMV of other species, restricting cell entry to human host cells and rendering 
humans the only reservoir. Primary infection results in lifelong latency with intermittent 
reactivation and excretion, applying the dictum ‘once infected, always infected’. Viral 
latency is established within myeloid cells including myeloid progenitors, monocytes, 
macrophages, and dendritic cells. About 1 per 10,000 peripheral blood mononuclear 
cells of healthy seropositive individuals harbor several copies of the CMV genome12, 
which is present in an episomal form.13 
transmission of Cmv
Transmission of CMV occurs by acquisition of cell free virus at mucosal sites, by 
close contact with a person shedding the virus in body fluids including urine, saliva, 
breast milk, cervical and vaginal secretions, and semen.7 Particularly urine and saliva 
of young children may contain high virus titers and are therefore major sources of 
CMV.7 No studies have supported transmission of CMV through respiratory droplets. 
Blood-borne transmission through blood products and organ allografts can occur, 
and transplacental transmission results in congenital infection (discussed below).7 
Perinatal transmission of CMV in the birth canal and during breast-feeding is common. 
Up to 96% of CMV seropositive mothers shed CMV (DNA) in mature cell free breast 
milk at some time during lactation, with a peak excretion between 2 weeks and 2 
months postpartum.7,14 About 40% of the preterm newborns breastfed for at least 1 
month by CMV seropositive mothers become infected postnatally.7,14,15
epidemiology of Cmv infection
CMV circulates worldwide and is endemic in the whole human population, without 
seasonal variation. The seroprevalence of CMV increases with age and varies 
widely depending on ethnic and socioeconomic background. CMV seroprevalence 
is high in developing countries, up to 95-100% among preschool children in sub-
Saharan Africa, South America, and Asia.7 In contrast, CMV seroprevalence of 
less than 20% has been found in subpopulations in the United Kingdom and the 
United States.7 In women of childbearing age, CMV seroprevalence is above 90% in 
developing countries, and 40-85% in the United States and Western Europe.7,16 In the 
Netherlands, maternal CMV seroprevalence ranges between 41-73% among various 
subgroups.17,18 High CMV seroprevalence among populations of low socioeconomic 
status reflects increased exposure to CMV due to factors including large household 
size, crowding, certain child care practices, and possibly sexual practices.7 Day-
care centers facilitate transmission of CMV. About half of the infants attending day 
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care centers with middle- to upper-income background shed CMV in their urine and 
saliva.19 
The reproductive number (R0) of CMV has been estimated using mathematical 
models based on age-specific seroprevalence data.20,21 This R0 is relatively modest, 
being 1.7-2.4 in Western populations, indicating that an infected person transmits 
CMV to approximately two susceptible people.20,21 The R0 is somewhat higher in 
subpopulations of low socioeconomic status, up to 4.1 in non-Hispanic blacks in 
the Unites States.20,21 Corresponding with this R0, the force of infection is relatively 
low and has been calculated as an average annual seroconversion rate of 1.6-2.3% 
among pregnant women in the United States and the United Kingdom, and 5-20% in 


















Figure 1 Meta-analysis of studies reporting annual CMV IgG seroconversion rates among 
 pregnant women, as a function of CMV seroprevalence in the underlying population. (Adapted 
 from Hyde et al.22)  
 
 
Clinical manifestations in adults 
Primary CMV infection in the immunocompetent child or adult has been described as being usually 
asymptomatic4, however there are no data on the exact proportion of symptomatic primary infections. 
Uncommonly, primary infection in the immunocompetent host results in a mononucleosis syndrome 
clinically similar to the syndrome associated with Epstein-Barr virus infection.6,24 CMV mononucleosis may 
account for 8-20% of cases with mononucleosis syndrome presentations.6,24 Infrequent complications of 
CMV mononucleosis include pneumonia, hepatitis, central nervous system involvement (Guillain-Barré 
syndrome), aseptic meningitis, encephalitis, pericarditis, and myocarditis.4,6 Most postnatally infected 
newborns do not develop symptoms4,25, although occasional cases of severe disease including 
pneumonitis, hepatosplenomegaly, lymphadenopathy, and aseptic meningitis within the first 3 months of 
life have been reported.4,25 Low birth weight (<1500 g) has been described as a risk factor for symptomatic 
postnatal infection.4,25 No association of postnatal CMV infection with hearing loss or neurological 
developmental impairment has been found, though data on the long-term follow-up of postnatally 
infected (premature) infants are limited.25 In immunocompromised patients, CMV can cause significant 

























figure 1  Meta-analysis of studies reporting annual CMV IgG seroconversion rates among 
pregnant w men, as a function of CMV seroprevalence in the und rlying population. 
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Clinical manifestations in adults
Primary CMV infection in the immunocompetent child or adult has been described 
as being usually asymptomatic4, however there are no data on the exact proportion 
of symptomatic primary infections. Uncommonly, primary infection in the 
immunocompetent host results in a mononucleosis syndrome clinically similar to 
the syndrom  associated with Epstein-Barr virus infection.6,24 CMV mononucleosis 




Infrequent complications of CMV mononucleosis include pneumonia, hepatitis, 
central nervous system involvement (Guillain-Barré syndrome), aseptic meningitis, 
encephalitis, pericarditis, and myocarditis.4,6 Most postnatally infected newborns do 
not develop symptoms4,25, although occasional cases of severe disease including 
pneumonitis, hepatosplenomegaly, lymphadenopathy, and aseptic meningitis within 
the first 3 months of life have been reported.4,25 Low birth weight (<1500 g) has been 
described as a risk factor for symptomatic postnatal infection.4,25 No association of 
postnatal CMV infection with hearing loss or neurological developmental impairment 
has been found, though data on the long-term follow-up of postnatally infected 
(premature) infants are limited.25 In immunocompromised patients, CMV can 
cause significant morbidity and mortality due to CMV colitis, hepatitis, encephalitis, 
pneumonitis and retinitis. 
epidemiology of congenital Cmv infection
Intrauterine infection with CMV is thought to result from maternal viremia and 
associated placental infection.4,7 In a meta-analysis, intrauterine transmission was 
estimated to occur in approximately 32% (95%CI 30-35%, range 14-52%) of the 
pregnant women with primary infection.16 The maternal-to-fetal transmission risk after 
primary infection increases with gestational age and has recently been reported to be 
up to 64-73% in the third trimester.26,27,28 In contrast, the highest risk of fetal damage 
(including hearing loss) exists around conception and in the first two trimesters 
of pregnancy.28,29,30,31 In contrast to congenital rubella and toxoplasmosis, where 
intrauterine transmission occurs principally as a result of primary maternal infection, 
intrauterine transmission of CMV can occur as a consequence of non-primary or 
recurrent infection, i.e. reactivation of latent virus or re-infection with a new strain. In a 
meta-analysis of data on the birth prevalence of congenital CMV among the offspring 
of seropositive women, the pooled risk of maternal-to-fetal transmission following 





Epidemiology of congenital CMV infection 
Intrauterine infection with CMV is thought to result from maternal viremia and associated placental 
infection.4,7 In a meta-analysis, intrauterine transmission was estimated to occur in approximately 32%  
(95%CI 30-35%, range 14-52%) of the pregnant women with primary infection.16 The maternal-to-fetal 
transmission risk after primary infection increases with gestational age and has recently been reported to 
be up to 64-73% in the third trimester.26,27,28 In contrast, the highest risk of fetal damage (including 
hearing loss) exists around conception and in the first two trimesters of pregnancy.28,29,30,31 In contrast to 
congenital rubella and toxoplasmosis, where intrauterine transmission occurs principally as a result of 
primary maternal infection, intrauterine transmission of CMV can occur as a consequence of non-primary 
or recurrent infection, i.e. reactivation of latent virus or re-infection with a new strain. In a meta-analysis 
of data on the birth prevalence of congenital CMV among the offspring of seropositive women, the 
pooled risk of maternal-to-fetal transmission following recurrent infection was 1.4% (95%CI 1.1-1.7%) 



















Figure 2 Meta-analysis of studies reporting the prevalence of CMV at birth (congenital infection) among 
 the offspring of CMV seropositive pregnant women, described as the maternal-to-fetal 
 transmission risk following recurrent maternal infection. Lines represent 95%CI. (Adapted from 
 Kenneson et al.16) 
 
 

















figure 2  Meta-analysis of studies reporting the prevalence of CMV at birth (congenital 
infection) among the offspring of CMV seropositive pregnant women, described as 
the maternal-to-fetal transmission risk following recurr nt maternal infection. Lines 
represent 95%CI. (Adapted from Kenneson et al.16)
In the same meta-analysis, the combined birth prevalence of congenital CMV reported 
by 27 worldwide study groups was 0.64% (95%CI 0.60-0.69%), with considerable 
variability among different populations.16 Data on the birth prevalence of congenital 
CMV in the Netherlands are limited (until publication of the work presented in this 
thesis) to a single study reporting a birth prevalence of 0.09% in a selected sample 
of newborns with a low proportion of immigrants.17 In general, the birth prevalence 
of congenital CMV increases with maternal CMV seroprevalence in the population, 
with a birth prevalence estimate of about 2% or higher in populations with >95% 
seroprevalence (Figure 3).16 Recently, a prospective, serological study has shown 
that re-infection with new strains occurred in about 8% of seroimmune pregnancies 
among a population with nearly 100% CMV seroprevalence (Brazil).41 Risk factors for 
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figure 3  Birth prevalence of congenital CMV is positively correlated with maternal CMV 
seroprevalence in the population. Each circle represents the birth prevalence 
estimate from one study group. In lineair regression analysis, every 10% increase 
in seroprevalence corresponded to a 0.26% increase in birth prevalence. The 
coefficient of determination (R2) was 0.29 16,42, and 0.55 in an earlier report16,42, 
indicating that maternal seroprevalence accounted for respectively 29% 16 and 55% 
43 of the variability of birth prevalence of CMV between study populations. (Adapted 
from Kenneson et al.16)
table 1  Factors reported to be significantly associated with congenital CMV infection. 
risk factor reference
High maternal seroprevalence in the population 16
Non-white race 16
Low socioeconomic status 16
Caring for preschool children 43
Household size >3 people 43
Maternal age <25 years 43
Onset of sexual activity <2 years before delivery 43
STD during pregnancy 43
STD; sexually transmitted disease
Clinical manifestations of congenital Cmv
Approximately 10% of the infants born with congenital CMV infection are 
symptomatic at birth.16,44 Half of these symptomatic infants present with typical and 
potentially fatal generalized cytomegalic inclusion disease (CID), characterized by 
hepatosplenomegaly, microcephaly, jaundice, and petechiae, with or without ocular 
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and auditory damage.3,7,45 In total 40-58% of these infants symptomatic at birth 
will have permanent sequelae.44 Because early studies focussed on symptomatic 
infections, congenital CMV was considered a rare and often fatal disease.7 Nowadays, 
we realize that 10-15% of the infants born with asymptomatic congenital infection 
develop neurologic complications throughout the first years of life and will have long-
term sequelae.44 Isolated sensorineural hearing loss (SNHL) is the most common 
long-term complication of congenital CMV.46 Because of the late-onset nature of the 
hearing loss (Figure 4), up to half of the children with congenital CMV-related hearing 
loss may not be detected in the newborn hearing screening.47 Among children with 
hearing loss at later ages, the hearing loss is associated with congenital CMV in 15-
40% of the cases.48,49,50 Other neurologic complications in newborns with congenital 




















Figure 4 Cumulative hearing loss (>20 dB) in children with congenital CMV infection according to 




Table 2 Frequency of neurologic complications in newborns with congenital CMV infection, according to 
 symptomatic and asymptomatic status at birth. (Adapted from Remington and Klein.7)  
 





Hearing loss 58% 7% 
IQ <70 55% 4% 
Chorioretinitis 20% 3% 
Seizures 23% 1% 
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figur  4  Cumulative hearing loss (>20 dB) i  children with conge ital CMV infection 





table 2  Frequency of neurologic complications in newborns with congenital CMV infection, 
according to symptomatic and asymptomatic status at birth. (Adapted from 





Hearing loss 58% 7%





Clinical symptoms are more frequently seen in newborns from preconceptionally 
seronegative women45 (Table 3), indicating that maternal antibodies provide 
substantial protection against harmful infection in the newborn.
table 3  Neurologic sequelae in children with congenital CMV infection after primary and 
non-primary maternal infection. (Adapted from Fowler et al.45)
Primary infection non-primary infection
Any sequelae 25% 8%
Sensorineural hearing loss 15% 5%




Paresis or paralysis 1% 0%
Death 2% 0%
Postnatal diagnosis of congenital Cmv
The gold standard in the diagnosis of congenital CMV is viral culture of urine, sampled 
within the first 2-3 weeks of life.51,52,53 After this period, congenital CMV infection cannot 
be differentiated from the generally harmless postnatally acquired CMV infection.53 
CMV DNA detection (PCR) in urine, saliva, and blood is mentioned in recent literature 
and described in guidelines as acceptable alternative for diagnosing congenital CMV. 
54,55,56 Furthermore, CMV DNA detection in dried blood stored on filter paper (dried 
blood spots, DBS; Guthrie cards) has become of interest and has the advantage 
that congenital CMV can be diagnosed retrospectively, e.g. when late-onset hearing 
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loss becomes manifest.57,58,59,60,61,62,63 Serological testing for CMV IgM in the newborn 
lacks adequate sensitivity (range 20%16,64,65-70%66) and specificity (about 95% 66) for 
the diagnosis of congenital infection. Sensitivity of IgM serology in the congenitally 
infected newborn is hampered by the time-frame between fetal infection and birth, 
and the immature immune system at the time of infection. CMV IgM antibodies can be 
detected in only about 25% of the DBS of newborns with congenital CMV.67
 
Postnatal antiviral therapy
Antiviral treatment of congenitally CMV infected newborns with clinically apparent 
disease is generally accepted54,68,69,70. Few studies have addressed the efficacy 
of antiviral treatment on hearing preservation in newborns with symptomatic 
and asymptomatic congenital CMV infection (Table 4). Results from 1 RCT show 
that congenitally infected newborns with central nervous system (CNS) disease 
benefit from ganciclovir with preserved hearing71 and recent guidelines include 
the recommendation of antiviral treatment in this specific group of newborns.54,56 
In addition to preserved hearing, improvement of neuro-developmental status 
after treatment of newborns with CNS disease has been found.72 Treatment of 
asymptomatic congenitally CMV infected newborns is currently not recommended 


















































































































































































   
   







   
   








   
   
   





















































































































   
   







   
   
















































































































   
   









   
   




















































































































   
   








   
   








   
   
   
   




















































































































































































































































































































































Preventive programs for CMV infection have been developed by the United States 
Centers for Disease Control and Prevention (CDC), and the American College of 
Obstetricians and Gynecologists (Figure 5). Because exposure to saliva and urine of 
young children is a major cause of CMV infection among pregnant women76, it is likely 
that good personal hygiene can reduce the risk of CMV acquisition. Evidence for the 
efficacy of hygiene counseling is limited to studies showing a reduced rate of CMV 
seroconversion of pregnant woman after hygiene counseling.76,77,78  
ways a pregnant woman may help
reduce her exposure to Cmv
• Washing hands frequently with soap and 
water, especially after changing diapers, 
feeding a child, wiping a child’s nose or 
drool, or handling children’s toys.
• Not sharing cups, plates, utensils, food, or 
toothbrushes.
• Not sharing towels or washclothes.
• Not putting a child’s pacifier in her mouth.
• Cleaning toys, countertops, and anything 
else that comes in contact with children’s 
urine or saliva.
figure 5  Hygienic measures recommended by the CDC to pregnant women to reduce the 




newborn screening for congenital Cmv
General criteria for screening have been proposed by Wilson and Jungner (Table 
5).79 In the Netherlands, newborns are routinely screened for 18 metabolic and 
inherited disorders, including PCR-based screening on cystic fibrosis using DBS 
(since May 2011). Newborn screening for congenital CMV has only recently been 
seriously considered, despite earlier appeals for preventive measures for congenital 
CMV infection.80,81 The potential for newborn screening for CMV would lie in the 
identification of the large proportion of asymptomatic congenitally infected newborns 
at risk for developing late-onset hearing loss. These newborns at risk could benefit 
from intervention measures such as extensive audiological follow-up and potentially, 
antiviral therapy. 
table 5  Criteria for screening as proposed by Wilson and Jungner.79
the disease The condition should be an important health problem
The natural history should be well understood
There should be a detectable early stage
the screening test The test should be suitable for the early stage
The test should be acceptable to patient and staff
Intervals for repeating the test should be determined
the treatment Early treatment should be of more benefit than at a later stage
Adequate health service provision should be made
The risks should be less than the benefits
The costs should be balanced against the benefits
Chapter 1
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outline of the thesis
The aim of this thesis is to study several aspects of congenital CMV infection in 
general and more specifically in the Netherlands, in order to determine the necessity 
and feasibility of newborn screening for congenital CMV. The major topics addressed 
in this thesis are the following. 
Part i
The disease burden of congenital CMV infection in the netherlands. 
This topic is addressed in several ways. Firstly, the birth prevalence of congenital 
CMV in the Netherlands was determined in a cross-sectional study. A large sample 
of DBS from infants born in the Netherlands was retrospectively tested for CMV 
DNA (Chapter 2). To address the clinical impact of congenital CMV disease in the 
Netherlands, the proportion of congenital CMV infections among Dutch children with 
permanent bilateral hearing loss was determined (Chapter 3). Additionally, to address 
subpopulations at risk for congenital CMV infection, risk factors for congenital CMV in 
the Dutch population were analyzed (Chapter 2). Furthermore, maternal immunity to 
CMV as risk factor for congenital infection was assessed by means of a population-
based prediction model (Chapter 4). Finally, awareness of the disease burden of 
congenital CMV among doctors in the Netherlands was studied using a digital 
questionnaire sent to doctors involved in mother and childcare. (Chapter 5).
Part ii
Postnatal sCreening Tools for congenital CMV were studied by evaluating 
a large number of DNA extraction methods for dried blood spots (DBS) (Chapter 
6 and 7), and by evaluating real-time PCR on urine in the diagnosis of congenital 
CMV (Chapter 9). Following CMV DNA detection in DBS, the potential to use DBS for 
genotyping of CMV was assessed (Chapter 8).  
 
Part iii
Pros and cons of newborn sCreening for congenital CMV are summarized 
and discussed in detail in Chapters 10, 11 and 12. Rationale for potential benefits 
and disadvantages of newborn screening on congenital CMV are addressed, using 
the criteria of Wilson and Jungner to summarize the disease burden, the currently 
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Congenital cytomegalovirus (CMV) infection is the most common congenital viral 
infection worldwide. The sequela encountered most frequently is hearing impairment, 
affecting approximately one out of five infants congenitally infected. Data on the 
birth prevalence and risk factors of congenital CMV infection in the Netherlands are 
scarce. The aim of this study was to determine the birth prevalence of congenital 
CMV in the Netherlands. A sample of 6,500 dried blood spots (DBS) from infants born 
in the Netherlands was tested anonymously for CMV DNA. The sample was stratified 
by the number of live births in different regions of the Netherlands of the year 2007. 
Additionally, on a regional level, risk factors for congenital CMV were analyzed. The 
birth prevalence of congenital CMV in the Netherlands was 0.54% (35/6,433, 95%CI 
0.36–0.72). Congenital CMV infection was significantly higher in regions with more 
than 15% young children (0–5 years) compared with regions with a lower proportion of 
young children (OR 5.9, 95%CI 1.4–25.2). Congenital CMV infection was significantly 
higher in regions with more than 30% immigrants compared with regions with a lower 
proportion of immigrants (OR 2.2, 95%CI 1.1–4.6). This association was strongest for 
regions with more than 30% non-Western immigrants (OR 3.3, 95%CI 1.5–7.5). Based 
on the knowledge of the natural history of congenital CMV infection, approximately 
1,000 children are born with congenital CMV infection in the Netherlands annually, of 
whom eventually approximately 180 children (0.1% of all newborns) will be affected 
by long term sequelae, with hearing loss being the symptom encountered most 
frequently. 




Cytomegalovirus (CMV) infection is the most common congenital viral infection 
worldwide. The symptom of congenital CMV infection encountered most frequently is 
sensorineural hearing loss, which will affect approximately one out of five congenitally 
infected newborns.1,2 About 10% of the live-born infants with congenital CMV infection 
are symptomatic at birth1,2, whereas an additional 10% of the infected newborns will 
develop permanent sequelae in the following years.1-3 Among children with bilateral 
profound sensorineural hearing loss, the hearing disability is attributable to congenital 
CMV infection in one out of five patients.4-6 This makes CMV the leading cause of non-
genetic congenital hearing impairment. 
The overall birth prevalence of congenital CMV was estimated at 0.64%2, with 
significant variety among different countries and populations. The birth prevalence 
has been shown to be correlated positively with maternal CMV seroprevalence in the 
population.2 Established risk factors for congenital CMV infection include preschool 
children in the household, household size more than three people, non-white race, 
low socioeconomic status, preconception maternal seronegative status, and maternal 
age below 25 years.2,7-9 
Data on the birth prevalence and risk factors for congenital CMV infection in the 
Netherlands are scarce. Only one study has been published on the birth prevalence 
of congenital CMV in the Netherlands, estimating a prevalence of congenital CMV of 
0.09%.10 This estimate is low when compared to the birth prevalence estimates from 
other northern European countries, ranging from 0.18 to 2.0%.11-16 Furthermore, it is 
not in accordance with the maternal seroprevalence of CMV in the Netherlands of 
41–73%.20,37 Maternal seroprevalence rates of CMV of 50–70% in other countries have 
been associated with birth prevalence rates of approximately 0.3–0.6%.2 
The aim of this study was to determine the birth prevalence of congenital CMV in 
the Netherlands, in order to estimate the disease burden. A large, random sample 
of dried blood spots (DBS) was selected from all infants born in the Netherlands in 
2007 and analyzed for the presence of CMV DNA. Additionally, the contribution of risk 
factors for congenital CMV infection was analyzed on a regional level by comparing 
the birth prevalence of congenital CMV with the demographic characteristics and 
socioeconomic status parameters of the regions. 
Chapter 2
30
materials and methods 
study design 
Of all live newborns in the Netherlands in 2007 (n = 182,765), 99.8% participated in the 
nationwide metabolic and endocrine screening program for which DBS are collected 
routinely within a few days after birth17 and stored at the National Institute for Public 
Health and the Environment (RIVM, Bilthoven, the Netherlands) (room temperature). 
Of those DBS, a total of 6,500 DBS were selected for this study, stratified for the 
number of live births per region and the month of birth. Fourteen different regions 
were identified (12 provinces + Amsterdam + Rotterdam). Testing of the DBS was 
performed anonymously, thus no information was available on the clinical outcome 
of these children. The study was approved by the Program Committee Neonatal 
Screening (RIVM, the Netherlands), and the Medical Ethics Committee (CME) of the 
Leiden University Medical Center (LUMC, the Netherlands). 
Cmv dna detection in dbs 
DNA extraction
DNA was extracted from DBS using the protocol described by Barbi et al.36 (details 
obtained by personal communication), as evaluated previously.18 In short, one punch 
of 3.2 mm per tube (approximately 3 μl dried blood), in triplicate, was incubated 
overnight in 35 μl Minimum Essential Medium (Gibco/Life Technologies, Breda, The 
Netherlands), with a fixed aliquot of phocine herpes virus (PhHV, kindly provided 
by Bert Niesters, University Medical Center Groningen, the Netherlands) to monitor 
nucleic acid isolation and PCR inhibition. Incubation was followed by heating for 60 
min at 55°C, and for 7 min at 100°C. After cooling, the sample was centrifuged and 
the supernatant was frozen. After thawing, the DNA extract was used for CMV DNA 
amplification. 
CMV DNA amplification
CMV DNA amplification was performed by means of an internally controlled quantitative 
real-time PCR as described previously [Kalpoe et al.40], with minor modifications.18 
Briefly, 10 μl of DNA extract was added to 40 μl PCR pre-mixture containing CMV 
and PhHV primers, CMV and PhHV TaqMan probes, MgCl2, and HotStar Master mix 
(QIAGEN, Hilden, Germany), followed by amplification of a 126-bp DNA fragment 
of the CMV immediate-early antigen region. Quantification was performed using a 
dilution series of titrated CMV (Advanced Biotechnologies Inc., Columbia MD, USA) 
as an external standard. 
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Interpretation of triplicate PCR results
Interpretation of triplicate PCR results was performed using the flow diagram as 
proposed by Barbi et al.22, in which every positive result was confirmed with at least 
one other positive result. In cases where in the initial test procedure a single positive 
result was found, a confirmatory PCR procedure including DNA extraction was 
performed. 
demographic and socioeconomic status characteristics
For analysis of the contribution of risk factors for congenital CMV infection, the 
postal code numbers (four-digit) of the DBS tested for CMV DNA were retrieved. 
Demographic and socioeconomic status parameters of the postal code areas of the 
DBS tested (for the year 2007) were retrieved from Statistics Netherlands (Centraal 
Bureau voor de Statistiek (CBS), www.CBS.nl/en). Characteristics of the postal 
code areas of the CMV-positive DBS were compared to the characteristics of the 
postal code areas of the CMV-negative DBS (analogue to a comparison of the birth 
prevalence of congenital CMV between regions with and without these characteristics). 
Demographic characteristics analyzed were (non-Western) immigrants, young 
children (0–5 years) in the population, and household size. Socioeconomic status 
characteristics analyzed were income and educational level. 
sample size and statistical analysis
The sample size calculation was based on an estimated birth prevalence of 0.4%, 
a significance level of 5%, and 80% power. For risk factor analysis, sub-population 
numbers were expressed as proportions of the total populations in that area (e.g., 
the number of non-Western immigrants was divided by the total number inhabitants 
in that area), and categorized. Category cut-offs were based on the distribution of 
the characteristics in the community, while maintaining sufficient numbers in the 
contingency table in order to achieve reasonable power. Differences in categorical 
data were compared with the Chi-square test and the Fisher’s exact test (for expected 
frequencies below 5), and odds ratios (ORs) with 95% confidence intervals (CIs) were 
calculated. Data were analyzed using SPSS version 17.0 (SPSS Inc., Chicago, IL) 




birth prevalence of congenital Cmv in the netherlands
Out of 6,500 selected DBS, 6,433 DBS were available for CMV detection. The 67 DBS 
were not available for testing since parents had not given permission for storage of 
the DBS at the time of metabolic and endocrine screening. Out of the 6,433 DBS 
tested, 35 DBS were positive for CMV DNA. This corresponds with a birth prevalence 
of congenital CMV in the Netherlands of 0.54% (95%CI 0.36–0.72%). The median 
CMV DNA load was 3.7 log10 (5,012) copies/ml whole blood, with a median cycle 
threshold of 40 (range 37–44). Fifteen, 7, and 13 of the 35 confirmed CMV positive 
DBS were initially positive in respectively one, two, and three of the triplicates. 
risk factors for congenital Cmv 
Postal code numbers were retrievable for 6,022 of the 6,433 DBS, resulting in 
2,180 different postal code areas. On average, a postal code area contained 8,261 
inhabitants (range 30–27,030). Demographic characteristics of the postal code 
areas of the 6,022 DBS were retrieved, and data on households/immigrants, income, 
and education were available for the 5,930, 5,424, and 4,589 DBS, respectively. 
Demographic characteristics and socioeconomic status parameters of the postal 
code areas and the prevalence of congenital CMV in those areas are shown in Table 1. 
Two out of 32 CMV positive DBS were from regions with a population with more 
than 15% young children (0–5 years), whereas 66 out of 5,898 CMV negative DBS 
were from regions with a population with more than 15% young children. This is 
analogous to a birth prevalence of 2/68 (2.94%) in regions with more than 15% young 
children, whereas the birth prevalence was 5.9 times less prevalent in regions with a 
lower proportion of young children (30/5,862 (0.51%), OR 5.89, 95%CI 1.38–25.16). 
Furthermore, congenital CMV was significantly more prevalent in regions with more 
than 30% immigrants compared to regions with a lower proportion of immigrants (OR 
2.20, 95%CI 1.06–4.57). This association was strongest in regions with more than 
30% non-Western immigrants (OR 3.33, 95% CI 1.49–7.46), but remained significant 
when the category cut-off was lowered to more than 20% non-Western immigrants. 
When analyzed in a multivariate logistic regression model, the variables more than 
15% young children in the population (OR 4.46, P = 0.048) and more than 30% 
non-Western immigrants (OR 3.08, P = 0.007) remained significantly associated 
with congenital CMV infection. No significant association was found between the 
prevalence of congenital CMV and a mean household size of more than 3.0 persons. 
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Additionally, congenital CMV infection was not found to be significantly associated 
with regions with a high proportion of households with lower income, a low proportion 





































































   
   
   
   
   
   
   
   
   
















   
   
   
   
   
   
   
   
   
































































































































































































































































































































































































































































































































This study shows that the birth prevalence of congenital CMV in the Netherlands 
is approximately 0.54%. It is the first report on the birth prevalence of congenital 
CMV testing a large selection of DBS covering all regions of the Netherlands. Given 
the large sample size and the stratification by the number of births in the different 
regions, the birth prevalence determined is expected to be valid and representative 
for the Netherlands as a whole. The birth prevalence found in this study corresponds 
with the birth prevalence of congenital CMV reported in other northern-European 
countries (0.18–2.0%)11-16, where significant differences are found among different 
(sub)populations. Furthermore, the birth prevalence calculated in this study is in line 
with the maternal seroprevalence of CMV in the Netherlands of 41–73%10,19, which 
has been shown to be correlated positively with the birth prevalence of congenital 
CMV in a population.2 Previously, Gaytant et al.10 described a birth prevalence of 
0.09% in the Netherlands. The major drawback of that prospective study was that 
the newborns studied were born in the south-eastern part of the Netherlands with 
a probable under-representation of newborns from non-native parents. They found 
that the seroprevalence of CMV was significantly lower in this area than in the 
metropolitan area of Amsterdam and Rotterdam. Also, though several studies have 
shown reasonable sensitivities of 87–100%20,21 of saliva sampling, the diagnostic 
approach used by Gaytant et al., consisting of cord blood serology followed by throat 
swab PCR and subsequently urine culture, may not have been optimal technically. 
Thus, the birth prevalence number reported by Gaytant et al.10 is not likely to be 
representative of the birth prevalence of congenital CMV in the Netherlands. 
It is likely that the actual birth prevalence of congenital CMV in the Netherlands is even 
higher than the number calculated in our study, due to possible suboptimal sensitivity 
of DBS testing. Analytical and clinical sensitivities of CMV DNA detection reported 
previously using DBS vary within a wide range from 34% up to 100%.18,22-33 A small 
number of prospective studies have analyzed the sensitivity of CMV DNA detection 
in DBS, testing a large population of unselected newborns in comparison with the 
gold standard, i.e., urine CMV culture or PCR at 2–3 weeks after birth, and reported 
sensitivities of 34–83%.25,26,29,32,34 Using these sensitivities, the actual birth prevalence 
of congenital CMV in the Netherlands could be as high as 0.65–1.59%. We and others 
have shown that optimizing DNA extraction protocols, PCR techniques and testing 
algorithms, e.g., by means of performing independent triplicate testing, increases 
analytical sensitivity significantly18,28,32, and the DBS assay used in this study was 
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optimized previously.18 Besides above mentioned technical aspects, CMV load in 
blood has been described to be significantly lower than that in urine35, which may 
have affected the detection of CMV in DBS in our study. In addition to the possible 
suboptimal sensitivity, the CMV status of the 67 DBS without parental permission for 
storage was not known. These DBS originated from a rural region of the Netherlands 
referred to as the Bible Belt, containing a low proportion of immigrants, rendering it 
unlikely that a high number of congenital CMV cases were among these unavailable 
DBS. The specificity of CMV PCR assays for DBS has been reported to range between 
99.3 and 100%.22,36,37 In the current study, the possibility of false positive test results 
was minimized by using an optimized test strategy including confirmatory testing of 
(initial single) positive test results, resulting in a specificity approaching 100%. 
This study illustrates that congenital CMV infection is approximately six times more 
prevalent in those areas in the Netherlands with more than 15% young children 
in the population compared with areas with a lower proportion of young children. 
Additionally, we show that congenital CMV infection was more prevalent in areas with 
a higher proportion of immigrants, with the birth prevalence being three times higher 
in areas with more than 30% non-Western immigrants compared with areas with a 
lower proportion of non-Western immigrants. The findings correspond with results 
from studies assessing risk factors for congenital CMV infection in other countries.2,7-9 
The proportion of young children and immigrants in a population are demographic 
markers for environmental factors and behaviors that facilitate CMV transmission. 
Young children shed CMV in their body fluids and are, therefore, a common source 
for CMV. A CMV shedding child is a known risk factor for maternal CMV infection.33 
Among immigrants, maternal CMV seroprevalence has been shown to be higher than 
among native mothers in the Netherlands.10 A higher maternal seroprevalence implies 
a more frequent exposure to CMV, which may be related to cultural differences in 
childcare practices (with frequent contact with children’s saliva, urine, and maternal 
breast milk) and/ or sexual activities. Previous studies suggest a positive correlation 
of congenital CMV with a household size more than three persons and low 
socioeconomic status.2,7-9 However, in the present study no significant association 
between a big household size and congenital CMV infection was found. Due to the 
anonymized data of the DBS tested, no information was available on the clinical 
outcome of the children and risk factors could not be assessed at the individual level. 
Despite the latter limitation, risk factors were analyzed at regional level. Since the 
sample size was calculated to assess a reliable estimate of the birth prevalence of 
congenital CMV in the Netherlands, the risk factor analysis had limited power due to 
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relatively low numbers. It is possible that parameters lacking a significant association 
in the study, might in fact be significantly associated when analyzed with a larger 
sample size. Finally, the limited availability of demographic and socioeconomic status 
variables made that not all risk factors important for congenital CMV infection could 
be studied. 
Based on the knowledge of the natural history of congenital CMV infection1, a 
birth prevalence of congenital CMV of 0.54% implicates that approximately 1,000 
children are born with congenital CMV infection in the Netherlands annually, of whom 
approximately 180 children (0.1% of all newborns) will develop long term sequelae 
(Fig. 1). These long term sequelae include hearing loss, cognitive and/or motor 
deficits and have significant impact on the lives of patients and their families, rendering 
congenital CMV infection an important public health problem. The number of children 
with sequelae due to congenital CMV infection is the same order of magnitude as the 
total number of newborns detected annually with the newborn hearing screening and 
metabolic screening programs in the Netherlands.17 CMV infection is, therefore, an 
important public health issue warranting further research to assess which preventive 
measures are most cost-effective.39 
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Total births in the Netherlands/yr
n=182 765a
Congenital CMV-infected newborns (0.54% [present paper])
n=987
Symptomaticb at birth (12.7%c)
n=125














figure 1  Birth prevalence and implications for disease burden of congenital CMV in the 
Netherlands.
 a Lanting et al.17 
 b Symptomatic: Petechiae, jaundice, hepatosplenomegaly, thrombocytopenia, 
chorioretinitis, seizures, microcephaly, intracranial calcifications, or fetal hydrops.1 
 c Dollard et al.1 
 d Sequelae: Sensorineural hearing loss (uni-and bilateral), cognitive deficit (mental 
retardation, neurological impairment and developmental delay), and motor deficit.1 
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A significant number of asymptomatic newborns infected with congenital 
cytomegalovirus (CMV) will present with permanent childhood hearing impairment 
(PCHI) during early childhood. 
objectives
To investigate the role of congenital CMV infection in causing PCHI in the Netherlands, 
and assess the efficacy of two different hearing screening strategies and the 
developmental outcome following each strategy. 
study design 
We included 192 children with PCHI at the age of 3–5 years, who were offered hearing 
screening in their first year of life. Dried blood spots from 171 children were available 
for CMV detection using real-time PCR. The results of eight previously tested 
samples were also available. Clinical baseline characteristics were collected from 
medical records and the Child Development Inventory was used to investigate the 
developmental outcome. 
results 
The rate of congenital CMV among the 179 children was 8% (14/179) and 23% (9/39) 
among children with profound PCHI. Two of eight CMV-positive children with PCHI 
at the age of 3–5 years had passed the newborn hearing screening (NHS) test. 
Developmental outcome measures showed a significantly greater delay in language 
comprehension in children with both PCHI and congenital CMV infection (the largest 
in symptomatic children) than in the children with PCHI without congenital CMV 
infection. 
Conclusions 
Congenital CMV infection is important in the etiology of PCHI. Universal NHS is 
not a guarantee of normal hearing and development in childhood for children with 
congenital CMV infection. This is a problem which might be solved by universal 
congenital CMV screening. 




The leading non-genetic cause of permanent childhood hearing impairment (PCHI) 
is congenital cytomegalovirus (CMV) infection.1 Approximately 85% of infants with 
congenital CMV infection do not exhibit signs or symptoms at birth, but about 15% 
of these children will develop permanent sequelae, such as PCHI and general 
developmental delay, during early childhood.2–4 Isolated PCHI is the most frequent 
long-term sequel in children with congenital CMV infection.5,6 To diagnose congenital 
CMV later in life, e.g. in children presenting with PCHI, stored dried blood spots from 
blood drawn within the first week of life can be used for CMV DNA detection. This is 
a practical and reliable method for diagnosing congenital CMV infection later in life, 
since dried blood spots can be stored for very long periods without loss of sensitivity.7 
It has been suggested that newborn hearing screening (NHS) may fail to detect 
children with progressive or delayed-onset hearing loss linked to congenital CMV 
infection.8 Since 2002, infant hearing screening using distraction methods has been 
gradually replaced by universal newborn hearing screening (NHS) in the Netherlands. 
One of the aims of our study was to determine the efficacy of the NHS program in 
relation to congenital CMV-related hearing loss. 
Furthermore, little is known about the developmental outcome of children with both 
PCHI and congenital CMV. Previous studies on the developmental outcome of 
children with congenital CMV infections show marked heterogeneity.3 
objectives 
The aim of the present study was to investigate the contribution of congenital CMV 
infection to PCHI in children in the Netherlands. Furthermore, the efficacy of two 
hearing screening strategies and the developmental outcomes that followed these 
were determined. 
study design 
The contribution of congenital CMV to causing PCHI, and its consequences for hearing 
screening strategies and child development were studied within the framework of the 
DECIBEL study. The current sub-analysis included all children for whom congenital 




The DECIBEL study is a pseudo-randomized study investigating the effects of two 
different hearing screening strategies on the development of children with PCHI. The 
development of 3-, 4- and 5-year-old children with PCHI, who were offered either the 
distraction hearing screening strategy (DHS, at 9 months) or the NHS (within 2 weeks 
of birth), was evaluated. 
The NHS program for healthy newborns, fully implemented in 2006, has a national 
coverage of approximately 98%, and is a threestep screening program. The first 
step uses otoacoustic emission testing. In the case of absent emissions in one or 
both ears this procedure is repeated once. This is followed by automated auditory 
brain stem response (A-ABR) testing when an abnormal result persists. Referral for 
extensive audiological diagnostic evaluation follows when these three steps fail to 
produce a normal screening result. Early hearing screening for infants admitted to a 
neonatal intensive care unit is carried out using three-step A-ABR testing. Since NHS 
has gradually replaced DHS in the Netherlands from 2002 onwards, approximately 
half of the children available for participation in the DECIBEL study have been tested 
by NHS and the other half by DHS. Diagnostic investigations for congenital CMV 
infection took place in the workup to determine the etiology of the PCHI in children in 
the DECIBEL study. 
study population 
The study population consisted of children born in the Netherlands between January 
2003 and December 2005, who were offered hearing screening in the first year of 
life and were known to have PCHI at the age of 3, 4 or 5 years at any of the Dutch 
Audiological Centers. PCHI was defined as a hearing loss of ≥40 dB in the better ear. 
The children were identified at the participating Audiological Centers. To date, 192 
children eligible for participation have taken part in the developmental and etiological 
assessments of the DECIBEL study, of whom 188 gave informed consent for 
congenital CMV detection using their dried blood spots. These were not available for 
17 children, but it was known that 8 of these had previously been tested for congenital 
CMV by other institutions. This resulted in 171 dried blood spot cards available for 
testing, and a total of 179 available results. 
Participating children were classified as symptomatic for congenital CMV infection 
when one of the following conditions was present at birth: intrauterine growth 
retardation, microcephaly, prolonged hyperbilirubinemia, thrombocytopenia, 
petechiae or hepatosplenomegaly. 
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study specimens and specimen processing 
In the Netherlands a blood sample is routinely taken from all newborns during the 
first week of life for screening for metabolic, endocrine and other disorders. The 
remaining blood is stored for 5 years as dried blood spots on Guthrie cards by the 
National Institute for Public Health and Environment (RIVM). The Guthrie cards from 
the children participating in the DECIBEL study could be recalled with written parental 
permission. Medical and audiological files, including hearing screening strategies, 
and correspondence from medical specialists, were used to characterize the study 
population. 
DNA extraction from dried blood spots was performed according to the method 
described by Barbi et al.9 using one 3.2 mm punch, as evaluated by de Vries et al.10 
Extraction was performed in 96well plates, and was followed by amplification of 
a 126-bp fragment from the CMV immediate-early antigen region by means of an 
internally controlled quantitative real-time polymerase chain reaction as described 
previously by Kalpoe et al.11 Each sample was tested in triplicate with a negative 
control punch between each sample. The results of the triplicates were interpreted 
using the algorithm described by Barbi et al.12 The parents of the participants, and 
their family doctors, were personally informed about the results of the CMV DNA 
detection.
assessment of development 
The Minnesota Child Development Inventory was translated, according to the rules 
formulated by Guillemin et al., into the Dutch language and adjusted for sign language 
(CDI-NL).13 This parental questionnaire consisted of 270 yes or no statements on 
child behavior and development, and was sent to parents of participating children by 
mail or e-mail. The developmental items were grouped to form scales including social 
development, self-help, gross and fine motor development, expressive language and 
language comprehension. The general development score was a summary score 
that provided an overall index of development. The developmental quotients (GDQ, 
general development quotient; ELC, expressive language quotient; LCQ, language 
comprehension quotient) were derived using the developmental age divided by the 




The prevalence of congenital CMV among children with PCHI was calculated. 
Statistical tests were carried out using SPSS version 16.0 (SPSS Inc., Chicago, IL, 
USA), with the significance level set at P < 0.05. The χ2-test was used to compare 
the differences in baseline characteristics. Linear regression modeling was used to 
analyze the developmental outcome based on the CDI-NL. Adjustment was made for 
age at examination and severity of hearing loss.
results 
Contribution of congenital Cmv to PChi 
CMV DNA was detected in 10 of the 171 dried blood spots tested during this study. 
When the eight children who had been tested previously, but who could not be 
retested because of missing dried blood spots (four positive and four negative) 
were added, the total contribution of congenital CMV infection in young children with 
PCHI was 8% (14/179). Twenty-three percent (9/39) of all cases of profound PCHI 
(hearing loss > 90 dB) in this sample were attributable to congenital CMV infection. 
The baseline characteristics of the children with congenital CMV, and those without 
congenital CMV are presented in Table 1.
No significant differences were found between the two groups in the baseline 
characteristics of gender, ethnicity, gestational age, type of hearing screening 
strategy and parity of the mother. The degree of hearing loss was more severe, and 
progression of hearing loss was significantly more frequent in children with congenital 
CMV infection than in children without congenital CMV. Additionally, children with 
congenital CMV infection had received cochlear implants significantly more frequently 
than children without congenital CMV infection.
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table 1  Baseline characteristics of the study population: children with permanent childhood 
hearing impairment with and without a congenital cytomegalovirus infection. 
PCHI with PCHI without 
congenital CMV congenital CMV 
n = 14 (%) n = 165 (%) 
Gender 
Male 5 (35.7) 100 (60.6) 
Female 9 (64.3) 65 (39.4) 
Ethnicity 
Caucasian 13 (92.9) 139 (84.2) 
Mediterranean/African/Asian 0 10 (6.1) 
Mixed 1 (7.1) 12 (7.3) 
Unknown 0 4 (2.4) 
Gestational age 
25–30 weeks 0 11 (6.6) 
31–37 weeks 2 (14.3) 30 (18.2) 
≥38 weeks 12 (85.7) 122 (74.0) 
Unknown 0 2 (1.2) 
Parity 
Primi-para 2 (14.3) 53 (32.2) 
Multi-para 12 (85.7) 102 (61.8) 
Unknown 0 10 (6.0) 
Type of hearing screening strategy 
Distraction hearing screening 4 (28.6) 44 (26.7) 
Newborn hearing screening 8 (57.1) 109 (66.0) 
Audiological examination on indication 0 7 (4.3) 
No hearing screening 2 (14.3) 4 (2.4) 
Unknown 0 1 (0.6) 
Severity of hearing loss* 
Moderate (40–60 dB) 3 (21.4) 90 (54.5) 
Severe (60–90 dB) 2 (14.3) 44 (26.7) 
Profound (>90 dB) 9 (64.3)* 30 (18.2) 
Unknown 0 1 (0.6) 
Progression of hearing loss* 6 (43.0)* 33 (20.0) 
Type of amplification* 
Hearing aid 5 (35.7) 117 (70.9) 
Bone-anchored hearing aid 0 9 (5.5) 
Cochlear implant 8 (57.1)* 33 (20.0) 
No hearing aid 1 (7.2) 5 (3.0) 
Unknown 0 1(0.6) 
* p < 0.05. 
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hearing screening in children with symptomatic and asymptomatic congenital 
Cmv infection at birth 
The hearing screening history and the long-term characteristics of children with 
congenital CMV infection are shown in Table 2. Four children had been screened by 
DHS, of whom two passed. Two children born in a region where DHS was offered did 
not take part in the hearing screening program. Eight children had been screened 
by NHS, of whom two (symptomatic children) passed. These children presented 
for audiological evaluation at 27 and 51 months, respectively, because of parental 
concern. One of them presented with profound hearing loss. Six children had 
symptomatic disease, of whom two were recognized at birth as having congenital 
CMV infection. These two children both had a referral at hearing screening and were 
treated for their symptoms. One received antiviral therapy (ganciclovir 12 mg/kg/day 
intravenously for 5 weeks and 1 week oral therapy). All children with symptomatic 
disease at birth had profound PCHI at the age of 3–5 years. 
Cerebral imaging had been previously performed in eight children; in three because of 
multidisciplinary workup to determine the cause of PCHI, in one because of cochlear 
implant candidacy, and in four because of the suspicion of congenital infection in 
childhood. Abnormalities that could be interpreted as being caused by congenital 
CMV infection were seen in six children. 
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table 2  Characteristics of the children with permanent childhood hearing 
impairment and congenital cytomegalovirus (CMV) infection. 
                   Children positive for congenital 
                   CMV infectiona (n = 14) 
Type of hearing screening Distraction hearing screening 
offered and result of Refer 2 (1) 
screening Pass 2 (0) 
Newborn hearing screening 
Refer 6 (2) 
Pass 2 (2) 
No screening 2 (1) 
Reason for audiological Refer at hearing screening 7 (4) 
evaluation Parental concernb 7 (2) 
Reported long-term effects Motor delay 6 (4) 
Visual impairment 12 (2) 
Cognitive delay 3 (3) 
a 
Figures in brackets are children with symptomatic infection at birth. 
b 
One of these children refused audiological evaluation after referral following distraction hearing screening, 
but presented later in childhood because of parental concern. 
developmental outcome 
CDI-NL results were available from 158 children with PCHI (Table 3). The presence 
of congenital CMV infection was accompanied by lower raw mean developmental 
quotients. These scores were even lower for children with symptomatic infection. 
There was a significant difference in ELQ and LCQ between children with and without 
congenital CMV infection, in favor of the children with PCHI without congenital CMV 
infection. Adjustment for age at developmental evaluation or for the severity of 
hearing loss did not add to the results. Among the children with congenital CMV, a 
developmental difference, although not significant, was found between asymptomatic 
children and children with symptoms at birth. In these children, adjustment for age 
and severity of hearing loss decreased the mean difference. The one child treated 
















































































































































































































































































































































































































































































































































































































































































































































































The prevalence of congenital CMV infection in young children with PCHI found in this 
study was 8%. In children with profound PCHI the prevalence of congenital CMV was 
23%. Children with congenital CMV infection are at risk for PHCI, even if they have a 
normal hearing result at NHS, and the developmental outcome of children with PCHI 
is significantly negatively affected by the presence of congenital CMV infection. 
When interpreting the results, some advantages and a few potential weaknesses of 
this study need to be taken into account. The 5-year storage of dried blood spots 
in the Netherlands provided us with the opportunity to diagnose congenital CMV 
retrospectively.14 Long-term sequelae of congenital CMV, such as PCHI, had time 
to become apparent in the intervening years. In the absence of systematic hearing 
screening in the preschool years, moderate hearing losses may have gone unnoticed, 
leading to underestimation of the prevalence of PHCI, and underestimation of the 
overall contribution of congenital CMV infection to PCHI in this study. 
The sensitivity of CMV DNA detection in dried blood spots is limited, with sensitivities 
reported ranging from 50% (for dried blood spots with CMV DNA loads of 3–2 log10 
copies/ml) to 100% (for dried blood spots with CMV DNA loads of 5–4 log10 copies/ml) 
when using the most sensitive methods.9,10,15,16 Therefore, the contribution of congenital 
CMV to PCHI found in this study might be underestimated. The underrepresentation 
of ethnic minorities (non-whites in the DECIBEL study 15%; in the Netherlands as a 
whole 20%), in whom congenital CMV infection is found more frequently, might be a 
bias in our study.17,18 A second possible bias may have been introduced by the urge 
of parents to gain insight in the etiology of their child’s PCHI, leading to a possible 
overrepresentation of children with PCHI of unknown cause. Only 54% of parents 
were aware of an underlying cause of the PCHI at the start of the DECIBEL study. The 
potential (co-)existence of genetic causes of PCHI in these children is the subject 
of further study. Finally, the limited sample size of children identified with congenital 
CMV infection is of importance with respect to the interpretation of the results on 
developmental outcome. 
In our study population, bilateral PCHI was attributable to congenital CMV in 8% 
of cases, and in 23% of children with profound PCHI. Evidence on the contribution 
of congenital CMV infection to PCHI has been minutely studied by Grosse et al.19 
Reported figures vary between 15% and 40%20–23; the fraction of 23% found in the 
children with bilateral profound PCHI is in concordance with these studies. The 
prevalence of congenital CMV in children with PCHI reflects the prevalence of 
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congenital CMV in the country of the study. We expect the prevalence of congenital 
CMV infection in the Netherlands (0.6–0.7%) to be lower than the estimated overall 
international prevalence of congenital CMV (0.64%), but the exact prevalence in the 
Netherlands is unknown to date.3,14 
Hearing loss caused by congenital CMV might be apparent at birth, but very often 
it presents during the first years of life.8 In our study, two children with congenital 
CMV passed NHS, probably because of delayed-onset or progressive hearing loss. 
The Joint Committee on Infant Hearing suggests additional hearing evaluations in 
children with congenital CMV.24 One should be aware that, lacking universal screening 
for congenital CMV infection, many congenitally infected children with delayed-onset 
or progressive hearing loss may be missed by NHS.25,26 
PCHI in children is expected to lead to a delayed developmental outcome.27,28 Only 
a limited number of earlier studies have described the developmental outcome in 
children with congenital CMV infection, who are considered to be at substantial risk of 
developmental delay, regardless of auditory involvement.29,30 The results of our study 
show that children with PCHI caused by congenital CMV show lower developmental 
quotients than children with PCHI without congenital CMV. The difference in language 
development is significant. The raw differences in the language development 
quotients between children with PCHI with and without congenital CMV infection are 
large (15 for comprehension and 16.6 for expression). The significant difference in 
the comprehension quotient persisted when corrected for age and the severity of 
hearing loss. Further research is necessary to identify possible factors contributing 
to these results, such as cerebral damage resulting from congenital CMV infection. 
We recommend that it would be good clinical practice to regularly assess the 
development of children with congenital CMV, so necessary interventions may be 
started as soon as possible. 
In conclusion, congenital CMV infection is important in the etiology of PCHI. Universal 
NHS is not a guarantee of normal hearing and development in childhood for children 
with congenital CMV infection. This is a problem which might be solved by universal 
congenital CMV screening. Subsequent audiological follow-up of those children with 
congenital CMV infection could decrease the developmental delay caused by later 
diagnosis and intervention. 
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Maternal immunity to cytomegalovirus (CMV) provides substantial protection against 
severe congenital CMV disease. Paradoxically, the prevalence of congenital CMV 
infection increases with CMV seroprevalence in the underlying population. 
objective
To quantify the contribution of non-primary maternal CMV infection on the disease 
burden of congenital CMV as a function of the seroprevalence in the population. 
methods
A population-based prediction model was developed and applied for a wide range 
of CMV seroprevalence. Main outcome measures were: the estimated proportion of 
children with congenital CMV and CMV-related sequelae attributable to non-primary 
maternal infection, with CMV seroprevalence in the population as independent 
variable, and the risk for preconceptionally seropositive pregnant women of having 
a congenitally-infected newborn, compared to this risk for seronegative pregnant 
women, as a function of the seroprevalence. 
results
Both the proportion of newborns with congenital CMV infection and the proportion of 
newborns with sequeale, attributable to non-primary maternal infections increased 
with CMV seroprevalence in the underlying population. These proportions ranged up 
to 96% (95%CI 88-99%) and 89% (95%CI 26-97%), respectively, in populations with 
seroprevalence of 95%. 
Furthermore, seropositive pregnant women were found to be at higher risk of having a 
congenitally infected newborn than seronegative pregnant women, for all population 
CMV seroprevalence values. In contrast, seropositive pregnant women were at lower 
risk of having a newborn with sequelae related to congenital CMV than seronegative 
pregnant women. 
Conclusions
Our data stress the impact of non-primary congenital CMV infection on the disease 
burden of congenital CMV, among all (sub)populations. Awareness of the risk for 
seropositive women of having a newborn with CMV-related sequelae will have 
significant consequences for preventive strategies including hygiene counseling, 
maternal serological screening, and immunization studies.




Congenital cytomegalovirus (CMV) infection is an important public health problem with 
approximately 7 in 1,000 newborns affected.1 Approximately one in five congenitally 
infected infants will suffer from long-term neurological sequelae, with hearing 
impairment being encountered most frequently.2 Primary maternal CMV infection 
during pregnancy is transmitted to the fetus in 32 percent of the cases, whereas 
the transmission risk in CMV seropositive women is about 30-fold lower.1 Moreover, 
severe symptoms at birth and long-term sequelae are seen more frequently among 
congenitally infected newborns from preconceptionally CMV seronegative than 
seropositive women2, indicating that acquired maternal immune response provides 
substantial protection against harmful infection in the newborn. Thus, preventive 
measures for congenital CMV have mainly been focused on preconceptionally 
seronegative women.
Paradoxically, a positive correlation between the birth prevalence of congenital 
CMV and CMV seroprevalence in the underlying population has been found, with 
birth prevalence ranging from 0.3% to 2% or higher in (sub)populations with CMV 
seroprevalence of 30% to 98%.1;3;4 Recent calculations addressed the contribution 
of non-primary maternal CMV infections to the number of congenital CMV infections 
in the United States5 and demonstrated their non-negligible impact. The precise 
effect of the CMV seroprevalence in the underlying population on the proportion of 
congenitally infected children with sequelae born to seropositive mothers is largely 
unknown. 
To quantify the contribution of non-primary maternal CMV infection on the 
disease burden of congenital CMV as a function of the seroprevalence in the 
population, a prediction model was developed, and applied for a wide range CMV 
seroprevalence.   
methods
A population-based prediction model was developed, estimating the proportion of 
children with congenital CMV infection and CMV-related sequelae for non-primary 
and for primary maternal infection, with seroprevalence in the underlying population 
as an independent variable. After development, the model was applied for a wide 





The proportion of children with congenital CMV infection and CMV-related sequelae 
in a population, as a function of the seroprevalence, was estimated as the sum of 
the proportion of newborns with congenital CMV infection and CMV-related sequelae 
from seropositive women and from seronegative women (Figure 1). The risk of 
seropositive pregnant women of having a newborn with congenital CMV infection 
was composed of the maternal-to-fetal transmission rate in seropositive women. The 
risk of having a newborn with congenital CMV infection and CMV-related sequelae 
for seronegative women was composed of the product of the rate of seroconversion 
during pregnancy and the maternal-to-fetal transmission rate after primary maternal 
infection. Parameters in this model were based on sero-survey data in the literature, 
and were estimated as follows. 
CMV seroprevalence
Seropositive pregnant women











Children with congenital CMV infection















figure 1 Flow diagram summarizing the model used in this study, estimating the number 
of children with congenital CMV and CMV-related sequelae, as a function of the 
seroprevalence in the underlying population, classified by maternal preconceptional 
CMV IgG seroimmune status. 
 a; per pregnancy, b; per year
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Maternal-to-fetal transmission rate in seropositive women 
The maternal-to-fetal transmission rate in seropositive women, as a function of 
the seroprevalence in the underlying population, was estimated by performing 
an analysis of the raw data from reports on the CMV birth prevalence among 
preconceptionally CMV IgG seropositive women6-12, listed in a meta-analysis by 
Kenneson et al.1 We combined these birth prevalence data with CMV seroprevalence 
data from the original reports. Only reports with seroprevalence data representative 
for the underlying population were included (N=7, Figure 2).6-12 We fitted a logistic 
regression model on these data-points (curved line) and included random effects to 
account for heterogeneity between the studies, computing 
 
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s  et al.1 We combined these bi th prevalence data with CMV seroprevalence data from the 
original reports. Only reports with seroprevalence data representative for the underlying population were 
included (N=7, Figure 2).6-12 We fitted a logistic regression model on these data-points (curved line) and 
included random effects to account for heterogeneity between the studies, computing 
) enceseropreval  2.44 - exp(6.15 1
1
  pregnancy) seropos.  |  newborn P(CMV

   
(Formula A) 
In this logistic regression model, CMV seroprevalence was a predictor of the birth prevalence among 
newborns from seropositive mothers (p=.067, 2 test, two-sided).  
 
 
Figure 2 Birth prevalence of congenital CMV among preconceptionally CMV IgG seropositive women (%), 
 as a function of CMV seroprevalence in the underlying population, for each study group.6-12 The 
 curved line is our logistic regression fit. Each circle represents a study group, previously listed by 
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In this logistic regression model, CMV seroprevalence was a predictor of the birth 
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figure 2 Birth prevalence of congenital CMV among preconceptionally CMV IgG seropositive 
women (%), as a function of CMV seroprevalence in the underlying population, 
for each study group.6-12 The curved line is our logistic regression fit. Each circle 
represents a study group, previously listed by Kenneson et al.1  
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Maternal seroconversion rate 
To quantify the effect of CMV seroprevalence in the underlying population on the 
seroconversion rate during pregnancy, we fitted a logistic regression model on the 
combined raw data of the studies listed in meta-analysis by Hyde et al13 and Wang et 
al5 (Figure 3). Hyde et al13 analysed studies with data on annual CMV seroconversion 
rates among pregnant women combined with CMV seroprevalence in the study 
population (N=24 data points).10-12;14-32 Wang et al5 reported data on annual CMV 
seroconversion rates combined with CMV seroprevalence data among several ethnic 
subgroups in the United States (N=12), extracted from Colugnati et al.33 We fitted a 
logistic regression model on these data-points (curved line) and included random 
effects to account for heterogeneity between the studies, computing
 
aternal seroconversion rate  
To quantify the effect of CMV seroprevalence in the underlying population on the seroconversion rate 
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In this logistic regression model, CMV seroprevalence was a significant predictor of the birth prevalence 




Figure 3 Annual seroconversion rates (%) among seronegative pregnant women, as a function of CMV 
 seroprevalence in the underlying population, for each study group. The curved line is our logistic 
 regression fit, the straight line represents the linear fit of Hyde et al.13 Circles represent data from 
 studies reported by Hyde et al13, crosses represent data from subpopulations reported by Wang 











In this logistic regression model, CMV seroprevalence was a significant predictor of 
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figure 3 Annual seroconversion rates (%) among seronegative pregnant women, as a 
function of CMV seroprevalence in the underlying population, for each study group. 
The curved line is our logistic regression fit, the straight line represents the linear fit 
of Hyde et al.13 Circles represent data from studies reported by Hyde et al13, crosses 
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The maternal-to-fetal transmission rate following seroconversion was estimated in a 
previous meta-analysis by Kenneson et al1 as 32% per pregnancy (95% confidence 
interval (CI) 29.8%-34.9%).
Overall proportion of congenital CMV 
The overall proportion of children with congenital CMV in a population, as a function 
of the seroprevalence, was the sum of the proportion of newborns with congenital 
CMV from non-primary and from primary maternal infections, including the 
proportion of seropositives and seronegatives in the population (seroprevalence and 
1-seroprevalence, respectively), resulting in  
 
ternal-to-fetal transmission rate 
The maternal-to-fetal transmission rate following seroconversion was estimated in a previous meta-
analysis by Kenneson et al1 as 32% per pregnancy (95% confidence interval (CI) 29.8%-34.9%). 
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Risk of sequelae related to congenital CMV 
The risk of having a newborn with sequelae related to congenital CMV as a function of the seroprevalence 
was estimated by supplementing the model with the risk of sequelae following non-primary and primary 
maternal infection (8% and 25%, respectively 2). Congenital CMV-related sequelae were defined as 
sensorineural hearing loss, IQ ≤70, chorioretinits, microcephaly, seizures, paresis or paralysis, and death.2 
 
Model application  
To quantify the effect of the CMV seroprevalence in the underlying population on the contribution of non-
primary maternal infection, the developed model was applied for a wide range of (worldwide present) 
CMV seroprevalence (30-95%). Outcome measures were the number and proportion newborns with 
congenital CMV and CMV-related sequelae, and the relative risk for seropositive women. 
 
Newborns with congenital CMV 
For CMV seroprevalence 30-95%, the number of children with congenital CMV per 10,000 births for non-
primary infection was estimated )1 Formula x enceseropreval x (10,000  and for primary infection 
0.32) x 2 Formula x ence)seropreval-(1 x (10,000 .  
Additionally, for CMV seroprevalence 30-95%, the proportion (%) of children with congenital CMV 
attributable to non-primary and primary maternal infection, relative to the total number of children with 
congenital CMV was estimated (
C Formula
A Formula x enceSeropreval
  and
C Formula
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relative to the total number of children with congenital CMV was estimated 
(
 
Maternal-to-fetal transmission rate 
The maternal-to-fetal transmission rate following seroconversion was estimated in a previous meta-
analysis by Kenneson et al1 as 32% per pregnancy (95% confidence interval (CI) 29.8%-34.9%). 
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Sequelae related to congenital CMV
The number and proportion of children with sequelae attributable to non-primary and 
primary infection, for CMV seroprevalence 30-95%, was estimated by supplementing 
the estimates of the number and proportion of newborns with the risk on sequelae 
described above. 
Relative risk for seropositive women
For CMV seroprevalence 30-95%, the risk (relative risk, or risk ratio, RR) for 
preconceptionally seropositive pregnant women of having a newborn with congenital 
CMV and CMV-related sequelae estimated, relative to this risk for seronegative 
pregnant women (
0.32 x B Formula
A Formula
  and
0.25 x 0.32 x B Formula
0.08 x A Formula
 , respectively). 
Sensitivity analysis
Simultaneous 95% confidence intervals (CI) were computed using Monte Carlo 
simulations34 (10,000 runs) in which all parameters (maternal-to-fetal transmission 
rate for seropositive and for seronegative women, maternal-to-fetal transmission rate, 
and risk on sequelae after non-primary and primary maternal infection) were varied 
simultaneously. Single-point estimates were selected for each parameter from the 
respective probability distributions for each evaluation run. 95%CIs, incorporated the 
uncertainty surrounding each variable. 
All statistical analysis were conducted using R (version 2.11.1).
results
model application
newborns with congenital Cmv
The estimated number and proportion of newborns with congenital CMV attributable 
to non-primary and for primary maternal infections, for CMV seroprevalence 30-95% 
in the underlying population, is shown in Figures 4 and 5. 
For example, in a population with 50% CMV seroprevalence, 36 newborns with 
congenital CMV per 10,000 births were estimated to be attributable to non-primary 
infections (Figure 4A) and 15 newborns with congenital CMV were attributable to 
primary infections (Figure 4B). This results in a birth prevalence of congenital CMV of 
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51 per 10,000 births. The proportion of congenital CMV attributable to non-primary 
infections in that population is 70% (36 per 10,000 /51 per 10,000 births) (Figure 5A). 
The estimated number of newborns with congenital CMV attributable to non-primary 
maternal infections increased with CMV seroprevalence, and ranged from 13 (95%CI 
1-54) to 202 (95%CI 82-345) per 10,000 births for seroprevalence of 30% to 95% 
(Figure 4A). In contrast, the number of newborns with congenital CMV attributable 
to primary maternal infections ranged from 10 (95%CI 4-16) to 8 (95%CI 4-13) per 
10,000 births for seroprevalence of 30% to 95% (Figure 4B).
The proportion of newborns with congenital CMV attributable to non-primary maternal 
infections increased with CMV seroprevalence, and ranged from 57% (95%CI 24-
85%) to 96% (95%CI 88-99%) in populations with CMV seroprevalence of 30% to 95% 
(Figure 5A). 
sequelae related to congenital Cmv
In a similar way, the estimated number and proportion of newborns with sequelae 
related to congenital CMV (including sensorineural hearing loss) for CMV 
seroprevalence 30-95% in the underlying population are shown in Figures 4C/D and 
5B. 
For example, in a population with 50% CMV seroprevalence, 43% of the congenital 
CMV infections with sequelae were attributable to non-primary maternal infections 
(3 infected newborns born to seropositive women per 10,000 births, out of in total 7 
congenitally infected newborns per 10,000 births). 
Both the number and proportion of congenitally infected children with CMV-related 
sequelae attributable to non-primary maternal infections increased with CMV 
seroprevalence in the underlying population. The estimated number of children 
with sequelae attributable to non-primary infections ranged from 1 (95%CI 0-4) to 
16 (95%CI 0-37) per 10,000 births in populations with CMV seroprevalence of 30% 
to 95%(Figure 4C). In contrast, the number of children with sequelae attributable to 
primary infections ranged from 3 (95%CI 1-5) to 2 (95%CI 1-4) per 10,000 births in 
populations with CMV seroprevalence of 30% to 95%(Figure 4D). 
The proportion of congenital infections with sequelae attributable to non-primary 
infections ranged from 29% (95%CI 2-70%) to 89% (95%CI 26-97%) in populations 
with CMV seroprevalence of 30% to 95% (Figure 5B). Non-primary CMV infections 
were estimated to account for the majority of children with CMV-related sequelae 



























































































































































































































































































































figure 4 A/B: The estimated number of newborns with congenital CMV per 10,000 births, 
as a function of the CMV seroprevalence in the underlying population, classified by 
non-primary (A) and primary maternal infection (B).  
 C/D: The estimated number of children with congenital CMV-related sequelae per 
10.000 births, as a function of the CMV seroprevalence in the underlying population, 
classified by non-primary (C) and primary maternal infection (D). Sequelae include 
sensorineural hearing loss, IQ≤70, chorioretinitis, microcephaly, seizures, paresis 
and paralysis, and death.2 Grey zones represent 95%CIs.



















































































































































































































































































































































































































































































































































































































































































































































































































































































Cmv population seroprevalence (%)
figure 5 Estimated proportion (%) of children with congenital CMV (A) and CMV-related 
sequelae (B) born to seropositive mothers, relative to the total number of children 
with congenital CMV and CMV-related sequelae respectively, as a function of the 
seroprevalence in the underlying population.
relative risk for seropositive women
The estimated risk for preconceptionally seropositive women of having a newborn with 
congenital CMV and CMV-related sequelae, compared to this risk for seronegative 
pregnant women (relative risk, RR), is shown in Figure 6. E.g., in a population with 
50% seroprevalence, the relative risk for seropositive women of having newborn with 
congenital CMV was 2.3 (absolute risk for seropositive women / absolute risk for 
seronegative women in that population, 0.72% / 0.31%). 
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For all CMV seroprevalence values, seropositive women were at higher risk of having 
a congenitally-infected newborn than seronegative women (RR>1), with a relative risk 
of 3.0 (95%CI 0.7-27) to 1.3 (95%CI 0.6-3.5) in populations with CMV seroprevalence 
of 30% to 95% (absolute risks of 0.44% / 0.15% to absolute risks of 2.12% / 1.67%). 
In contrast, the risk of having a child with sequelae related to congenital CMV was 
lower for seropositive women (RR<1), for all seroprevalence values. This relative risk 
ranged from 0.97 (95%CI 0.06-12) to 0.41 (95%CI 0.05-1.80) in populations with CMV 
seroprevalence of 30% to 95% (absolute risk of 0.04% / 0.04% to absolute risks of 
0.17% / 0.42%). This is similar to a 1.0 to 2.5 times higher relative risk for seronegative 


































































































































































































































































































































































































Cmv population seroprevalence (%)
figure 6 The estimated risk (RR) for preconceptionally seropositive pregnant women 
of having a child with congenital CMV (dotted line) and CMV-related sequelae 
(continuous line), relative to this risk for seronegative pregnant women, as a function 
of the seroprevalence. 




Using our model, we found that both the number and the proportion of newborns with 
congenital CMV infection attributable to non-primary maternal infections increased with 
CMV seroprevalence in the underlying population. Importantly, both the number and 
proportion of newborns with sequelae attributable to non-primary maternal infections 
was also highest in highly seroprevalent populations. Furthermore, seroimmune 
pregnant women were found to be at higher risk of having a congenitally infected 
newborn than seronegative pregnant women, for all population CMV seroprevalence 
values. This relative risk was up to three times higher among seroimmune pregnant 
women in populations with low CMV seroprevalence values, and decreased with CMV 
seroprevalence in the population. In contrast, seropositive pregnant women were at 
lower risk of having a newborn with sequelae than seronegative pregnant women. 
Our findings are supported by earlier findings7 and recent calculations on the absolute 
number of congenital CMV infections in the United States attributable to non-primary 
maternal infections.5 Additional to these reports, our model predicted the contribution 
of non-primary infections for a wide range of CMV seroprevalence, and took into 
account an exponential effect of CMV seroprevalence on both the maternal-to-fetal 
transmission rate and the seroconversion rate. Furthermore, we added the risk for 
sequelae to these population-based estimates.
Parameters used in our model were based on data from previous studies listed in 
recent and extensive meta-analysis, and robustness of the parameters was assessed 
in our sensitivity analysis. It must be noted that the estimated proportion of newborns 
had wide 95%CIs, resulting from the denominator (total congenital infections), 
combined with the crude estimate of the risk for sequelae, and should therefore be 
interpreted with care.  
It would be of interest to quantify the contribution of non-primary CMV infection 
on different sequelae seperately, since it may well be that sequelae associated 
with primary infection are more severe than sequelae associated with non-primary 
infection.2 However, outcomes from studies assessing e.g. hearing impairment 
following non-primary maternal infections vary widely2;4;35, and render it difficult 
to produce reliable estimates on the risk on these different sequelae to date. A 
complicating factor might be be that the severity of disease, including hearing loss, 
following primary infections may vary with gestational age at infection.36;37 More 
detailed studies are needed to calculate the exact impact of non-primary maternal 
infections on the different sequelae seperately, as a function of the seroprevalence.  
Chapter 4
70
The apparent contradiction of maternal immunity as a risk factor for congenital CMV 
can be understood as follows. Once infected, previously seronegative pregnant 
women are at much higher risk of transmitting CMV to their fetuses compared to 
preconceptionally seropositive pregnant women. However, it is also necessary to 
include the risk of actually acquiring an infection. If this risk is also taken into account, 
seropositive pregnant women are at higher risk of having a congenitally infected 
newborn compared to preconceptionally seronegative pregnant women. The risk of 
re-infection or reactivation in seropositive pregnant women outweighs the combined 
risks of the risk of acquisition and transmission in seronegative pregnant women. 
Recent serological studies assessing strain-specific CMV antibody responses have 
shown that maternal re-infection with a new strain is a major source of congenital 
infection in seroimmune women, with re-infection occurring in 8% of the seroimmune 
pregnancies.38 The circulation of CMV or the force of infection appeared to be highest 
in highly seroprevalent populations, based on age-specific seroprevalence data.33;39 
Differences in acquisition rates between high and low seroprevalent (sub)populations 
seem plausible given their difference in first exposure, and are likely based on 
environmental and behavioral differences. 
Our data stress the relevance of non-primary maternal congenital CMV infection 
for the disease burden of congenital CMV, among all (sub)populations. Awareness 
of the risk for seroimmune pregnant women of having a congenitally infected and 
neurologically disabled newborn will have significant consequences for preventive 
strategies to reduce the disease burden of congenital CMV. Preventive measures 
such as hygienic behavior should be advised for both seronegative and seroimmune 
pregnant women. In that case, prenatal maternal serological screening will be futile 
as long as no adequate intervention is available. Awareness of the fact that CMV 
seroimmunity is only partially protective for congenital infection raises questions on 
the role of re-infections with new strains and reactivations of latent virus in seroimmune 
pregnant women. Passive and active immunization efforts will be challenged since 
the induction of a specific CMV immune response may not fully protect against fetal 
infection and disease, and an immunological correlate of full protection is lacking. 
A CMV glycoprotein B vaccine boosted immunity in CMV seropositive women 40, 
however a potential effect on maternal to fetal transmission rate and congenital 
CMV disease remains to be tested. In short, awareness of the paradox of maternal 
seroimmunity as a risk factor for congenital infection as addressed in this study will 
have significant consequences for preventive strategies including hygiene counseling, 
maternal serological screening, and immunization studies.    
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Because of limited treatment options for congenital cytomegalovirus (CMV) infection, 
preventive strategies are important. Knowledge and awareness are essential for the 
success of preventive strategies. 
objectives
To investigate the knowledge of congenital CMV among doctors involved in mother 
and child care in the Netherlands. 
study design
A questionnaire on CMV infection was sent to doctors by snowball sampling. 
Knowledge concerning epidemiology, transmission, symptoms and signs of CMV 
infection in adults and children, and treatment options were evaluated. 
results
The questionnaire was completed by 246 doctors involved in mother and child care. 
The respondents estimated a prevalence of congenital CMV varying between 0.1 and 
500 per 1000 live-born infants. The mean knowledge scores regarding transmission 
and postnatal symptoms increased with a more advanced career stage (i.e. older 
age). Gender and parenthood did not contribute to knowledge, but the field of 
expertise did. Respondents in the field of pediatrics had the highest mean score 
on postnatal symptoms and long-term effects. Respondents working in the field of 
gynecology and obstetrics were unaware of the precise transmission route of CMV. 
More than one-third of the respondents assumed that treatment was readily available 
for congenital CMV infection. 
Conclusions
The knowledge of CMV infection among doctors in the Netherlands contained several 
gaps. Increasing knowledge and awareness is expected to enhance the prevention of 
transmission, to improve recognition, and to stimulate diagnostic investigations and 
follow-up programs. 




Congenital cytomegalovirus (CMV) infection is the most common congenital viral 
infection in newborns, with an estimated worldwide prevalence in live newborns of 
0.64%.1 Symptoms and signs are present at birth in 10–15% of these children, and 
another 15–20% will have sequelae that become apparent later in life.2 We estimate 
that each year in the Netherlands approximately 800 children congenitally infected with 
CMV are born, of whom an estimated 160 will have long-term effects.3 The symptoms 
and signs of congenital CMV, such as intrauterine growth retardation (IUGR), elevated 
liver enzymes, convulsions, and long-term effects such as developmental delay and 
permanent childhood hearing impairment2 have a great impact on the lives of children 
and their parents. Although several vaccines are being developed and tested, no 
vaccine has been licensed for use. Furthermore, in most countries no prenatal or 
neonatal screening program for congenital CMV infection exists, and only limited data 
exist on the effectiveness of prenatal or postnatal treatments. 
While awaiting treatment options, the burden of disease can be decreased by 
preventive strategies that reduce the risk of transmission of CMV to the pregnant 
woman.4,5 A recent review of the implementation of educational hygiene interventions 
provides preliminary support for the positive effect of preventive strategies.6 The 
success of preventive strategies depends on the active involvement of the doctors 
involved in mother and child care.4 Awareness of the epidemiology, transmission, 
diagnosis and prevention of congenital CMV is essential for every doctor. Recent 
studies report on the knowledge of women of childbearing age, and obstetricians, 
concerning congenital CMV.7,8 One-fifth of the women of childbearing age had heard 
of congenital CMV, but only very few had specific knowledge about the clinical 
symptoms and signs, or the modes of transmission or prevention, even when these 
women were medical professionals themselves. 
Half of the women who were aware of congenital CMV had heard about the virus from 
a doctor.7 A recent survey reported that most obstetricians do not include congenital 
CMV in their advisory consultation with their pregnant patients.8 Increased awareness 
of congenital CMV is important, not only to reduce the transmission rate, but also to 
improve the recognition of symptoms and signs in congenitally infected children.9 
Such awareness could improve the subsequent diagnostic investigation and follow-




The objective of this study was to determine the knowledge of doctors involved in 
mother and child care in the Netherlands concerning congenital CMV. 
methods 
Questionnaire development 
A 12-item questionnaire on CMV, taking less than 4 min to complete, was developed. 
The questionnaire tested knowledge of the prevalence of congenital CMV; the 
symptoms and signs of CMV in healthy adults, newborns and children; the mode of 
transmission; and the treatment options. All but two questions regarding epidemiology 
and possible treatment were multiple choice. The possible answers were based on 
the literature, and included 20% false answers (i.e. non-symptoms). Multiple answers 
were accepted. Several demographic variables were asked for, including gender, 
age, parenthood and professional field. When a respondent had not heard of CMV 
at all, the questionnaire ended after recording the characteristics of the respondent. 
The questionnaire was pilot tested using a convenience sample, and ambiguous 
questions were rephrased. The questionnaire summary is given in Fig. 1. 
what is the transmission route of cytomegalovirus?
Air Kissing Breastfeeding
Sexual intercourse Changing diapers Don’t know
Direct skin contact Blood contact
what is the most frequent presentation of Cmv infection in immune competent adults?
No symptoms Not feeling well Visual problems
Fever Thrombosis Don’t know
Cardiac problems Elevated liver enzymes
what symptoms can be seen in newborns with congenital Cmv infection?
No symptoms Microcephaly Seizures
Petechiae Growth retardation Anal atresia
Elevated liver enzymes Renal problems Hearing loss
Congenital heart defect Macrosomia
what long-term effects can present in children with congenital Cmv infection?
Hearing loss Visual problems Obesity
Cognitive delay Autism Increased risk of malignancy
Cardiac problems Seizures Motor delay
figure 1  Summary of CMV survey, including possible answers. 
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sampling frame and questionnaire administration 
The digital questionnaire, accompanied by a covering letter, was sent to the medical 
contacts of the researchers. Snowball sampling was used; all participants were asked 
to forward the link of the online questionnaire to medical colleagues.10 These contacts 
were interns, residents, hospital-based senior doctors, general practitioners and 
medical researchers. In addition to the digital questionnaire, a hard-copy version was 
completed by attendees at two local specialist meetings (Department of Pediatrics 
and Department of Otolaryngology). The questionnaire was anonymous, and the 
response period was closed after 2 months. One month after closure, an information 
brochure on congenital CMV was sent to all respondents who had indicated that they 
were interested. In this study the analysis was restricted to the replies of the doctors 
directly involved in mother and child care. 
data analysis 
All statistical tests were carried out using SPSS version 16.0 (SPSS Inc., Chicago, 
IL, USA), with the significance level set at P < 0.05. Frequency responses to all 
questionnaire items were determined, and overall scores were calculated per 
questionnaire item. This overall score was based on the sum of the correctly stated 
true answers and the correctly not chosen false answers, assigning one point per 
correct answer. The maximum achievable score varied between 7 and 12 points, 
depending on the questionnaire item. Comparisons between different groups of 
respondents were made using χ2 tests. 
results 
The questionnaire was completed by 415 respondents, of whom 246 were involved 
in the care of mothers and children. The characteristics of the respondents and 
their mean scores on the questionnaire’s topics are shown in Table 1. There were 
no significant gender differences in the mean scores. The mean knowledge scores 
regarding transmission and postnatal symptoms increased with a more advanced 
career stage (corresponding with an older age). Parenthood or plans to have children 
did not contribute significantly to knowledge of CMV infection. The field of expertise 
did contribute significantly to knowledge of CMV. Respondents in the field of infectious 
diseases had the highest mean knowledge score on transmission routes. The lowest 
(total) scores were achieved by general practitioners and otorhinolaryngologists. 
Respondents in the field of pediatrics had the highest mean score on postnatal 
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symptoms, as well as on knowledge of the long-term effects. The details and 
background variables of non-respondents could not be identified because of the 
sampling method used. The respondents estimated a prevalence of congenital CMV 
varying between 0.1 and 500 per 1000 live-born infants. 
In Table 2, the number and proportion of stated true and false answers to CMV 
questionnaire items are shown. The relevant knowledge of respondents in pediatrics 
(postnatal symptoms and long-term effects) and respondents in gynecology and 
obstetrics (transmission route) is shown in detail. Fifty-six percent of the respondents 
were aware that CMV infection may not produce any symptoms in healthy adults. 
More than 50% of the respondents realized that microcephaly, growth restriction 
and hearing loss can be signs of congenital CMV in newborns, and the potential 
long-term effects were known by more than 65%. Half of the respondents thought 
air conduction was a true transmission route of congenital CMV. One-third of the 
pediatricians were aware that congenital CMV infection might not give rise to any 
symptoms at birth. Hearing loss and cognitive delay were accurately acknowledged 
as long-term effects of congenital CMV. Most of the respondents working in the field 
of gynecology and obstetrics were unaware of the precise transmission route of CMV. 
Of the respondents working in pediatrics, 55% were convinced that treatment options 
for congenital CMV infection were readily available, compared with 34.6% of the total 
respondents. 













































































































































































































































































































































































































































































table 2  The number and percentage of stated “yes” responses per multiple-choice item on 
the CMV questionnaire for all respondents and for respondents in pediatrics and 
obstetrics and gynecology in more detail. 
Knowledge concerning Total number of 
Number of 
pediatricians 
Number of obstetricians 
and gynecologists
respondents (n = 246) (%) (n = 85) (%) (n = 18) (%) 
transmission route 
True answers 
Kissing 129 (52.4) 40 (47.1) 7 (38.9) 
Changing diapers 56 (22.8) 34 (40) 4 (22.2) 
Breast milk 85 (34.6) 42 (49.4) 8 (44.4) 
Blood contact 141 (57.3) 69 (81.2) 11 (61.1) 
Sexual intercourse 98 (39.8) 43 (50.6) 8 (44.4) 
False answers 
Air conduction 126 (51.2) 31 (36.5) 9 (50.0) 
Direct skin contact 38 (15.5) 9 (10.6) 6 (33.3) 
symptoms in immune competent adults 
True answers 
No symptoms 137 (55.7) 60 (70.6) 10 (55.6) 
Not feeling well 159 (64.6) 48 (56.5) 14 (77.8) 
Fever 88 (35.8) 25 (29.4) 8 (44.4) 
Elevated liver enzymes 72 (29.3) 21 (24.7) 5 (27.8) 
False answers 
Cardiac problems 0 (0) 0 (0) 0 (0) 
Thrombosis 0 (0) 0 (0) 0 (0) 
Visual problems 5 (2.0) 1 (1.2) 2 (11.1) 
Postnatal symptoms 
True answers 
No symptoms 50 (20.3) 27 (31.8) 3 (16.7) 
Petechiae 71 (28.9) 45 (52.9) 5 (27.8) 
Elevated liver enzymes 109 (44.3) 57 (67.1) 5 (27.8)
Microcephaly 138 (56.1) 73 (85.0) 12 (66.7) 
IUGR 146 (59.3) 61 (71.8) 16 (88.9) 
Hearing loss 138 (56.1) 67 (78.8) 12 (66.7) 
Seizures 68 (27.8) 40 (47.1) 6 (33.3) 
False answers 
Heart defect 53 (21.6) 20 (23.5) 1 (5.6) 
Macrosomia 2 (0.8) 0 (0) 0 (0) 
Renal problems 29 (11.8) 13 (15.3) 1 (5.6) 
Anal atresia 1 (0.4) 0 (0) 0 (0) 





Hearing loss 161 (65.5) 78 (91.8) 13 (72.2) 
Cognitive delay 171 (69.5) 77 (90.6) 15 (83.3) 
Motor delay 89 (36.2) 42 (49.4) 6 (33.3) 
Seizures 49 (19.9) 32 (37.6) 0 (0) 
Autism 10 (4.1) 6 (7.1) 0 (0) 
Visual problems 99 (40.2) 50 (58.8) 11 (61.1) 
False answers 
Cardiac problems 39 (15.9) 14 (16.5) 1 (5.6) 
Obesity 1 (0.4) 0 (0) 0 (0) 
Increased risk for malignancy 4 (1.6) 2 (2.4) 0 (0) 
There is treatment available 85 (34.6) 47 (55.3) 5 (27.8) 
Note that multiple answers were accepted so the percentage adds up to more than 100%. 
discussion and conclusion 
We investigated the knowledge of congenital CMV infection among doctors in the 
Netherlands involved in mother and child care. Several interesting findings were 
shown. First, doctors seemed to miscalculate the chance of encountering a child 
with congenital CMV infection in medical practice. There seemed to be a risk of 
underdiagnosis, since the prevalence of congenital CMV, internationally estimated 
to be 0.64%, was sometimes overestimated, but more frequently underestimated by 
respondents in this study. Secondly, preventive strategies are assumed to be effective 
only when doctors are sufficiently well informed to advise their patients properly. 
The data in this study show that most of the doctors were aware that most healthy 
adults and pregnant women do not experience any symptoms of a CMV infection. 
Worryingly, however, only one-fifth of the respondents, including those working with 
pregnant patients, were aware that kissing, and changing diapers, are risk factors for 
the transmission of CMV. Thirdly, including congenital CMV infection in the differential 
diagnosis in symptomatic newborns is crucially important. Since only half of the total 
respondents in this study and two-thirds of those working in pediatrics were aware 
that microcephaly, IUGR and hearing loss could be symptoms of congenital CMV, 
it seems possible that these children may be left undiagnosed, with possibilities for 
treatment and follow-up not explored. It is worrying that only 20% of all respondents 
and 32% of respondents in pediatrics realized that congenital CMV frequently does 
not give rise to any symptoms and signs at birth, and that 14% of these asymptomatic 
newborns will develop long-term sequelae.2 Finally, we were surprised that 55% of the 
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respondents in the field of pediatrics thought that the antiviral therapy of newborns 
with congenital CMV infections is common practice in the Netherlands. Even though 
antiviral therapy has been shown to prevent hearing deterioration in newborns with 
symptomatic CMV infections, this practice is not yet widespread here.11 
This study has several shortcomings: the sampling frame and questionnaire 
administration might have introduced bias, since the invitation started among the 
medical contacts of the researchers. These contacts might have had an advantage 
in knowing more about congenital CMV. Additionally, completing the questionnaire 
might have been subject to response bias, since respondents who felt unsure about 
their knowledge of CMV could refuse to respond to the questionnaire. This bias, 
however, might imply that the true knowledge concerning congenital CMV infection is 
even poorer than reported. 
Medical information is available from various sources: Internet, TV, radio, newspapers 
and magazines. However, information is generally not sought if the public is not 
aware of a health risk or health problem. It is the responsibility of a doctor to be aware 
of the risks to a population in special situations, and supply information to reduce 
the health risk. When the doctor lacks awareness, this information is not available to 
the population or the individual patient. In the case of CMV it is especially important 
that doctors involved in the care of women who are or who may become pregnant 
are able to advise on the risk of congenital CMV and how this risk may be reduced. 
To date, information on congenital CMV is not regularly included in preconception 
and antenatal consultations. Fig. 2 gives a brief overview of what doctors should 
know about congenital CMV infection, for those working in pediatrics or obstetrics 
and gynecology. 
In summary, this study focused on one of the essential aspects of successful 
preventive strategies for congenital CMV infections: the knowledge of doctors 
involved in mother and child care. Consistent with earlier findings, we show that most 
doctors concerned with mother and child care in the Netherlands do not possess 
optimal knowledge on CMV. The results of this study can be used for discussions 
on awareness and relevant knowledge for each specific medical field, individualized 
education for doctors, and for the development of preventive strategies. Awareness 
and knowledge will subsequently improve the recognition of early and late symptoms 
and signs, improve diagnostic and follow-up programs, and might even promote the 
development of evidence-based treatment in the near future. 
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Pediatricians obstetricians and gynecologists
Presentation of congenital infection in newborns Presentation of CMV infection in adults
• Asymptomatic • Asymptomatic
• Growth retardation and/or microcephaly • Fever
• Hearing loss • Elevated liver enzymes
• Thrombocytopenia
• Elevated liver enzymes
Late effects of congenital infection Transmission route
• Hearing loss • Body fluids
• Developmental delay • Blood contact
Estimated prevalence in newborns Preventive strategies
0.64% worldwide • Wash hands after changing diapers
• Aviod kissing young children on the mouth
• Don’t share food, drink or cutlery with young children
figure 2  What doctors should know about congenital CMV infection. 
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Dried blood spots (DBS) may be valuable in the diagnosis of congenital 
cytomegalovirus (CMV) infection. However, the 2007 European Quality Control for 
Molecular Diagnostics (QCMD) proficiency testing programme showed that CMV 
DNA detection in DBS was lacking sensitivity in a considerable number of participating 
laboratories. 
objective
To compare DNA extraction methods for DBS for detecting CMV. Sensitivity and 
applicability of the methods for high-throughput usage were assessed. 
study design
Guthrie cards were spotted with CMV DNA-positive whole blood (n = 15). DNA 
was extracted from the DBS using different extraction methods, followed by CMV 
amplification by means of real-time PCR. 
results
Significant differences between the extraction methods with respect to the sensitivity 
were found. Optimal sensitivity was achieved when samples were tested in triplicate, 
demonstrating that the methods in general operated around their detection limits. 
Triplicate testing using the protocol by Barbi et al. [Barbi M, et al. Cytomegalovirus 
DNA detection in Guthrie cards: a powerful tool for diagnosing congenital infection. 
J Clin Virol 2000;17:159–65], representing the most sensitive methods, resulted in 
sensitivities of 100%, 86%, and 50% for DBS with CMV DNA loads of 5–4, 4–3, and 
3–2 log10 copies/ml, respectively. This indicates that sensitivity limitations apply in the 
clinically relevant concentration range. Few methods appeared suitable for 96-well 
format high-throughput testing. 
discussion
When considering universal neonatal screening for congenital CMV infection, an 
assay which is both sensitive and applicable for high-throughput testing is required. 
The protocol by Barbi et al. and the BioRobot Universal System appear appropriate 
candidates currently available for 96-well format application in neonatal screening 
using DBS. 




Cytomegalovirus (CMV) infection is the most common cause of congenital infection 
worldwide with an overall birth prevalence of 6–7 per 1000 births.1,2 About 12% of 
the live-born infants with congenital CMV infection are symptomatic at birth.1,2 Of 
the children asymptomatic at birth, an additional 11–13.5% will develop permanent 
sequelae in the following years.1–3 The most frequently encountered symptom of 
congenital CMV infection is sensorineural hearing loss (SNHL). Congenital CMV 
infection is responsible for 15–20% of SNHL in infants and children.4,5 
Neonatal blood collected on filter paper within the first week of life (dried blood 
spots, DBS) has been proven useful for (retrospectively) diagnosing congenital 
cytomegalovirus (CMV) infection. The sensitivity of CMV DNA detection in DBS 
reported in literature is 71–100%, depending on the method used and the population 
tested.6–11 However, the 2007 Quality Control for Molecular Diagnostics (QCMD) 
proficiency testing programme in which 33 European and South African laboratories 
participated, showed that CMV DNA detection in DBS was lacking sensitivity in a 
considerable number of participants. Only 50% of the laboratories were able to detect 
CMV DNA in a DBS sample with a load of 9.4 × 103 (4.0 log10) copies/ml whole 
blood.12 
Currently, several non-commercial and commercial DNA extraction methods for DBS 
are available. A number of reports evaluating DNA extraction methods for DBS have 
been published. However, comparison of these data is complicated by inter-study 
differences, such as the origin of the samples, and the input and output volumes.6–11 
The aim of our study was to test a panel of DNA extraction methods for DBS currently 
available. CMV-positive whole blood samples from transplant patients were spotted 
and DNA was extracted using the various methods, with identical input and output 
volumes, followed by CMV DNA amplification by real-time PCR. Sensitivity and 
applicability of the methods for high-throughput usage were determined. 
methods 
dried blood spots (dbs) 
DBS samples were prepared by spotting CMV-positive EDTA-anticoagulated whole 
blood from transplant recipients with a broad range of CMV DNA loads (range 2–5 
log10 copies/ml whole blood, n = 15) on Whatman 903 filter paper (kindly provided 
by Bert Elvers, RIVM, The Netherlands). The samples were air-dried, stored at room 
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temperature and tested within 3 months after spotting. In addition, CMV DNA-
negative EDTA-anticoagulated whole blood from CMV-seronegative healty volunteers 
was spotted and used as negative controls. Furthermore, DBS from the QCMD CMV 
DBS 2007 panel (manufactured by Sandro Binda and Maria Barbi, Dept. of Public 
Health-Microbiology-Virology, University of Milan, Italy) were used to further analyse 
the protocol previously published by Barbi et al.,6 representing the most sensitive 
methods. 
extraction of dna from whole blood 
CMV loads of the EDTA-anticoagulated whole blood from transplant recipients were 
determined prior to spotting using 200 μl for DNA extraction with the MagNa Pure LC 
Total Nucleic Acid Isolation Kit (Roche Diagnostics, Almere, The Netherlands). DNA 
extraction was followed by CMV amplification (see Section 2.12). 
extraction of dna from dbs 
DNA was extracted from DBS using the following extraction methods: the protocol 
described by Barbi et al.,6 the QIAamp DNA Investigator Kit (QIAGEN), the BioRobot 
Universal System (QIAGEN), the MagNA Pure LC (Roche Diagnostics), the NucliSens 
easyMAG (bioMeriéux), the QIAsymphony (QIAGEN), and Dynabeads Silane 
(Invitrogen). Sample input per tube/well was 3 punches, each measuring 3.2 mm 
in diameter, corresponding with approximately 9 μl dried blood per tube/well for all 
extraction methods tested. DBS were punched using an automated plate punch 
type 1296-071 (Perkin Elmer-Wallac, Zaventem, Belgium). For all extraction methods, 
samples were tested in triplicate with a negative control punch between each sample. 
Output volume was 100 μl for all extraction methods tested. DNA extraction was 
followed by CMV amplification (see Section 2.12). 
Since the above-mentioned fixed input and output volumes meant a significant 
deviation from the original protocol by Barbi et al. (dictating 1 punch input and 35 μl 
output volume), the original protocol by Barbi et al. (unmodified) was tested as well. 
Extraction of DNA from DBS using the protocol by Barbi et al. (unmodified) 
DNA was extracted from DBS using the protocol described by Barbi et al.6 (details 
obtained by personal communication). One punch of 3.2 mm per tube (in triplicate) 
was incubated at 4 °C overnight in 35 μl Minimum Essential Medium (+Earle’s, +25 
mM HEPES, −l-glutamine, Gibco/Life Technologies, Breda, The Netherlands) without 
additives in 96-well cluster tube strips. An aliquot of phocine herpes virus (PhHV) was 
Evaluation of DNA extraction methods for dried blood spots 
91
6
added as nucleic acid isolation and PCR inhibition control, as described previously.13 
Incubation was followed by heating at 55 °C for 60 min, and 100 °C for 7 min in 
a thermal cycler. After rapid cooling at 4 °C, the sample was centrifuged at 
3220 × g for 15 min. The supernatant was transferred to a 96-well plate, frozen at 
−80 °C for at least 1 h, and thawed. This protocol resulted in an output solution which 
was approximately 20% more concentrated than when using the modified protocol 
by Barbi et al. described below. 
Extraction of DNA from DBS using the protocol by Barbi et al. (modified) 
Essentially the same procedure was followed for the modified protocol by Barbi et 
al., except that 3 punches of 3.2 mm per tube (in triplicate) were incubated in 125 μl 
Minimum Essential Medium, obtaining an output volume of 100 μl. 
Extraction of DNA from DBS using the QIAamp DNA Investigator Kit 
DNA was extracted using the QIAamp DNA Investigator Kit (column-based manual 
extraction) following the protocol “Isolation of total DNA from FTA and Guthrie 
cards” with a modification in the elution buffer according to the manufacturer’s 
recommendations. Briefly, 280 μl buffer ATL and 20 μl proteinase K were added 
to the punches in screw-capped tubes, followed by vortexing, and incubation at 
56 °C while shaking at 900 rpm for 1 h. After addition of 300 μl buffer AL (with 1 μg 
carrier RNA and internal PhHV control), the mix was pulse-vortexed and incubated at 
70 °C while shaking at 900 rpm for 10 min. Additionally, 150 μl ethanol (96–100%) was 
added, the sample was pulse-vortexed, and the mix was transferred to the QIAamp 
MinElute column and centrifuged. The column was washed with 500 μl buffer AW1, 
700 μl buffer AW2, and 700 μl ethanol (96–100%) subsequently, followed by drying of 
the column membrane at room temperature for 10 min, and eluting of DNA with 100 
μl buffer AE (provided with the QIAamp DNA Mini Kit). 
Extraction of DNA from DBS using the BioRobot Universal System 
DNA extraction using the BioRobot Universal System (columnbased automated 
extraction) was performed using the QIAamp Investigator BioRobot Kit with manual 
pretreatment according to the manufacturer’s recommendations. Tests were 
performed by QIAGEN application specialists in application laboratory Hilden, 
Germany. Briefly, 280 μl buffer ATL (with 2.75 μg carrier RNA and internal PhHV 
control) and 20 μl proteinase K were added manually to the punches in a QIAGEN 96-
well S-Block. Samples were incubated at 56 °C overnight while shaking at 900 rpm in 
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a heatable shaker (Eppendorf Thermomixer Comfort with Thermoblock for Microtiter 
and Deepwell Plates with lid). After pretreatment, the supernatant was transferred 
manually to an empty S-Block and loaded on the BioRobot Universal System running 
the protocol “QIAamp DNA BloodCard UNIV” with an input volume of 300 and 100 μl 
elution volume. 
Extraction of DNA from DBS using the MagNA Pure LC 
DNA extraction using the MagNA Pure LC (magnetic particlebased automated 
extraction) was performed with manual pretreatment according to manufacturer’s 
recommendations (Ref. 14, with minor modifications). The MagNA Pure LC DNA 
Isolation Kit III (Bacteria, Fungi) (Roche Diagnostics, Almere, The Netherlands) was 
used. Briefly, pretreatment was performed by adding a premix of 230 μl Bacteria 
Lysis/Binding Buffer, 20 μl proteinase K, and internal PhHV control to the punches in 
screw-capped tubes, vortexing and incubating at room temperature overnight. The 
following day, the mixture was incubated at 95 °C for 10 min, centrifuged briefly, and 
cooled at 4 °C. Supernatant was transferred manually to the MagNA Pure LC running 
the protocol “DNA Isolation Kit III” with an input volume of 200 μl and an elution 
volume of 100 μl. 
Extraction of DNA from DBS using the QIAsymphony 
DNA extraction using the QIAsymphony (magnetic particlebased automated 
extraction) was performed using the QIAsymphony DNA Mini Kit with manual 
pretreatment according to manufacturer’s recommendations since this method was 
originally not designed for application of DBS (however currently in development). 
Pretreatment was performed following the QIAsymphony protocol “Pretreatment 
of Tissues” with minor modifications. Briefly, 180 μl buffer ATL (with added internal 
PhHV control) and 20 μl proteinase K were added to the punches in screw-capped 
tubes, followed by incubation at 56 °C with shaking at 900 rpm overnight. Supernatant 
was loaded manually on the QIAsymphony (magnetic particles based) running the 
protocol “Purification of DNA from tissues, cultured cells and bacterial cultures/DNA 
Tissue Low Content” with an input volume of 200 and 100 μl elution volume. 
Extraction of DNA from DBS using the easyMAG 
DNA extraction using the easyMAG (magnetic particle-based automated extraction) 
was performed using the NucliSENS easy-MAG Extraction Kit with manual pretreatment 
according to manufacturer’s recommendations (Ref. 9, with minor modifications). 
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Briefly, punches were transferred into 2 ml NucliSens easyMAG lysis buffer in 10 
ml lidded glass tubes, and incubated by gently rocking on a roller in horizontal 
position at room temperature for 30 min. After spinning down potential filter fibers at 
1500 × g for 15 s, supernatant was loaded on the easyMag manually, running the off 
board extraction protocol (Generic, version 2.0.1). Internal PhHV control was added 
to extraction buffer 3, the elution volume was 100 μl. 
Extraction of DNA from DBS using Dynabeads Silane 
Dynabeads Silane extraction (magnetic particle-based manual extraction) was 
performed using the Dynabeads Silane viral NA kit with pretreatment according 
to manufacturer’s suggestions since this method was originally not designed for 
application of DBS (however currently in development). Briefly, 200 μl phosphate 
buffered saline was added to the punches in screw-capped tubes and incubated at 
85 °C for 10 min, followed by incubation with 20 μl proteinase K (20 mg/ml, Invitrogen/
Life Technologies, Breda, The Netherlands) at 55 °C for 10 min. Additionally, the mixture 
was incubated with 300 μl viral NA lysis buffer (including internal PhHV control) on a 
rotating wheel at room temperature for 10 min. The supernatant was transferred to an 
empty tube and suspended in 150 μl isopropanol and 50 μl Dynabeads suspension 
(silica-like magnetic beads) and incubated on a rotating wheel at room temperature 
for 10 min. Using the magnet, supernatant was removed and the Dynabeads were 
washed twice with 850 μl Washing Buffer 1 and 450 μl Washing Buffer 2. After drying 
the bead-pellet at room temperature for 10 min, the pellet was resuspended in 100 
μl viral NA elution buffer and incubated at 70 °C for 3 min. Using the magnet, beads 
were separated from the supernatant, which was harvested. 
Quantitative real-time PCr 
CMV DNA amplification was performed by means of an internally controlled quantitative 
real-time PCR as described previously13 with minor modifications. Briefly, 10 μl of DNA 
extract was added to 40 μl PCR pre-mixture obtaining final concentrations of 0.5 
μM forward CMV primer, 0.5 μM reverse CMV primer, 0.2 μM CMV TaqMan probe, 
0.3 μM forward PhHV primer, 0.3 μM reverse PhHV primer, 0.05 μM PhHV TaqMan 
probe, 3 mM MgCl2, and 25 μl HotStar Master mix (QIAGEN, Hilden, Germany). The 
PCR running 50 cycli was carried out in an iQ5 Multi-colour Real-Time PCR Detection 
System (BioRad, Veenendaal, The Netherlands), amplifying a 126-bp fragment from 
the CMV immediate-early antigen region. Quantification was performed using a 
dilution series of titrated CMV (Advanced Biotechnologies Inc., Columbia, MD, USA) 
as an external standard. 
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Qualitative and quantitative data analysis 
Qualitative data of DBS (n = 15), tested in triplicate, were analysed as follows. DBS 
were counted positive when ≥1 of the triplicates tested positive.7 Additionally, to 
compare single and triplicate testing, ordinal means of the triplicates were calculated 
and considered the result of single testing (thereby enhancing the distinctive character 
compared with true single testing). Statistical analysis of ordinal data was performed 
using the Wilcoxon signed ranks test (two-tailed). The sign test (two-tailed) was used 
for comparison of single and triplicate testing. 
In the quantitative data analysis, undetected samples were assigned the minimum 
detected load and mean loads were calculated per spotted CMV load categories. 
CMV DNA loads detected in 3 punches of each 3.2 mm, corresponding with in total 
approximately 9 μl dried blood, were converted to CMV DNA loads per ml spotted 
whole blood. 
high-throughput applicability 
Throughput characteristics determined were the maximum number of tubes/wells per 
run and the applicability of an automated system. 
results 
Qualitative results 
Qualitative results of the extraction methods tested are shown in Fig. 1(A) and 
(B). Fig. 1(A) shows the number of detected CMV-positive DBS (%) per method, 
comparing single testing (left) with triplicate testing (the DBS was counted positive 
when ≥1 of the triplicates was positive,7 right). Single testing of DBS resulted in CMV 
DNA detection ranging from 32% (4.8/15) using the extraction method Dynabeads 
Silane, to 73% (11.0/15) using the protocol by Barbi et al. (unmodified). The highest 
number of samples were detected using the protocol by Barbi et al. (unmodified), the 
QIAamp DNA Investigator Kit (71%, 10.7/15), the BioRobot Universal System (67%, 
10.0/15), the modified protocol by Barbi et al. (67%, 10.0/15), and MagNA Pure LC 
(62%, 9.3/15), respectively. The protocol by Barbi et al. (unmodified) was significantly 
more sensitive than extraction using the QIAsymphony (54%, 8.2/15, P = 0.031, 
Wilcoxon signed ranks test), the easyMAG (53%, 8.0/15, P = 0.031) and Dynabeads 
Silane (P = 0.003). Extraction using Dynabeads Silane was significantly less sensitive 
than all other extraction methods tested (P ≤ 0.039). For all methods, sensitivity was 
enhanced when testing was performed in triplicate compared with single testing (P 
= 0.008, sign test). 
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Fig. 1(B) shows the number of detected CMV-positive DBS (%) per spotted CMV DNA 
load category resulting from single testing. DBS with low CMV DNA loads (2–3 log10 
copies/ml whole blood, n = 2) were not detected by four out of eight methods in any 
of the triplicates. When testing DBS with moderate CMV loads (3–4 log10 copies/ml 
whole blood, n = 7), the number of detected samples varied from 17% (1.2/7) using 
the extraction method Dynabeads Silane, to 67% (4.7/7) using the protocol by Barbi 
et al. (unmodified). DBS with high CMV DNA loads (4–5 log10 copies/ml whole blood, 
n = 6) tested positive in all triplicates using the protocol by Barbi et al. (unmodified 
and modified), and the QIAamp DNA Investigator Kit. 
Sensitivity of CMV DNA detection per CMV load category was increased when 
samples were tested in triplicate (not shown in graph). When tested in triplicate, all 
DBS with CMV DNA loads of 3–4 log10 copies/ml (100%, 7/7) were detected using 
the BioRobot Universal System. All DBS with CMV DNA loads of 4–5 log10 copies/
ml (100%, 6/6) were detected by all methods tested, except for Dynabeads Silane. 
Triplicate testing using the protocol by Barbi et al. (unmodified) resulted in sensitivities 
of 50% (1/2), 86% (6/7), and 100% (6/6) for spotted CMV DNA loads of 2–3, 3–4, and 
4–5 log10 copies/ml, respectively. 
All 120 CMV DNA-negative control samples (15 per extraction method) tested 
negative. No PCR inhibition was found using any of the extraction methods. 
Quantitative results 
Quantitative results of the DNA extraction methods tested are shown in Fig. 1(C). 
Depicted are the detected mean CMV DNA loads of triplicates per spotted CMV DNA 
load categories. Detected CMV DNA loads in DBS with spotted CMV DNA loads of 
2–3, and 3–4 log10 copies/ml were lower than the spotted load category in six out of 
eight and five out of eight methods tested, respectively. CMV DNA loads detected in 
DBS with high spotted CMV DNA loads (4–5 log10 copies/ml) were within the ranges 
of the spotted load category in seven out of eight methods tested. 
Chapter 6
96
S40 J.J.C. de Vries et al. / Journal of Clinical Virology 46S (2009) S37–S42
Fig. 1. (A) Qualitative results of CMV DNA detection from DBS of the extraction
methods tested, demonstrating the effect of triplicate testing on sensitivity. Left:
single testing, right: triplicate testing (DBS was counted positive when ≥1 of the
triplicates was positive). *P ≤ 0.05, **P ≤ 0.01. (B) Qualitative results of CMV detec-
tion from DBS of the extraction methods, per spotted CMV DNA load category,
after single testing. (C) Quantitative results of CMV DNA detection from DBS of
the extraction methods tested, per spotted CMV DNA load category. Depicted are
detected mean CMV DNA loads of triplicates per category. DBS, dried blood spot;
CMV, cytomegalovirus.
samples varied from 17% (1.2/7) using the extraction method Dyn-
abeads Silane, to 67% (4.7/7) using the protocol by Barbi et al.
(unmodified). DBS with high CMV DNA loads (4–5 log10 copies/ml
whole blood, n = 6) tested positive in all triplicates using the proto-
col by Barbi et al. (unmodified and modified), and the QIAamp DNA
Investigator Kit.
Sensitivity of CMV DNA detection per CMV load category was
increased when samples were tested in triplicate (not shown
in graph). When tested in triplicate, all DBS with CMV DNA
loads of 3–4 log10 copies/ml (100%, 7/7) were detected using the
BioRobot Universal System. All DBS with CMV DNA loads of
4–5 log10 copies/ml (100%, 6/6) were detected by all methods
tested, except for Dynabeads Silane. Triplicate testing using the
protocol by Barbi et al. (unmodified) resulted in sensitivities of 50%
(1/2), 86% (6/7), and 100% (6/6) for spotted CMV DNA loads of 2–3,
3–4, and 4–5 log10 copies/ml, respectively.
All 120 CMV DNA-negative control samples (15 per extraction
method) tested negative. No PCR inhibition was found using any of
the extraction methods.
3.2. Quantitative results
Quantitative results of the DNA extraction methods tested are
shown in Fig. 1(C). Depicted are the detected mean CMV DNA
loads of triplicates per spotted CMV DNA load categories. Detected
CMV DNA loads in DBS with spotted CMV DNA loads of 2–3,
and 3–4 log10 copies/ml were lower than the spotted load cate-
gory in six out of eight and five out of eight methods tested,
respectively. CMV DNA loads detected in DBS with high spot-
ted CMV DNA loads (4–5 log10 copies/ml) were within the ranges
of the spotted load category in seven out of eight methods
tested.
3.3. QCMD panel
The QCMD CMV DBS 2007 panel (manufactured by Sandro
Binda and Maria Barbi, Dept. of Public Health-Microbiology-
Virology, University of Milan, Italy) was used to test the
extraction method by Barbi et al. (unmodified, tested and anal-
ysed in triplicate), representing the most sensitive methods.
Results are shown in Table 1. DBS with spotted CMV DNA
loads from 3.9 × 106 (6.6 log10) to 9.4 × 103 (4.0 log10) copies/ml
were detected in all triplicates. One out of two DBS with
spotted CMV DNA loads of 7.3 × 102 (2.9 log10) copies/ml was
detected (in 1/3 triplicates). Only 50% and 4% of the QCMD CMV
DBS 2007 participants detected CMV DNA in DBS with spot-
ted loads of 9.4 × 103 (4.0 log10) and 7.3 × 102 (2.9 log10) copies/ml,
respectively.12
Table 1
Qualitative and quantitative results of CMV detection in the QCMD CMV DBS 2007 panel using the DNA extraction protocol by Barbi et al. (unmodified), and the qualitative
results of all QCMD participants. Quoted with permission of QCMD. QCMD, Quality Control for Molecular Diagnostics; CMV, cytomegalovirus; DBS, dried blood spot.
QCMD CMV DBS 2007 panela Results using Barbi et al. (unmodified) Results of all QCMD participants
Spotted viral load (copies/ml whole blood) Qualitative results Detected viral load (copies/ml whole blood) % correct qualitative results
3.9 × 106 Positive (3/3 triplicates) 2.2 × 106 100
9.6 × 105 Positive (3/3) 3.0 × 105 96
8.8 × 104 Positive (3/3) 4.4 × 104 93
9.4 × 103 Positive (3/3) 5.0 × 103 52
9.4 × 103 Positive (3/3) 4.2 × 103 48
7.3 × 102 Positive (1/3) 1.1 × 102 7
7.3 × 102 Negative – 0
Negative Negative – 96
Negative Negative – 96
a Panel manufactured by Sandro Binda and Maria Barbi, the Dept. of Public Health-Microbiology-Virology, University of Milan, Italy.
Barbi et al. (unmodified)
QIAamp DNA Investigator Kit
BioRobot Universal System
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figure 1  (A) Qualitative results of CMV DNA detection from DBS of the extraction methods 
tested, demonstrating the effect of triplicate testing on sensitivity. Left: single 
testing, right: triplicate testing (DBS was counted positive when ≥1 of the triplicates 
was positive). *P ≤ 0.05, **P ≤ 0.01. 
 (B) Qualitative results of CMV detection from DBS of the extraction methods, per 
spotted CMV DNA load category, after single testing. 
 (C) Quantitative results of CMV DNA detection from DBS of the extraction methods 
tested, per spotted CMV DNA load category. Depicted are detected mean CMV 
DNA loads of triplicates per category. DBS, dried blood spot; CMV, cytomegalovirus. 




The QCMD CMV DBS 2007 panel (manufactured by Sandro Binda and Maria Barbi, 
Dept. of Public Health-Microbiology-Virology, University of Milan, Italy) was used 
to test the extraction method by Barbi et al. (unmodified, tested and analysed in 
triplicate), representing the most sensitive methods. Results are shown in Table 1. 
DBS with spotted CMV DNA loads from 3.9 × 106 (6.6 log10)to9.4 × 10
3 (4.0 log10) 
copies/ml were detected in all triplicates. One out of two DBS with spotted CMV DNA 
loads of 7.3 × 102 (2.9 log10) copies/ml was detected (in 1/3 triplicates). Only 50% and 
4% of the QCMD CMV DBS 2007 participants detected CMV DNA in DBS with spotted 
loads of 9.4 × 103 (4.0 log10) and 7.3 × 10
2 (2.9 log10) copies/ml, respectively.
12 
table 1  Qualitative and quantitative results of CMV detection in the QCMD CMV DBS 
2007 panel using the DNA extraction protocol by Barbi et al. (unmodified), and 
the qualitative results of all QCMD participants. Quoted with permission of QCMD. 
QCMD, Quality Control for Molecular Diagnostics; CMV, cytomegalovirus; DBS, 
dried blood spot. 
QCMD CMV DBS 2007 
panela 
Results using Barbi et al. (unmodified) Results of all QCMD 
participants
Spotted viral load 
(copies/ml whole blood) 
Qualitative results Detected viral load 
(copies/ml whole blood) 
% correct qualitative 
results 
3.9 × 106 Positive (3/3 triplicates) 2.2 × 106 100 
9.6 × 105 Positive (3/3) 3.0 × 105 96 
8.8 × 104 Positive (3/3) 4.4 × 104 93 
9.4 × 103 Positive (3/3) 5.0 × 103 52 
9.4 × 103 Positive (3/3) 4.2 × 103 48 
7.3 × 102 Positive (1/3) 1.1 × 102 7 
7.3 × 102 Negative – 0 
Negative Negative – 96 
Negative Negative – 96 
a Panel manufactured by Sandro Binda and Maria Barbi, the Dept. of Public Health-Microbiology-Virology, 
University of Milan, Italy. 
high-throughput applicability 
Throughput characteristics of the DNA extraction methods tested are shown in Table 2. 
Methods applicable for 96-well format (32 samples/run when testing in triplicate) were 
the protocol by Barbi et al., the BioRobot Universal System, and the QIAsymphony. 
All automated systems tested required a manual pretreatment step (no primary tube 
input format for DBS was available). 
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table 2  Throughput characteristics of the DNA extraction methods tested.
No. of tubes/
wells per run 
Manual/
automated 
Input type Throughput 
Dynabeads Silanea (Invitrogen) 1–16 Manual Tube Low 
QIAamp DNA Investigator Kitb (QIAGEN) 1–24 Manual Tube Low 
NucliSens easyMAGa (bioMérieux) 1–24 Automatedc Tube Medium 
MagNA Pure LCa (Roche Diagnostics) 1–32 Automatedc Tube Medium 
Barbi et al. (un)modified 1–96 Manual Tube or 96-well plate Medium 
QIAsymphonya (QIAGEN) 1–96 Automatedc Tube or 96-well plate High 
BioRobot Universal Systemb (QIAGEN) 8–96 Automatedc 96-Well plate High 
a Magnetic particle-based extraction.
b Column-based extraction.
c Manual pretreatment step, no primary tube input format for DBS available.
discussion 
The data presented here show that sensitivity of CMV DNA detection in DBS varies 
widely depending on the DNA extraction method used. The most sensitive methods 
were the protocol described by Barbi et al. (unmodified and modified), the QIAamp 
DNA Investigator Kit, the BioRobot Universal System, and the MagNA Pure LC. 
Interestingly, the unmodified protocol by Barbi et al. using only 1 punch was not 
less sensitive than the modified protocol by Barbi et al. using 3 punches, probably 
resulting from a DNA concentration effect: the unmodified protocol by Barbi et al. 
resulted in an output solution which was approximately 20% more concentrated than 
the modified protocol. For all extraction methods, optimal sensitivity was achieved 
when samples were tested in triplicate. Triplicate testing using the protocol by Barbi 
et al. resulted in sensitivities of 100%, 86%, and 50% for DBS with CMV DNA loads 
of 5–4, 4–3, and 3–2 log10 copies/ml, respectively. DBS with low spotted CMV loads 
had lower detected loads reflecting the presence of not detected samples. The 
protocol by Barbi et al., the QIAsymphony, and the BioRobot Universal System were 
suitable for 96-well format testing, which would be a requirement for application in 
newborn screening laboratories. It must be stressed that in the automated systems 
tested, pretreatment had to be performed manually (lacking primary tube input for 
DBS), thereby significantly increasing hands-on time. Considering cost-efficacy, the 
protocol by Barbi et al. has the advantage of the lower costs (<0.30€ per sample, 
triplicate testing) compared to the other methods tested (7–15€ per sample, triplicate 
testing). 
Evaluation of DNA extraction methods for dried blood spots 
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Several reports have been published comparing a limited amount of DNA extraction 
methods for DBS.6–11 However, comparison of these data is complicated by inter-study 
differences. Potential variables influencing the sensitivity are the origin of the DBS 
sample (e.g. spiked virus versus clinical samples from symptomatic or asymptomatic 
patients with congenital CMV infection), the amount of dried blood volume used, 
the elution volume, and the amplification method. The QIAamp DNA Blood Mini Kit 
(QIAGEN) has been reported to have a 95% sensitivity at a spotted CMV DNA load 
of 3.6 log10 copies/ml in an experiment with diluted blood from a transplant recipient, 
using a whole DBS (50 μl dried blood).10 A modified QIAamp DNA Micro Kit (QIAGEN) 
protocol has been described to have a sensitivity of 100% when testing DBS from 
seven neonates with congenital CMV (of whom three known to be symptomatic), using 
a whole DBS.8 Soetens et al. reported 73% sensitivity of extraction by the NucliSens 
easyMAG when testing DBS from 53 asymptomatic and 2 symptomatic congenital 
infected neonates, using a whole DBS.9 Considering DNA extraction by means of 
heat shock, Yamamoto et al. reported a 71.4% sensitivity of heat shock in combination 
with a nested PCR when testing DBS from seven congenitally infected children (of 
whom five symptomatic), using 3 × 6 mm punches.11 The highest detection rate 
using heat shock was reported by Barbi et al., whose method had a 100% sensitivity 
when testing DBS from 72 congenital infected babies (of whom 26 symptomatic), 
using one 3 mm punch tested in triplicate followed by nested PCR.6 In our study, the 
influence of potential differences was excluded by using identical clinical samples 
(samples from transplant recipients, containing both extra-and intracellular CMV 
DNA), identical input and output volumes, and an identical amplification assay for all 
extraction methods tested. 
The sample size in our study was small, but partially amended by calculating ordinal 
means of triplicates, thereby enhancing the differences. However, the power of the 
study did not yet allow to detect potential other statistically significant differences 
between the extraction methods. 
A number of studies have been published on the viral load levels in whole blood 
of neonates with congenitally infected CMV. Halwachs-Baumann et al. reported a 
median viral load of 2.3 × 103 (3.4 log10) copies/ml cord vein blood in 18 neonates with 
congenital CMV. No significant difference was found in virus load between children 
that were symptomatic (n = 7) or asymptomatic (n = 11) at birth.15 In contrast, 
Boppana et al. reported a mean peripheral blood CMV DNA load of 4.0 × 105 
(5.6 log10)copies/ml in congenitally infected symptomatic newborns (n = 18), which 
was significantly higher than the mean load of asymptomatic newborns: 
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8.2 × 104 (4.9 log10) copies/ml (n = 58). Among asymptomatic newborns, those 
with hearing loss at follow-up had a significantly higher mean CMV DNA load (8.7 
× 105, 5.9 log10 copies/ml, n =4) than those with normal hearing (1.1 × 10
4, 4.0 
log10 copies/ml, n = 54).
16 The results of Boppana et al. corresponded with data from 
Lanari et al. and Revello et al., both reporting a significantly higher mean CMV DNA 
load in symptomatic newborns (3.2 log10 copies/10
5 PMNLs and 3000 copies/105 
PBL, respectively) than in asymptomatic newborns (2.8 log10 copies/10
5 PMNLs and 
30 copies/105 PBL, respectively).17,18 In our study, the 86% sensitivity of CMV DNA 
detection in DBS using the extraction protocol by Barbi et al. was 3–4 log10 copies/ml. 
This sensitivity combined with the median viral load of 3.4 log10 copies/ml mentioned 
by Halwachs-Baumann et al. would implicate that a significant amount of cases with 
congenital CMV would not be detected even using one of the most sensitive methods 
available. In contrast, when considering the mean viral loads of 4.0 and 5.9 log10 
copies/ml in asymptomatic newborns with respectively normal hearing and hearing 
loss at follow-up mentioned by Boppana et al., the clinical significance of loads below 
the detection limit are debatable. 
The usage of dried urine specimens on filter paper (placed in diapers) has been 
suggested by Nozawa et al. as urine generally contains higher CMV loads than 
blood.19 Though not evaluated in our study, it is likely that the above described 
extraction methods will be applicable to dried urine specimens on filter paper as well. 
When considering universal neonatal screening for congenital CMV infection, a 
cost-efficient assay which is both sensitive and applicable for 96-well format testing, 
using only a very small amount of dried blood, is required. In our hands, the protocol 
by Barbi et al. and the BioRobot Universal System appear appropriate candidates 
currently available for application in neonatal screening. Further studies are needed 
to optimize test characteristics (e.g. primary tube input) and to assess the clinical 
relevance of the detection limit in the intended population of asymptomatic newborns 
at risk for developing hearing loss later in life. 
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Viral DNA detection in dried blood spotted on filter paper, dried blood spots (DBS), 
is valuable in the diagnosis of viral infections, with at the moment congenital 
cytomegalovirus (CMV) being the most common application. CMV detection in clinical 
samples taken within the first 2-3 weeks after birth differentiates congenital CMV 
infection from the in general harmless postnatally acquired cytomegalovirus infection. 
DBS render the possibility to diagnose congenital CMV infection retrospectively, e.g. 
when late-onset hearing loss, the most frequently encountered symptom of congenital 
CMV infection, becomes manifest. Additionally, CMV DNA detection in DBS can be 
of usage in recently advocated newborn screening on congenital CMV infection. The 
procedure of CMV DNA detection in DBS consists of two separate steps: 1. DNA 
extraction from the DBS, followed by 2. CMV DNA amplification. Here, we describe 
two efficient methods for the extraction of DNA from DBS. Sensitivity, specificity, and 
applicability of the methods for high-throughput usage are discussed.




Newborn blood taken within a few days after birth and dried on filter paper (dried 
blood spots, DBS), are widely used for newborn screening on metabolic diseases. 
Additionally, DBS have been proven valuable and are increasingly used in the 
diagnosis of viral infections. It is most often used in the diagnosis of congenital 
cytomegalovirus (CMV) infection, the most common congenital viral infection 
worldwide.1 Congenital CMV infection can be retrospectively diagnosed using DBS, 
differentiating congenitally acquired CMV infection from postnatally acquired CMV 
infection, which is generally much less harmful. DBS render the possibility to diagnose 
congenital CMV infection when the most common symptom of congenital CMV 
infection, late-onset hearing loss, becomes manifest. Additionally, CMV detection in 
DBS can be of usage in recently advocated newborn screening on congenital CMV 
infection.2-11 
CMV DNA detection in DBS includes DNA extraction followed by CMV DNA 
amplification and is increasingly used in clinical virological laboratories worldwide. 
Whereas detection of CMV DNA in blood and other clinical samples is a routine 
diagnostic procedure, the extraction of CMV DNA from filter paper is still challenging 
due to the limited amount of dried blood available; one whole spot of 1 cm in diameter 
equals approximately 50 μL blood, and one punch of 3 mm in diameter, frequently 
used for routine metabolic screening, contains as little as 3-5 μL blood. Thus, optimal 
DNA extraction is crucial in the procedure for CMV DNA detection in DBS. 
Currently, several non-commercial and commercial DNA extraction methods for 
DBS are available. A number of reports evaluating extraction methods for DBS in 
the diagnosis of congenital CMV infections have been published.3-5,12-25 Significant 
differences between extraction methods with respect to the analytical and clinical 
sensitivity are reported, ranging from 35% to 100%3,14-18,20,21,24-26 depending on the 
extraction method used and the population tested. Optimizing DNA extraction 
protocols, PCRs, and algorithms, e.g. by means of performing independent triplicate 
testing, have been shown to increase analytical sensitivity significantly.15,16,18 Triplicate 
testing (of one punch of 3 mm in diameter per tube) using the heat-shock protocol 
by Barbi et al12, shown to be one of the most sensitive methods15, results in analytical 
sensitivities of approximately 100%, 86% and 50% for DBS with CMV DNA loads 
of 5-4, 4-3, and 3-2 log10 copies/ml, respectively.
15 This indicates that limitations in 
sensitivity apply in the clinically relevant concentration range for congenital CMV 
disease (reported mean CMV DNA blood loads of 3.427, 4.0, and respectively 5.9 
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log10 copies/ ml in asymptomatic newborns with hearing loss at follow-up
28). In this 
respect, it is important to note that defined clinically important CMV DNA loads, 
in the absence of an international CMV DNA quantification standard, are of use 
only in the laboratory setting where they were obtained. For a general application, 
standardization of CMV DNA values obtained by different PCR protocols and different 
quantification standards is essential.  
Specificity of CMV DNA detection using DBS has been reported to range between 
99.3% and 100%.12,14,25 To our knowledge, transfer of CMV DNA from one DBS to 
another during storage has been reported once.26 Transfer of CMV DNA during 
punching can be controlled for in the procedure (see below). However, both these 
potential contaminating events are not likely to be of practical significance given the 
above described limited analytical sensitivity. 
Above mentioned advocated newborn screening for congenital CMV can only be 
achieved using automated, high-throughput DNA extraction methods. Currently, few 
methods appear suitable for 96-well format high-throughput testing.15 
Here, we describe two methods for efficient extraction of DNA from DBS, used for 
CMV DNA detection.  
 
materials
DNA extraction from DBS using heat shock12, 24:
1. (Automated) paper puncher
2. Positive and negative control DBS (or blanc Guthrie card/ Whatman 903 
 filter paper) (see Note 1)
3. (Eppendorf) tubes or 96-well plate 
4. Minimal Essential Medium (MEM, without additives)
5. Cooler or thermal cycler (4°C)
6. Heating block or thermal cycler at 55°C and subsequently 100°C 
7. (Eppendorf table) centrifuge 
8. Internal control to monitor for PCR inhibition (e.g. phocine herpes virus 
 (PhHV) DNA)
Column-based DNA extraction from DBS:
1. (Automated) paper puncher
2. Positive and negative control DBS (or blanc Guthrie card/ Whatman 903 
 filter paper) (see Note 1)




4. QIAamp DNA Mini Kit (containing columns, collection tubes, lysis buffer 
 (ATL, AL), proteinase K, wash and elution buffer)
5. Heating block or water bath at 85°C, 56°C, and subsequently 70°C
6. Eppendorf table centrifuge 
7. Internal control to monitor for PCR inhibition (e.g. phocine herpes virus 
 (PhHV) DNA)
methods 
dna extraction from dbs using heat shock.12, 24
1. For each test DBS (see Notes 1 and 2), punch one disk of 3 mm (1/8 inch) in 
diameter per tube or well, in triplicate. Punch one disk from a negative control DBS 
between each test DBS (see Notes 1 and 3). 
2. Add 35 μLMEM, including internal control DNA (e.g. PhHV DNA, see Note 4) and 
spin the punches down (see Note 5). 
3. Incubate at 4°C overnight (see Note 6).
4. Perform heat shock (e.g. in thermal cycler or heating block) according the following 
protocol (see Note 7): 
 -55°C at 60 min
 -100°C at 7 min
 -cool rapidly to 4°C
5. Centrifugate at 3,320 x g for 15 min, or at 8,960 x g for 1-3 min (see Note 8).
6. Transfer the supernatant (approximately 25 μL) to an empty tube or 96-well plate 
and freeze at -80°C for at least 1 h (see Note 9).
7. Thaw; the extract is ready to use for PCR15.
8. Interpretation of PCR results of triplicates (see Note 10).
Column-based dna extraction from dbs (see Notes 11 and 12) 
1. For each test DBS (see Notes 1 and 2), punch one whole DBS (of approximately 1 
cm in diameter, corresponding with approximately 50 μL dried blood) (see Note 12) 
in a microcentrifuge tube, in triplicates. Punch a negative control DBS between each 
sample (see Note 1 and 3). 
2. Add 180 μL lysisbuffer (ATL), including internal control DNA (e.g. PhHV DNA, see 
Note 4) to each tube.
3. Incubate at 85°C for 10 min.
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4. Add 20 μL proteinase K, vortex, and incubate at 56°C for 1h.
5. Add 200 μL lysisbuffer (AL), vortex, incubate at 70°C for 10 min. 
6. Add 200 μL ethanol 96-100%, vortex.
7. Apply the mixture (approximately 600 μL) to column in a collection tube and 
centrifuge at 6,000 x g for 1 min, discard the filtrate.
8. Wash with 500 μL washbuffer (AW1) at 6,000 x g for 1 min, discard the filtrate.
9. Wash with 500 μL washbuffer (AW2) at 20,000 x g for 3 min, discard the filtrate.
10. Centrifuge once more at full speed for 1 min, discard the filtrate.
11. Elute the DNA with 150 μL elution buffer (AE) after incubation for 1 min and 
centrifugation at 6,000 x g for1 min.
12. The eluate is ready to use for PCR15.
13. Interpretation of PCR results of triplicates (see Note 10).
notes 
1. Positive and negative control DBS can be produced by spotting CMV DNA positive 
and negative (EDTA) blood on Whatman 903 filter paper (approximately 50 μL per 
spot of 1 cm diameter) followed by air-drying. DBS can be stored at 4°C or at room 
temperature.
2. When dried on filter paper, blood spots are considered non-infectious material.
3. DNA contamination from sample to sample during punching is controlled for by 
testing a negative control DBS in between each test DBS. 
4. PCR inhibition can be controlled for in a simultaneous reaction by adding a fixed 
amount of internal control (e.g. PhHV DNA) to each sample. Inhibition of internal 
control amplification is indicative of potential inhibition of amplification of target (CMV) 
DNA.  
notes specific for heat shock dna extraction:
5. Punches must be spun down until the disks are below liquid surface level (15 min 
at 3,320 x g may be necessary when using a 96-well plate).
6. Incubation at 4°C overnight significantly enhances extraction efficiency.
7. During the heat shock, DNA will be extracted from the DBS.
8. Centrifugation yields sufficiently purified DNA.
9. Freezing the supernatant for at least 3 h enhances extraction efficiency (no 
maximum freezing time implicated).
10. Triplicate testing results in optimal sensitivity.15 Interpretation of triplicate PCR 
results can be performed using the flow diagram as described by Barbi et al13, in 
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which every positive result should be confirmed with at least one additional positive 
result, in the same run, or in case of a single positive test result (1 of the 3 replicates), 
by means of a confirmatory PCR procedure including DNA extraction (second run) 
(Figure). 
figure Flow diagram for interpretation of triplicate testing results as proposed by 
Barbi et al13.
notes specific for column-based dna extraction:
11. Detailed protocol is described in the manufacturers “QIAamp DNA Mini and Blood 
Mini Handbook”, version April 2010.
12. Using one whole DBS (diameter of 1 cm, corresponding with approximately 50 μL 
blood) enhances sensitivity (DNA yield) significantly, when compared to three or six 
punches of 3 mm in diameter as proposed in the “QIAamp DNA Mini and Blood Mini 
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Genotyping of cytomegalovirus (CMV) is useful to examine potential differences in the 
pathogenicity of strains and to demonstrate coinfection with multiple strains involved 
in CMV disease in adults and congenitally infected newborns. Studies on genotyping 
of CMV in dried blood spots (DBS) are rare and have been hampered by the small 
amount of dried blood available. In this study, two multiplex real-time PCR assays 
for rapid gB and gH genotyping of CMV in DBS were developed. Validation of the 
assays with 39 CMV-positive plasma samples of transplant recipients and 21 urine 
specimens of congenitally infected newborns was successful in genotyping 100% of 
the samples, with gB1 and gB3 being the most prevalent genotypes. Multiple gB and 
gH genotypes were detected in 36% and 33% of the plasma samples, respectively. 
One urine sample from a newborn with symptomatic congenital CMV was positive 
for gB1 and gB2. DBS of congenitally infected newborns (n = 41) were tested using 
9 μl of dried blood, and genotypes were detected in 81% (gB) and 73% (gH) of 
the samples, with gB3 being the most prevalent genotype. No clear association of 
specific genotypes with clinical outcome was observed. In conclusion, the CMV gB 
and gH PCR assays were found to be rapid, sensitive for detecting mixed infections, 
and suitable for direct usage on DBS. These assays are efficient tools for genotyping 
of CMV in DBS of congenitally infected newborns. 
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Cytomegalovirus (CMV) is the most common cause of congenital infection worldwide 
and an important viral pathogen affecting immunocompromised patients.1,2 Both in 
congenitally infected newborns and in immunocompromised patients, genotyping of 
CMV has been used to study potential differences in pathogenicity of specific strains. 
However, few authors describe a correlation between specific CMV genotypes 
and severity of disease.3-6 More important, genotyping of CMV has enabled the 
discrimination of reactivation of latent virus from reinfection with new CMV strains 
in transplant patients, allowing a better definition of donor-to-recipient transmission 
patterns.7 Congenital CMV infections mainly result from recurrent infections among 
pregnant women8, comprising both reactivation and reinfection. The discrimination 
of reactivation from reinfection may give insight into the mother-to-fetus transmission 
pattern and the possible associations with the outcome of congenital CMV infections.
Genotyping of CMV has mainly focused on envelope glycoproteins gB (UL55) and 
gH (UL75), which play a role in virus entry and are major targets for neutralizing 
antibody response. The most frequently used methods for genotyping of CMV are 
nucleotide sequence analysis9 and restriction fragment length polymorphism of 
PCR products.10,11 Recently, real-time PCR-based assays have been used for rapid 
detection and quantification of CMV gB and gH genotypes.7,12-14 However, they 
have mainly been applied to plasma or other high-volume samples. Also, deep-
sequencing-based methods, sensitive in the detection of genotype mixtures with very 
low ratios, required a large input of CMV genomes.15 Studies on genotyping of CMV in 
dried blood spots (DBS) are rare16,17 and are hampered by the small amount of dried 
blood (50 μl per spot) available. In this study, two multiplex real-time PCR assays for 
rapid gB and gH genotyping of CMV were developed and applied to DBS obtained 
from congenitally infected neonates. 
materials and methods 
Plasma samples of immunocompromised patients 
A total of 39 CMV DNA-positive plasma samples (loads, ≥1,000 copies/ml) were 
randomly selected from the database of the Department of Medical Microbiology of 
the Leiden University Medical Center (time period, 2009 to 2011). The samples were 
from immunocompromised patients (median age, 50 years; range, 7 to 78 years): 
26 stem cell transplant patients (of whom 22 were allogeneic), 11 kidney transplant 
patients, and 2 liver transplant patients (median CMV DNA load of 25,000 copies/
ml; range, 1,000 to 25,000,000 copies/ml). The pretransplant donor/recipient (D/R) 
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CMV serostatus was distributed as follows: stem cell transplant patients, D+/R+ (n = 
18), D-/R+ (n = 3), D+/R- (n = 1), and D-/R- (n = 1); kidney transplant patients, D+/R+ 
(n = 10), D-/R+ (n = 3), and D+/R- (n = 5); and liver transplant patient, D-/R+ (n = 1) 
(D/R serostatus was not available for 5 patients). 
urine samples from newborns with congenital Cmv 
Urine samples with control gB1 to gB4 strains (determined by means of restriction 
fragment length polymorphism16) were kindly provided by Maria Barbi, Department of 
Public Health-Microbiology-Virology, University of Milan, Milan, Italy. Furthermore, 21 
CMV culture-positive urine samples from congenitally infected newborns (sampled 
within 3 weeks after birth) were derived from the database of the Department 
of Virology, Erasmus Medical Center, Rotterdam, the Netherlands (n = 19; time 
period, 2000 to 2011), and the Department of Medical Microbiology of the Leiden 
University Medical Center (n = 2; time period, 2009 to 2011), irrespective of clinical 
characteristics at birth (median CMV DNA load, 100,000 copies/ml; range, 4,000 to 
20,000,000 copies/ml). No clinical data were available for the congenitally infected 
newborns tested and the CMV serostatus of the mother. 
dried blood spots (dbs) from newborns with congenital Cmv 
A total of 41 DBS from newborns with congenital CMV infection were obtained from 
earlier studies (median CMV DNA load of 5,000 copies/ml whole blood; range, 
<1,000 to 800,000 copies/ml). Nine of the 41 newborns participated in the previously 
described DECIBEL study, which included infants with permanent bilateral hearing 
impairment (≥40 dB in the better ear) at the age of 3 to 5 years (median CMV DNA 
load of 32,000 copies/ml whole blood).18 Clinical data included symptoms at birth, 
developmental score, and severity of hearing loss. The remaining 32 CMV-positive 
DBS were derived from a prevalence study in which a random selection of DBS 
from the Netherlands (2007) was tested for CMV DNA (median load of 5,000 copies/
ml whole blood).19 Due to the anonymization of the samples, no clinical data were 
available from these 32 newborns. 
dna extraction from plasma and urine samples 
Nucleic acids from plasma samples were extracted using the Cobas AmpliPrep total 
nucleic acid kit. Nucleic acids from urine samples were extracted on the MagNA Pure 
LC using the total nucleic acid isolation kit and high performance kit (both from Roche 
Diagnostics, Almere, the Netherlands). The input volumes were 350 μl plasma and 
200 μl urine, and output volumes were 100 μl. 
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dna extraction from dbs 
DNA was extracted from DBS using the QIAamp DNA minikit according to the 
protocol for isolation of total DNA from FTA and Guthrie cards (Qiagen, Hilden, 
Germany). Sample input per well was 3 punches each measuring 3.2 mm in diameter, 
corresponding with approximately 9 μl dried blood per well. DBS were punched using 
an automated plate punch type 1296-071 (Perkin Elmer-Wallac, Zaventem, Belgium), 
with a negative-control punch between each sample. Output volume was 100 μl. DNA 
extraction was followed by CMV amplification in duplicate (DECIBEL DBS samples) 
or triplicate (DBS from prevalence study). 
Cmv gb-and gh-specific primers and probes 
For the selection of primers and probes, an alignment of CMV gB and gH gene 
sequences available in GenBank was made using the AlignX program (Vector NTI 
Advance 11; Invitrogen). The accession numbers of gB and gH sequences that 
were used were as follows: CMV gB genotype 1, M60929, EF999921, GQ466044, 
GQ221974, AY446894, U66425, GQ121041, and FJ616285; gB genotype 2, 
GQ221975, X17403, FJ527563, BK000394, X04606, M60931, and M60932; gB 
genotype 3, M60934, M85228, and M60933; gB genotype 4, M60926 and M60924; 
CMV gH genotype 1, AB275152, AB275255, AJ239007, BK000394, EF999921, 
FJ527563, GQ396663, GQ466044, GU179290, and X17403; gH genotype 2, 
AB275156, AY446894, FJ616285, GQ121041, GQ221973, GQ396662, GU179291, 
and M94233. Subsequently, specific primers and probes were designed for efficient 
amplification of multiple genotypes in one reaction, supported by the software 
package Beacon Designer 7.91 (Premier Biosoft International, Palo Alto, CA). The 
sequences of primers and probes are summarized in Tables 1 (gB) and 2 (gH). The 
gB3-specific probe was published by Gorzer et al.13 
Quantitative Cmv real-time PCr 
In the sensitivity analysis of the newly developed assays, our diagnostic real-time 
PCR was used to determine the CMV DNA load of the samples. Amplification of a 
126-bp fragment from the CMV immediate-early antigen region was performed using 
an internally controlled quantitative real-time PCR as described previously.20,21 
Quantification was performed using a dilution series of titrated CMV (strain AD169; 
Advanced Biotechnologies Inc., Columbia, MD) as an external standard. 
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multiplex Cmv gb1 to gb4 and gh1 and gh2 real-time PCr assays
CMV gB1 to gB4 and gH1 and gH2 specific DNA amplification was performed using 
two multiplex real-time PCR assays. Each multiplex assay contained 10 μl of DNA 
extract, 25 μl HotStar Master mix (Qiagen, Hilden, Germany), and final concentrations 
of 0.3 μM (all) specific forward and reverse primers (gB1 to gB4 or gH1 and gH2) 
(Tables 1 and 2), 0.2 μM (all) specific probes (gB1, gB2, gB3, gB4A, and gB4B or gH1 
and gH2) (Tables 1 and 2), and 4.5 mM MgCl2. Template denaturation and activation 
of HotStar Taq DNA polymerase for 15 min at 95°C were followed by 45 cycles of 
denaturation at 95°C for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 
30 s. The PCR assays were carried out in a CFX96 real-time PCR detection system 
(Bio-Rad, Veenendaal, the Netherlands). 
table 1  Sequences of primers and probes for cytomegalovirus gB genotyping 
Product 
Primer/probe name Sequence (5’–3’) size (bp) 
gB1 forward TCA CCA TTC CTC TCR TAC GAC 93 
gB1 reverse CAC CAT GGC TGA CCG TTT GG 
gB1 TaqMan probe FAM-TCT GCT GCT CAY TCT CGA 
TCC GGT TC–BHQ-1 
gB2 forward CTT TAA GGT ACG GGT CTA CCA A 152 
gB2 reverse GAA CTG TAG CAT TGG GCA AAC T 
gB2 TaqMan probe YAK-CTA CGC TTA CAT CYA CAC 
CAC TTA TCT GC–BHQ-1 
gB3 forward CCG GTG TGA ACT CCA CGC G 73 
gB3 reverse GAT TCG CTT TCA RGY GAC AGG 
gB3 XS probe (15)a TXR-TCG TAT TGC CCG TAC T–BHQ-2 
gB4 forward TCG TGC AAC TTC TAC TCA TAA TG 85 
gB4 reverse CGT TAC GCG TTG AGA GGA GAT 
gB4 TaqMan probe A Q705-AAA CCA TAC TTC TCA TAC 
GAC GTC TGC TC–BHQ-2 
gB4 TaqMan probe B Q705-AAG CCA TAT TTC TCG TAC 
AAC GTC TGC TC–BHQ-2 
a XS probe, minor groove binding replacement probe.
Abbreviations: FAM, 6-carboxyfluorescein; BHQ, black hole quencher; YAK, Yakima Yellow; TXR, 
Texas Red.
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table 2  Sequences of primers and probes for cytomegalovirus gH genotyping 
                                                                                                                         Product 
Primer/probe name Sequence (5’-3’) size (bp) 
gH1 forward GAG ACT TAA CAC CTA CGC AT 181 
gH1 reverse CGA TCC CTT CCA GTC G 
gH1 TaqMan probe FAM-GGG TCA GCA GCC CAC CAC 
C–BHQ-1 
gH2 forward TGG ACA CGA TCT ACT ATT CA 134 
gH2 reverse TGT CGT CGT CTA TGG AC 
gH2 TaqMan probe YAK-CAC CGT CAC ACC TTG TTT 
GCA CC–BHQ-1 
Abbreviations: FAM, 6-carboxyfluorescein; BHQ, black hole quencher; YAK, Yakima Yellow. 
results 
analytical sensitivity 
The analytical sensitivities of the multiplex real-time CMV gB and gH PCR assays were 
determined using 10-fold dilution series of CMV-positive plasma samples with single 
genotypes gB1, gB2, gB3, and gB4 and gH1 and gH2, respectively. Comparison of 
the multiplex CMV gB and gH PCR assays with the diagnostic CMV PCR21 resulted in 
equal detection limits of approximately 250 copies/ml. 
Comparison of the results of the multiplex gB and gH PCR assays with the monoplex 
gB and gH PCR assays, testing the above-mentioned plasma samples, revealed 
comparable cycle threshold values (<1.5 cycle threshold difference) (data not 
shown). 
Furthermore, plasma mixtures of CMV gB1-gB2, gB1-gB3, gB1-gB4, gB2-gB3, gB2-
gB4, gB3-gB4, and gH1-gH2 were prepared, each combination in different ratios. 
The detection limit of the minor variant in these mixtures was approximately 250 CMV 
DNA copies/ml, which could be detected in mixtures with a proportion of the minor 
variant down to about 0.2% (data not shown). 
The analytical sensitivity of the multiplex real-time CMV gB and gH PCR assays for 
DBS was determined using DBS with a broad range of CMV DNA loads (range, 50 to 
20,000 copies/ml whole blood) (the Quality Control for Molecular Diagnostics (QCMD) 
CMV DBS 2011 panel and DBS samples prepared in-house with CMV-positive blood 
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from transplant recipients [20]). Comparison of the multiplex CMV gB and gH PCR 
assays with the diagnostic CMV PCR21 using DBS resulted in equal detection limits of 
approximately 1,000 to 2,500 copies/ml (data not shown). 
Good precision was observed in the multiplex real-time CMV gB and gH PCR assays. 
Replicates of DNA from each genotype (gB1 to gB4 and gH1 and gH2) run on 
different days resulted in a mean difference of cycle threshold values of 0.6 ± 0.4 
(standard deviation [SD]) (range, 0 to 1.5) (data not shown). 
analytical specificity
The multiplex real-time CMV gB and gH PCR assays were negative for plasma and 
urine samples with noncorresponding gB1 to gB4 and gH1 and gH2 genotypes; no 
cross-reactions were observed. Furthermore, the assays tested negative for plasma 
samples with the genomes of Epstein-Barr virus, herpes simplex virus, and varicella-
zoster virus. 
detection of Cmv gb and gh genotypes in plasma samples of immuno-
compromised patients 
A random selection of CMV DNA-positive plasma samples of 39 transplant patients 
was tested using the multiplex CMV gB and gH PCR assays (Fig. 1). All 39 samples 
could be assigned to gB and gH genotypes (median cycle threshold value, 32; range, 
24 to 42). The most prevalent genotypes were gB1 (54%; 21/39) and gB3 (41%; 
16/39). 
Multiple CMV gB and gH genotypes were detected in 36% (14/39) and 33% (13/39), 
respectively, of the CMV-positive plasma samples (median CMV DNA load of 40,000 
copies/ml versus 25,000 copies/ml in single infections). Of these mixed gB infections, 
28% (11/39) were double and 8% (3/39) were triple infections. Double gB genotype 
infections included gB1-gB2 (n = 4), gB1-gB3 (n = 4), gB2-gB3 (n = 2), and gB1-
gB4 (n = 1). Triple gB/gH genotype infections included gB1-gB3-gB4/gH1-gH2 (n 
= 1 stem cell transplant, D+/R+), gB2-gB3-gB4/gH1-gH2 (n = 1 kidney transplant, 
D-/R+), and gB1-gB2-gB3/gH1-gH2 (n = 1 kidney transplant, D-/R+). The pretransplant 
CMV serostatuses of single compared to mixed gB infections were not significantly 
different (single gB: D+/R+ , n = 12; D-/R+ , n = 5; D+/R- , n = 5; mixed gB: D+/R+ , 
n = 8; D-/R+ , n = 2; D+/R- , n = 1; D-/R- , n = 1). 
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Comparison of the results of the multiplex gB and gH PCR
assays with the monoplex gB and gH PCR assays, testing the
above-mentioned plasma samples, revealed comparable cycle
threshold values (1.5 cycle threshold difference) (data not
shown).
Furthermore, plasma mixtures of CMV gB1-gB2, gB1-gB3,
gB1-gB4, gB2-gB3, gB2-gB4, gB3-gB4, and gH1-gH2 were pre-
pared, each combination in different ratios. The detection limit of
the minor variant in these mixtures was approximately 250 CMV
DNA copies/ml, which could be detected in mixtures with a pro-
portion of the minor variant down to about 0.2% (data not
shown).
The analytical sensitivity of the multiplex real-time CMV gB
and gH PCR assays for DBS was determined using DBS with a
broad range of CMV DNA loads (range, 50 to 20,000 copies/ml
whole blood) (the Quality Control for Molecular Diagnostics
[QCMD] CMV DBS 2011 panel and DBS samples prepared in-
house with CMV-positive blood from transplant recipients [20]).
Comparison of the multiplex CMV gB and gH PCR assays with the
diagnostic CMV PCR (20) using DBS resulted in equal detection
limits of approximately 1,000 to 2,500 copies/ml (data not
shown).
Good precision was observed in the multiplex real-time CMV
gB and gH PCR assays. Replicates of DNA from each genotype
(gB1 to gB4 and gH1 and gH2) run on different days resulted in a
mean difference of cycle threshold values of 0.6  0.4 (standard
deviation [SD]) (range, 0 to 1.5) (data not shown).
Analytical specificity. The multiplex real-time CMV gB and
gH PCR assays were negative for plasma and urine samples with
noncorresponding gB1 to gB4 and gH1 and gH2 genotypes; no
cross-reactions were observed. Furthermore, the assays tested
negative for plasma samples with the genomes of Epstein-Barr
virus, herpes simplex virus, and varicella-zoster virus.
Detection of CMV gB and gH genotypes in plasma samples of
immunocompromised patients. A random selection of CMV
DNA-positive plasma samples of 39 transplant patients was tested
using the multiplex CMV gB and gH PCR assays (Fig. 1). All 39
samples could be assigned to gB and gH genotypes (median cycle
threshold value, 32; range, 24 to 42). The most prevalent geno-
types were gB1 (54%; 21/39) and gB3 (41%; 16/39).
Multiple CMV gB and gH genotypes were detected in 36%
(14/39) and 33% (13/39), respectively, of the CMV-positive
plasma samples (median CMV DNA load of 40,000 copies/ml
versus 25,000 copies/ml in single infections). Of these mixed gB
infections, 28% (11/39) were double and 8% (3/39) were triple
infections. Double gB genotype infections included gB1-gB2 (n 
4), gB1-gB3 (n  4), gB2-gB3 (n  2), and gB1-gB4 (n  1). Triple
gB/gH genotype infections included gB1-gB3-gB4/gH1-gH2 (n 
1 stem cell transplant, D/R), gB2-gB3-gB4/gH1-gH2 (n  1
kidney transplant, D/R), and gB1-gB2-gB3/gH1-gH2 (n  1
kidney transplant, D/R). The pretransplant CMV serostatuses
of single compared to mixed gB infections were not significantly
different (single gB: D/R, n  12; D/R, n  5; D/R, n  5;
mixed gB: D/R, n  8; D/R, n  2; D/R, n  1; D/R,
n  1).
Detection of CMV gB and gH genotypes in urine samples
from newborns with congenital CMV. Urine samples obtained
from 21 newborns with congenital CMV infection were tested
using the multiplex real-time gB and gH assays (Fig. 2). A geno-
type could be assigned to all urine samples, with CMV gB1 (48%,
10/21), gB3 (29%, 6/21), and gH2 (62% 13/21) being the most
prevalent genotypes (median cycle threshold value, 27; range, 21
to 36). One urine sample of a newborn with symptomatic congen-
ital CMV was positive for both gB1 and gB2 (and gH2), indicating
a mixed congenital infection. Clinical data revealed that this new-
born was severely symptomatic at birth, with microcephaly, hy-
perbilirubinemia, thrombocytopenia, petechiae, and hepato-
splenomegaly, and at a later age was diagnosed with mental
retardation and hearing impairment. No clinical data were avail-
able from the other congenitally infected newborns tested.
Detection of CMV gB and gH genotypes in dried blood spots.
Dried blood spots (DBS) from 41 newborns with congenital CMV
infection were tested in the multiplex real-time CMV gB and gH
assays (Fig. 3). In total, 33 (81%) and 30 (73%) of the 41 DBS
could be assigned a gB and gH genotype, respectively (median
cycle threshold value, 36; range, 29 to 39). The most prevalent
genotype was gB3 (32%, 13/41). The gH genotypes were distrib-
uted evenly.
Clinical data were known for 9 of the 41 newborns and are
shown in Table 3. These children had permanent bilateral hearing
impairment at the age of 3 to 5 years, since that was an inclusion
criterion for participation in the DECIBEL study from which they
were recruited (22). A genotype could be assigned to 7 of the 9
(78%) DBS from children with hearing impairment. Genotype
gB1 was not detected in DBS of these infants with hearing impair-
ment. All 3 newborns with symptoms at birth had CMV loads of
200,000 copies/ml or higher and were genotyped as gB3/gH2, gB2/
FIG. 1. Distribution of CMV gB and gH genotypes (%) detected in CMV
DNA-positive plasma samples of immunocompromised patients (n  39).
Note that the percentages add up to more than 100% due to the detection of
multiple gB and gH genotypes in 36% (14/39) and 33% (13/39), respectively,
of the CMV-positive plasma samples, with double and triple gB types in 28%
(11/39) and 8%, respectively, of the samples. Error bars represent the 95%
confidence interval. CMV, cytomegalovirus.
FIG. 2. Distribution of CMV gB and gH genotypes (%) detected in CMV-
positive urine samples (3 weeks of age) of congenitally infected newborns
(n  21). Error bars represent the 95% confidence interval.
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figure 1  Distribution of CMV gB and gH genotypes (%) detected in CMV DNA-positive plasma 
samples of immunocompromised patients (n = 39). Note that the percentages add 
up to more than 100% due to the detection of multiple gB and gH genotypes in 
36% (14/39) and 33% (13/39), respectively, of the CMV-positive plasma samples, 
with double and triple gB types in 28% (11/39) and 8%, respectively, of the samples. 
Error bars represent the 95% confidence interval. CMV, cytomegalovirus. 
detection of Cmv gb and gh genotypes in urine samples from newborns with 
congenital Cmv
Urine samples obtained from 21 newborns with congenital CMV infection were 
tested using the multiplex real-time gB and gH assays (Fig. 2). A genotype could 
be assigned to all urine samples, with CMV gB1 (48%, 10/21), gB3 (29%, 6/21), and 
gH2 (62% 13/21) being the most prevalent genotypes (median cycle threshold value, 
27; range, 21 to 36). One urine sample of a newborn with symptomatic congenital 
CMV was positive for both gB1 and gB2 (and gH2), indicating a mixed congenital 
infection. Clinical data revealed that this newborn was severely sympto atic at 
birth, with microcephaly, hyperbilirubinemia, thrombocytopenia, petechiae, and 
hepatosplenomegaly, and at a later age was diagnosed with mental retardation 
and hearing impairment. No clinical data were available from the other congenitally 
infected newborns tested. 
Comparison of the results of the multiplex gB and gH PCR
assays with the monoplex gB and gH PCR assays, testing the
above-mentioned plasma samples, revealed comparable cycle
thresh ld values (1.5 cycle threshold difference) (data not
shown).
Furthermore, plasma mixtures of CMV gB1-gB2, gB1-gB3,
gB1-gB4, gB2-gB3, gB2-gB4, gB3-gB4, and gH1-gH2 were pre-
pared, each combination in different ratios. The detection limit of
the minor variant in these mixtures was approximately 250 CMV
DNA copies/ml, which could be detected in mixtures with a pro-
portion of the minor varia t down to about 0.2% (data not
shown).
The analytical se sitivity f the multiplex real-time CMV gB
and gH PCR assays for DBS was determined using DBS with a
road range of CMV DNA loads (range, 50 to 20,000 copies/ml
whole blood) (the Quality Control for Molecular Diagnostics
[QCMD] CMV DBS 2011 panel and DBS samples prepared in-
house with CMV-positive blood from transplant recipients [20]).
Comparison of the multiplex CMV gB and gH PCR assays with the
diagnostic CMV PCR (20) using DBS resulted in equal detection
limits of approximately 1,000 to 2,500 copies/ml (data not
shown).
Good precision was observed in the multiplex real-time CMV
gB and gH PCR assays. Replicates of DNA from each genotype
(gB1 to gB4 and gH1 and gH2) run on different days resulted in a
mean difference of cycle threshold values of 0.6  0.4 (standard
deviation [SD]) (range, 0 to 1.5) (data not shown).
Analytical specificity. The multiplex real-time CMV gB and
gH PCR assays were negative for plasma and urine samples with
noncorresponding gB1 to gB4 and gH1 and gH2 genotypes; no
cross-reactions ere observed. Furthermore, the assays tested
negative for plasma samples with the genomes of Epstein-Barr
virus, herpes simplex virus, and varicella-zoster virus.
Detection of CMV gB and gH genotypes in plasma samples of
immunocompromised patients. A random selection of CMV
DNA-positive plasma samples of 39 transplant patients was tested
using the multiplex CMV gB and gH PCR assays (Fig. 1). All 39
sa ples could be assigned to gB and gH genotypes (median cycle
threshold value, 32; range, 24 to 42). The most prevalent geno-
types were gB1 (54%; 21/39) and gB3 (41%; 16/39).
Multiple CMV gB and gH genotypes were detected in 36%
(14/39) and 33% (13/39), respectively, of the CMV-positive
plasma samples (median CMV DNA load of 40,000 copies/ml
versus 25,000 copies/ml in single infections). Of these mixed gB
infections, 28% (11/39) were double and 8% (3/39) were triple
infections. Double gB genotype infections included gB1-gB2 (n 
4), gB1-gB3 (n  4), gB2-gB3 (n  2), and gB1-gB4 (n  1). Triple
gB/gH genotype infections included gB1-gB3-gB4/gH1-gH2 (n 
1 stem cell transplant, D/R), gB2-gB3-gB4/gH1-gH2 (n  1
kidney transplant, D/R), and gB1-gB2-gB3/gH1-gH2 (n  1
kidney transplant, D/R). The pretransplant CMV serostatuses
of single compared to mixed gB infections were not significantly
different (single gB: D/R, n  12; D/R, n  5; D/R, n  5;
mixed gB: D/R, n  8; D/R, n  2; D/R, n  1; D/R,
n  1).
Detection of CMV gB and gH genotypes in urine samples
from newborns with congenital CMV. Urine samples obtained
from 21 newborns with congenital CMV infection were tested
using the multiplex real-time gB and gH assays (Fig. 2). A geno-
type could be assigned to all urine samples, with CMV gB1 (48%,
10/21), gB3 (29%, 6/21), and gH2 (62% 13/21) being the most
prevalent genotypes (median cycle threshold value, 27; range, 21
to 36). One urine sample of a newborn with symptomatic congen-
ital CMV was positive for both gB1 and gB2 (and gH2), indicating
a mixed congenital infection. Clinical data revealed that this new-
born was severely symptomatic at birth, with microcephaly, hy-
perbilirubinemia, thrombocytopenia, petechiae, and hepato-
splenomegaly, and at a later age was diagnosed with mental
retardation and hearing impairment. No clinical data were avail-
able from the other congenitally infected newborns tested.
Detection of CMV gB and gH genotypes in dried blood spots.
Dried blood spots (DBS) from 41 newborns with congenital CMV
infection were tested in the multiplex real-time CMV gB and gH
assays (Fig. 3). In total, 33 (81%) and 30 (73%) of the 41 DBS
could be assigned a gB and gH genotype, respectively (median
cycle threshold value, 36; range, 29 to 39). The most prevalent
genotype was gB3 (32%, 13/41). The gH genotypes were distrib-
uted evenly.
Clinical data were known for 9 of the 41 newborns and are
shown in Table 3. These children had permanent bilateral hearing
impairment at the age of 3 to 5 years, since that was an inclusion
criterion for participation in the DECIBEL study from which they
were recruited (22). A genotype could be assigned to 7 of the 9
(78%) DBS from children with hearing impairment. Genotype
gB1 was not detected in DBS of these infants with hearing impair-
ment. All 3 newborns with symptoms at birth had CMV loads of
200,000 copies/ml or higher and were genotyped as gB3/gH2, gB2/
FIG. 1. Distribution of CMV gB and gH genotypes (%) detected in CMV
DNA-positive plasma samples of immunocompromised patients (n  39).
Note that the percentages add up to more than 100% due to the detection of
multiple gB and gH genotypes in 36% (14/39) and 33% (13/39), respectively,
of th CMV-positive plasma samples, with double and triple gB types in 28%
(11/39) and 8%, respectively, of the samples. Error bars represent the 95%
confidence interval. CMV, cytomegalovirus.
FIG. 2. Distribution of CMV gB and gH genotypes (%) detected in CMV-
positive urine samples (3 weeks of age) of congenitally infected newborns
(n  21). Error bars represent the 95% confidence interval.
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Comparison of the results of the multiplex gB and gH PCR
assays with the monoplex gB and gH PCR assays, testing the
above-mentioned plasma samples, revealed comparable cycle
threshold values (1.5 cycle threshold difference) (data not
shown).
Furthermore, plasma mixtures of CMV gB1-gB2, gB1-gB3,
gB1-gB4, gB2-gB3, gB2-gB4, gB3-gB4, and gH1-gH2 were pre-
pared, each combination in different ratios. The detection limit of
the minor variant in these mixtures was approximately 250 CMV
DNA copies/ml, which could be detected in mixtures with a pro-
portion of the minor variant down to about 0.2% (data not
shown).
The analytical sensitivity of the multiplex real-time CMV gB
and gH PCR assays for DBS was determined using DBS with a
broad range of CMV DNA loads (range, 50 to 20,000 copies/ml
whole blood) (the Quality Control for Molecular Diagnostics
[QCMD] CMV DBS 2011 panel and DBS samples prepared in-
house with CMV-positive blood from transplant recipients [20]).
Comparison of the multiplex CMV gB and gH PCR assays with the
diagnostic CMV PCR (20) using DBS resulted in equal detection
limits of approximately 1,000 to 2,500 copies/ml (data not
shown).
Good precision was observed in the multiplex real-time CMV
gB and gH PCR assays. Replicates of DNA from each genotype
(gB1 to gB4 and gH1 and gH2) run on different days resulted in a
mean difference of cycle threshold values of 0.6  0.4 (standard
deviation [SD]) (range, 0 to 1.5) (data not shown).
Analytical specificity. The multiplex real-time CMV gB and
gH PCR assays were negative for plasma and urine samples with
noncorresponding gB1 to gB4 and gH1 and gH2 genotypes; no
cross-reactions were observed. Furthermore, the assays tested
negative for plasma samples with the genomes of Epstein-Barr
virus, herpes simplex virus, and varicella-zoster virus.
Detection of CMV gB and gH genotypes in plasma samples of
immunocompromised patients. A random selection of CMV
DNA-positive plasma samples of 39 transplant patients was tested
using the multiplex CMV gB and gH PCR assays (Fig. 1). All 39
samples could be assigned to gB and gH genotypes (median cycle
threshold value, 32; range, 24 to 42). The most prevalent geno-
types were gB1 (54%; 21/39) and gB3 (41%; 16/39).
Multiple CMV gB and gH genotypes were detected in 36%
(14/39) and 33% (13/39), respectively, of the CMV-positive
plasma samples (median CMV DNA load of 40,000 copies/ml
versus 25,000 copies/ml in single infections). Of these mixed gB
infections, 28% (11/39) were double and 8% (3/39) were triple
infections. Double gB genotype infections included gB1-gB2 (n 
4), gB1-gB3 (n  4), gB2-gB3 (n  2), and gB1-gB4 (n  1). Triple
gB/gH genotype infections included gB1-gB3-gB4/gH1-gH2 (n 
1 stem cell transplant, D/R), gB2-gB3-gB4/gH1-gH2 (n  1
kidney transplant, D/R), and gB1-gB2-gB3/gH1-gH2 (n  1
kidney transplant, D/R). The pretransplant CMV serostatuses
of single compared to mixed gB infections were not significantly
different (single gB: D/R, n  12; D/R, n  5; D/R, n  5;
mixed gB: D/R, n  8; D/R, n  2; D/R, n  1; D/R,
n  1).
Detection of CMV gB and gH genotypes in urine samples
from newborns with congenital CMV. Urine samples obtained
from 21 newborns with congenital CMV infection were tested
using the multiplex real-time gB and gH assays (Fig. 2). A geno-
type could be assigned to all urine samples, with CMV gB1 (48%,
10/21), gB3 (29%, 6/21), and gH2 (62% 13/21) being the most
prevalent genotypes (median cycle threshold value, 27; range, 21
to 36). One urine sample of a newborn with symptomatic congen-
ital CMV was positive for both gB1 and gB2 (and gH2), indicating
a mixed congenital infection. Clinical data revealed that this new-
born was severely symptomatic at birth, with microcephaly, hy-
perbilirubinemia, thrombocytopenia, petechiae, and hepato-
splenomegaly, and at a later age was diagnosed with mental
retardation and hearing impairment. No clinical data were avail-
able from the other congenitally infected newborns tested.
Detection of CMV gB and gH genotypes in dried blood spots.
Dried blood spots (DBS) from 41 newborns with congenital CMV
infection were tested in the multiplex real-time CMV gB and gH
assays (Fig. 3). In total, 33 (81%) and 30 (73%) of the 41 DBS
could be assigned a gB and gH genotype, respectively (median
cycle threshold value, 36; range, 29 to 39). The most prevalent
genotype was gB3 (32%, 13/41). The gH genotypes were distrib-
uted evenly.
Clinical data were known for 9 of the 41 newborns and are
shown in Table 3. These children had permanent bilateral hearing
impairment at the age of 3 to 5 years, since that was an inclusion
criterion for participation in the DECIBEL study from which they
were recruited (22). A genotype could be assigned to 7 of the 9
(78%) DBS from children with hearing impairment. Genotype
gB1 was not detected in DBS of these infants with hearing impair-
ment. All 3 newborns with symptoms at birth had CMV loads of
200,000 copies/ml or higher and were genotyped as gB3/gH2, gB2/
FIG. 1. Distribution of CMV gB and gH genotypes (%) detected in CMV
DNA-positive plasma samples of immunocompromised patients (n  39).
Note that the percentages add up to more than 100% due to the detection of
multiple gB and gH genotypes in 36% (14/39) and 33% (13/39), respectively,
of the CMV-positive plasma samples, with double and triple gB types in 28%
(11/39) and 8%, respectively, of the samples. Error bars represent the 95%
confidence interval. CMV, cytomegalovirus.
FIG. 2. Distribution of CMV gB and gH genotypes (%) detected in CMV-
positive urine samples (3 weeks of age) of congenitally infected newborns
(n  21). Error bars represent the 95% confidence interval.
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figure 2  Distribution of CMV gB and gH genotypes (%) detected in CMV positive urine 
samples (<3 weeks of age) of congenitally infected newborns (n = 21). Error bars 
represent the 95% confidence interval. 
detection of Cmv gb and gh genotypes i  dried blood spots
Dried bl od spots (DBS) from 41 newborns with congenital CMV infection were tested 
in the multiplex real-time CMV gB and gH assays (Fig. 3). In total, 33 (81%) and 30 
(73%) of the 41 DBS could be assigned a gB and gH genotype, respectively (median 
cycle threshold value, 36; range, 29 to 39). The most prevalent genotype was gB3 
(32%, 13/41). The gH genotypes were distributed evenly. 
Clinical data were known for 9 of the 41 newborns and are shown in Table 3. These 
children had permanent bilateral hearing impairment at the age of 3 to 5 years, since 
that was an inclusion criterion for participation in the DECIBEL study from which they 
were recruited.18 A genotype could be assigned to 7 of the 9 (78%) DBS from children 
with hearing impairment. Genotype gB1 was not detected in DBS of these infants with 
hearing impairment. All 3 newborns with symptoms at birth had CMV loads of 200,000 
copies/ml or higher and were genotyped as gB3/gH2, gB2/ gH1, and gB4/gH1, 
respectively. No clear differences were seen in the gH and gB genotype distributions 
between the CMV-positive DBS from the children with hearing i pairment and the 
DBS from the prevalence study. 






























































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   








   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   























































































































































































































































































































































































































































































































































































































gH1, and gB4/gH1, respectively. No clear differences were seen in
the gH and gB genotype distributions between the CMV-positive
DBS from the children with hearing impairment and the DBS
from the prevalence study.
DISCUSSION
In this study, two multiplex real-time PCR assays were used for
rapid CMV gB and gH genotyping on DBS. Validation of these
gB1- to gB4- and gH1- and gH2-specific PCR assays showed ex-
cellent sensitivity for genotyping plasma samples of immunocom-
promised patients and urine samples of congenitally infected new-
borns. Furthermore, the assays were able to detect a high number
of mixed infections (30%) in CMV-positive plasma samples and
in one urine sample of a severely symptomatic newborn. In DBS of
congenitally infected newborns, using only 9 l of dried blood, a
CMV genotype could be determined in 81% (gB) and 73% (gH),
respectively, of the cases.
Our finding that genotypes gB1 and gB3 were the most preva-
lent genotypes in immunocompromised patients and congenitally
infected infants is in agreement with previous studies assessing the
genotype distribution of CMV (4, 8, 15, 18, 19, 23, 26, 38, 41).
Potential significant variances in genotype distribution found in
different studies are potentially based on geographical distribu-
tion, the population of patients tested, and/or CMV tissue tro-
pism. In our study, no significant differences were found between
the genotype distributions as detected in the urine samples, which
were taken from mainly hospitalized newborns, and the DBS,
which were from a different group of newborns, including a selec-
tion of children with hearing loss at the age of 3 to 5 years. It must
be noted that the number of congenitally infected newborns tested
in our study is small, and therefore, we cannot exclude differences
in genotype distribution. Potential differences might be based on
the population of newborns tested (symptomatology/hearing im-
pairment), and also a slight difference in sensitivity between the
gB1 and gB3 assays cannot be excluded (due to the lack of
genotype-specific standards).
We could detect mixed-genotype infections in 30% of
plasma samples from immunocompromised patients. It must be
mentioned that potential mixed infections with viral loads below
the detection limit could be missed and, therefore, the actual pro-
portion of mixed infections might even be higher. The high pro-
portion of mixed infections detected in our study is comparable to
or exceeds the proportion found in previous studies, with a mixed
genotype detected in 15 to 21% of the (solid organ) transplant
recipients (12, 15, 16, 24, 26). This would suggest that our assays
were at least as sensitive. The risk of competitive amplification of
multiple genotypes by generic primers has been reduced by using
genotype-specific primers and probes. This method was found to
be more sensitive for detecting mixed infections (data not shown).
Furthermore, the high proportion of D/R and stem cell trans-
plant recipients in our study might also contribute to the high
proportion of mixed infections detected, since the highest geno-
type diversity has been found in these populations (14). It has been
demonstrated that the CMV load after transplantation reflects the
sum of relative levels of individual genotypes in time (15). Mixed
CMV genotypes could be detected significantly more often in pa-
tients with higher CMV loads than in patients with lower loads
(26), though the interpretation might be biased by underdetection
of mixed infections with low viral loads. In this way, an association
of mixed infections (and corresponding higher CMV loads) with
clinical outcome has been demonstrated in transplant patients (1,
8, 30).
The occurrence of mixed congenital CMV infections in live
FIG. 3. Distribution of CMV gB and gH genotypes (%) detected in CMV-
positive dried blood spots (DBS) of newborns with congenital CMV (n  41).
Error bars represent the 95% confidence interval. ND, not detected.















1 3 2 4.1 None 59 60–90 dB
2 ND ND 3.3 None 84 40–60 dB
3 4 1 4.9 None 72 90 dB (CI)
4 2 2 3.6 None 68 60–90 dB
5 3 2 5.9 IUGR, microcephaly, seizures 30 90 dB (CI)
6 2 1 5.3 IUGR, petechiae, hepatosplenomegaly, jaundice,
thrombocytopenia
50 90 dB (CI)
7 4 1 5.3 IUGR, jaundice, microcephaly Unknown 90 dB
8 2 1 3.0 None 82 90 dB (CI)
9 ND ND 3.6 Cataract 56 90 dB (CI)
a The general development score is a summary score that provides an overall index of development by including 10 of the most age-discriminating items from each scale of the
Child Development Inventory. The Child Development Inventory is a standardized instrument (parent questionnaire) designed to assess the social development, language
development, and motor development of young children. Higher scores indicate better development.
b Abbreviations: IE, immediate-early antigen; DBS, dried blood spots; gB, glycoprotein B; gH, glycoprotein H; CI, cochlear implant; IUGR, intrauterine growth retardation; ND, not
detected.
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figure 3  Distribution of CMV gB and gH genotypes (%) detected in CMV positive dried blood 
spots (DBS) of newborns with congenital CMV (n = 41). Error bars represent the 
95% confidence interval. ND, not detected. 
discussion 
In this study, two multiplex real-time PCR assays were used for rapid CMV gB and 
gH genotyping on DBS. Validation of these gB1 to gB4 and gH1 and gH2 specific 
PCR assays showed excellent sensitivity for genotyping plasma samples of 
immunocompromised patie ts and urin  samples of congenitally infected newborns. 
Furthermore, the assays were able to detect a high number of mixed infections 
(>30%) in CMV-positive plasma samples and in one urine sample of a severely 
symptomatic newborn. In DBS of congenitally infected newborns, using only 9 μl 
of dried blood, a CMV genotyp  could be determined in 81% (gB) and 73% (gH), 
respectively, of the cases. 
Our finding that genotypes gB1 and gB3 were the most prevalent genotypes in 
immunocompromised patients and congenitally infected infants is in agreement 
with pr vi us studies assessing the genoty e distribution f CMV.13,14,16,22-27 Potential 
signifi ant variances in genotype distribution found in different studies are potentially 
based on geographical distribution, the population of patients tested, and/or CMV 
tissue tropism. In our study, no significant differences were found between the 
genotype distributions as detected in the urine samples, which were taken from mainly 
hospitalized newborns, and the DBS, which were from a different group of newborns, 
including a selection of children with hearing loss at the age of 3 to 5 years. It must be 
noted that the number of congenitally infected newborns tested in our study is small, 
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and therefore, we cannot exclude differences in genotype distribution. Potential 
differences might be based on the population of newborns tested (symptomatology/
hearing impairment), and also a slight difference in sensitivity between the gB1 and 
gB3 assays cannot be excluded (due to the lack of genotype-specific standards). 
We could detect mixed-genotype infections in >30% of plasma samples from 
immunocompromised patients. It must be mentioned that potential mixed infections 
with viral loads below the detection limit could be missed and, therefore, the actual 
proportion of mixed infections might even be higher. The high proportion of mixed 
infections detected in our study is comparable to or exceeds the proportion found 
in previous studies, with a mixed genotype detected in 15 to 21% of the (solid 
organ) transplant recipients.7,12-14,28 This would suggest that our assays were at least 
as sensitive. The risk of competitive amplification of multiple genotypes by generic 
primers has been reduced by using genotype-specific primers and probes. This 
method was found to be more sensitive for detecting mixed infections (data not 
shown). Furthermore, the high proportion of D+/R+ and stem cell transplant recipients 
in our study might also contribute to the high proportion of mixed infections detected, 
since the highest genotype diversity has been found in these populations.15 It has 
been demonstrated that the CMV load after transplantation reflects the sum of relative 
levels of individual genotypes in time.13 Mixed CMV genotypes could be detected 
significantly more often in patients with higher CMV loads than in patients with 
lower loads14, though the interpretation might be biased by underdetection of mixed 
infections with low viral loads. In this way, an association of mixed infections (and 
corresponding higher CMV loads) with clinical outcome has been demonstrated in 
transplant patients. 22,29,30 
The occurrence of mixed congenital CMV infections in live newborns has rarely been 
described before. Though coinfection with multiple gB genotypes has been reported 
in two postpartum mothers of congenitally infected infants26, one report casually 
noted the detection of mixed gB types in urine specimens from two congenitally 
infected newborns31, and another report suggested the presence of multiple US28 
and UL144 genotypes in 8 of 10 autopsy tissues from fatal cases of congenital 
CMV infection.32 The association of mixed infections with severe disease found in 
immunocompromised patients, combined with the single report on frequent mixed 
congenital CMV infections in fetal deaths, may lead to the speculation that congenital 
CMV infections by multiple strains (correlated with higher viral loads) could be 
associated with severe symptomatology and possibly fetal death. Interestingly, very 
recent genome-wide next-generation sequencing of CMV present in urine of three 
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congenitally infected newborns revealed mixed gB and gN genotypes and offered 
strong evidence that CMV exists as a complex mixture of genome variants, with 
intrahost variability (0.2%) comparable to that of many RNA viruses.33 
In agreement with earlier studies that attempted genotyping CMV on DBS, a genotype 
could not be assigned to all strains from positive DBS.16,17 Detection of CMV DNA in 
DBS has been shown to be a challenge 20,34-40 due to the small amount of dried blood 
(50 μl per spot) available. Optimizing the DNA extraction step from the DBS has been 
shown to result in significantly increased sensitivity of CMV DNA detection in DBS. The 
DNA extraction method used in this study has been optimized previously, and despite 
a limited input of only 9 μl dried blood per well, a genotype could be determined in 
approximately 75 to 80% of the DBS samples. Recently developed deep-sequencing 
methods15 have been reported to be highly sensitive because of their ability to detect 
genotype mixtures in low ratios, but they require a large input of approximately 280 
μl of whole blood (30 times more than that used in our assay) containing 50,000 to 
500,000 CMV DNA copies/ml plasma.15 For comparison, the median CMV DNA whole-
blood load in congenitally CMV-infected newborns (symptomatic and asymptomatic 
newborns) has been reported to be 2,300 copies/ml blood.41 
The association of specific CMV genotypes with congenital CMV disease has 
previously been addressed with controversial results and is limited to the association 
of genotype gN4 with long-term sequelae3 and genotype gB3 being found more of-
ten among congenitally CMV-infected than in postnatally infected children.6 In our 
study, no clear association between specific CMV gB and gH genotypes and severity 
of disease was observed, though the sample numbers were low. 
Genotyping of CMV has been shown to enable the discrimination of reactivation 
of latent virus from reinfection with new CMV strains in transplant patients and has 
enabled the assessment of donor-to-recipient transmission patterns.7,28 Data from 
Manuel et al. suggest that, in seropositive transplant recipients, approximately 
half of the infecting CMV strains originate from the organ donor and the other half 
are reactivated endogenous strains.7 Though CMV is more frequently transmitted 
to the fetus in preconceptionally seronegative women, recent calculations have 
demonstrated that the majority of congenitally CMVinfected children in the United 
States are born from seroimmune women.8 This major role of recurrent maternal 
infections emphasizes the convenience of a sensitive and rapid CMV genotyping 
assay, suitable for usage on DBS, in order to compare potentially mixed genotypes 
present in maternal blood with CMV strains in the newborn. The rapid and sensitive 
genotyping tool described in this study may support a better definition of mother-
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to-fetus transmission patterns and may lead to enhanced insight into transmission 
risk and outcome of congenital CMV infections. The implications of this increased 
insight into transmission risks for preventive and therapeutic strategies, including 
CMV vaccine research, may be significant. 
acknowledgment 
We thank Eric Claas (Department of Medical Microbiology, LUMC, Leiden, the 




 1. Gandhi MK, Khanna R. 2004. Human cytomegalovirus: clinical aspects, immune regulation, and 
emerging treatments. Lancet Infect Dis 4:725–738. 
 2.  Kenneson A, Cannon MJ. 2007. Review and meta-analysis of the epidemiology of congenital 
cytomegalovirus (CMV) infection. Rev Med Virol 17:253–276. 
 3.  Pignatelli S, et al. 2010. Cytomegalovirus gN genotypes distribution among congenitally infected 
newborns and their relationship with symptoms at birth and sequelae. Clin Infect Dis 51:33–41. 
 4.  Rosen HR, Corless CL, Rabkin J, Chou S. 1998. Association of cytomegalovirus genotype with graft 
rejection after liver transplantation. Transplantation 66:1627–1631. 
 5.  Shepp DH, et al. 1996. Cytomegalovirus glycoprotein B groups associated with retinitis in AIDS. 
J Infect Dis 174:184–187. 
 6.  Yan H, et al. 2008. Genetic variations in the gB, UL144 and UL149 genes of human cytomegalovirus 
strains collected from congenitally and postnatally infected Japanese children. Arch Virol 153:667–
674. 
 7. Manuel O, et al. 2009. An assessment of donor-to-recipient transmission patterns of human 
cytomegalovirus by analysis of viral genomic variants. 
 8.  Wang C, Zhang X, Bialek S, Cannon MJ. 2011. Attribution of congenital cytomegalovirus infection to 
primary versus non-primary maternal infection. Clin Infect Dis 52:e11–e13. 
 9.  Pignatelli S, Dal MP, Landini MP. 2001. gpUL73 (gN) genomic variants of human cytomegalovirus 
isolates are clustered into four distinct genotypes. J Gen Virol 82:2777–2784. 
 10.  Novak Z, et al. 2008. Cytomegalovirus strain diversity in seropositive women. J Clin Microbiol 46:882–
886. 
 11.  Pignatelli S, et al. 2003. Human cytomegalovirus glycoprotein N (gpUL73-gN) genomic variants: 
identification of a novel subgroup, geographical distribution and evidence of positive selective 
pressure. J Gen Virol 84:647–655. 
 12.  Fan J, et al. 2009. Monitoring of human cytomegalovirus glycoprotein B genotypes using real-time 
quantitative PCR in immunocompromised Chinese patients. J Virol Methods 160:74–77. 
 13.  Gorzer I, et al. 2008. Virus load dynamics of individual CMV-genotypes in lung transplant recipients 
with mixed-genotype infections. J Med Virol 80:1405–1414. 
 14.  Pang X, Humar A, Preiksaitis JK. 2008. Concurrent genotyping and quantitation of cytomegalovirus 
gB genotypes in solid-organ-transplant recipients by use of a real-time PCR assay. J Clin Microbiol 
46:40044010. 
 15.  Gorzer I, Guelly C, Trajanoski S, Puchhammer-Stockl E. 2010. Deep sequencing reveals highly 
complex dynamics of human cytomegalovirus genotypes in transplant patients over time. J Virol 
84:7195–7203. 
 16.  Barbi M, et al. 2001. CMV gB genotypes and outcome of vertical transmission: study on dried blood 
spots of congenitally infected babies. J Clin Virol 21:75–79. 
 17.  Choi KY, et al. 2009. Detection of cytomegalovirus DNA in dried blood spots of Minnesota infants who 
do not pass newborn hearing screening. Pediatr Infect Dis J 28:1095–1098. 
 18.  Korver AM, et al. 2009. DECIBEL study: congenital cytomegalovirus infection in young children with 
permanent bilateral hearing impairment in the Netherlands. J Clin Virol 46(Suppl. 4):S27–S31. 
 19.  de Vries JJ, et al. 2011. Congenital cytomegalovirus (CMV) infection in the Netherlands: birth 
prevalence and risk factors. J Med Virol 83:1777– 1782. 
 20.  De Vries JJC, Claas ECJ, Kroes ACM, Vossen ACTM. 2009. Evaluation of DNA extraction methods 
for dried blood spots in the diagnosis of congenital cytomegalovirus infection. J Clin Virol 46(Suppl. 
4):S37– S42. 
 21.  Kalpoe JS, et al. 2004. Validation of clinical application of cytomegalovirus plasma DNA load 
measurement and definition of treatment criteria by analysis of correlation to antigen detection. 
J Clin Microbiol 42:14981504. 
Rapid genotyping of CMV in dried blood spots by multiplex real-time PCR
129
8
 22.  Coaquette A, et al. 2004. Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised 
patients. Clin Infect Dis 39:155–161. 
 23.  Humar A, Kumar D, Gilbert C, Boivin G. 2003. Cytomegalovirus (CMV) glycoprotein B genotypes and 
response to antiviral therapy, in solid-organ-transplant recipients with CMV disease. J Infect Dis 188: 
581–584. 
 24.  Jin H, Wang X, Li S. 2007. Human cytomegalovirus glycoprotein B genotype correlates with different 
symptoms of infected infants. Intervirology 50:219–223. 
 25.  Lukacsi A, et al. 2001. Human cytomegalovirus gB genotype 1 is dominant in congenital infections 
in South Hungary. J Med Virol 65:537–542. 
 26.  Yamamoto AY, et al. 2007. Human cytomegalovirus glycoprotein B genotypes in Brazilian mothers 
and their congenitally infected infants. J Med Virol 79:1164–1168. 
 27.  Yu ZS, Zou CC, Zheng JY, Zhao ZY. 2006. Cytomegalovirus gB genotype and clinical features in 
Chinese infants with congenital infections. Intervirology 49:281–285. 
 28.  Gorzer I, Kerschner H, Redlberger-Fritz M, Puchhammer-Stockl E. 2010. Human cytomegalovirus 
(HCMV) genotype populations in immunocompetent individuals during primary HCMV infection. 
J Clin Virol 48:100–103. 
 29.  Aquino VH, Figueiredo LT. 2000. High prevalence of renal transplant recipients infected with more 
than one cytomegalovirus glycoprotein B genotype. J Med Virol 61:138–142. 
 30.  Puchhammer-Stockl E, et al. 2006. Emergence of multiple cytomegalovirus strains in blood and lung 
of lung transplant recipients. Transplantation 81:187–194. 
 31.  Shen Z, Shang SQ, Zou CC, Zheng JY, Yu ZS. 2010. The detection and clinical features of human 
cytomegalovirus infection in infants. Fetal Pediatr Pathol 29:393–400. 
 32.  Arav-Boger R, et al. 2002. Polymorphisms of the cytomegalovirus (CMV)-encoded tumor necrosis 
factor-alpha and beta-chemokine receptors in congenital CMV disease. J Infect Dis 186:1057–1064. 
 33. Renzette N, Bhattacharjee B, Jensen JD, Gibson L, Kowalik TF. 2011. Extensive genome-wide 
variability of human cytomegalovirus in congen
 34.  Atkinson C, et al. 2009. Use of stored dried blood spots for retrospective diagnosis of congenital 
CMV. J Med Virol 81:1394–1398. 
 35.  Barbi M, Binda S, Primache V, Luraschi C, Corbetta C. 1996. Diagnosis of congenital cytomegalovirus 
infection by detection of viral DNA in dried blood spots. Clin Diagn Virol 6:27–32. 
 36.  Boppana SB, et al. 2010. Dried blood spot real-time polymerase chain reaction assays to screen 
newborns for congenital cytomegalovirus infection. JAMA 303:1375–1382. 
 37.  De Vries JJC, Vossen ACTM, Kroes ACM. 2010. Screening newborns for congenital cytomegalovirus 
infection. JAMA 304:407. 
 38.  Soetens O, et al. 2008. Evaluation of different cytomegalovirus (CMV) DNA PCR protocols for 
analysis of dried blood spots from consecutive cases of neonates with congenital CMV infections. 
J Clin Microbiol 46: 943–946. 
 39.  Vauloup-Fellous C, et al. 2007. Evaluation of cytomegalovirus (CMV) DNA quantification in dried 
blood spots: retrospective study of CMV congenital infection. J Clin Microbiol 45:3804–3806. 
 40. Yamamoto AY, Mussi-Pinhata MM, Pinto PC, Figueiredo LT, Jorge SM. 2001. Usefulness of blood 
and urine samples collected on filter paper in detecting cytomegalovirus by the polymerase chain 
reaction technique. J Virol Methods 97:159–164. 
 41.  Halwachs-Baumann G, et al. 2002. Human cytomegalovirus load in various body fluids of congenitally 
infected newborns. J Clin Virol 25(Suppl. 3):S81–S87. 

Chapter 9
real-time PCr versus viral culture 
on urine as a gold standard 
in the diagnosis of congenital 
cytomegalovirus infection 
Jutte JC de Vriesa, Annemiek A van der Eijkb, Katja C Wolthersc, 
Lisette G Rusmana, Suzan D Pasb, Richard Molenkampc, Eric C Claasa, 
Aloys CM Kroesa, Ann CTM Vossena 
J Clin Virol 2012 53:167-70 
a Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands 
b Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands 
c Laboratory of Clinical Virology, Department of Medical Microbiology, 





Cytomegalovirus (CMV) infection is the most common cause of congenital 
infection. Whereas CMV PCR has replaced viral culture and antigen detection in 
immunocompromised patients because of higher sensitivity, viral culture of neonatal 
urine is still referred to as the gold standard in the diagnosis of congenital CMV 
infection. 
objective
To compare real-time CMV PCR with shell vial culture on urine in the diagnosis of 
congenital CMV, in a multicenter design. 
study design
A series of neonatal urines (n = 340), received for congenital CMV diagnostics and 
routinely assessed with shell vial CMV culture, was retrospectively tested by real-time 
CMV PCR.
results
The proportion of newborns found to be congenitally infected by real-time CMV PCR 
was 8.2% (28/340, 95%CI 5.6–11.8%), and 7.4% (25/340, 95%CI 4.9–10.8%) by 
rapid culture. When considering rapid culture as reference, real-time PCR was highly 
sensitive (100%), whereas sensitivity of rapid culture was 89.3% when considering 
real-time PCR as reference. 
Conclusions
Our results, supported by analytical and clinical data on CMV DNA detection in 
neonatal urine, suggest enhanced sensitivity of recent PCR techniques when 
compared to viral culture. There is considerable rationale to favor real-time CMV PCR 
as a gold standard in the diagnosis of congenital CMV infection. A large-scale study 
combining both laboratory and clinical data is required to determine the exact time 
frame for sampling of neonatal urine when using real-time PCR. 




Cytomegalovirus (CMV) infection is the most common cause of congenital infection 
and a leading cause of non-genetic sensorineural hearing loss.1–3 For decades, the 
gold standard in the diagnosis of congenital CMV infection has been viral culture of 
urine, sampled within the first 2 or 3 weeks of life.4–6 After this period, CMV present 
in urine may be due to postnatally acquired infection. Meanwhile, PCR assays have 
been optimized by improved extraction and amplification techniques (e.g. real-
time detection and internal controls for PCR inhibition), resulting in highly sensitive 
and specific assays. CMV DNA detection has become a routine diagnostic tool at 
many centers thanks to its rapid, reproducible, automated and quantitative nature.7,8 
Experiments with dilution series have shown that the analytical sensitivity of CMV 
PCR on urine is approximately 100 times higher than both traditional tube and shell 
vial culture.9 In immunocompromised patients, CMV PCR has replaced CMV blood 
culture and pp65 antigen detection because of the higher sensitivity.10–12 Furthermore, 
the clinical sensitivity of CMV PCR on urine of kidney and liver transplant patients is 
higher than viral culture,13–15 with CMV DNA loads in urine being predictive of CMV 
disease.11,16,17Strikingly, in recent guidelines and reviews on congenital CMV, viral 
culture of neonatal urine remains referred to as the gold standard for confirmatory 
diagnosis, while CMV PCR is mentioned as plausible alternative more frequently.18–20 
objective 
The aim of this study was to compare real-time CMV PCR with shell vial culture on 
urine in the diagnosis of congenital CMV, in a multicenter design. 
study design 
urine samples 
A series of neonatal urines, sampled within the first 3 weeks after birth, received for 
congenital CMV diagnostics and routinely assessed with shell vial CMV culture,21 was 
retrospectively tested by real-time CMV PCR.22–24 All CMV culture positive samples 
(n = 25) and a large random selection of CMV culture negative urine samples 
(n = 315) dating from 2001 to 2011, were included in the analysis, irrespective of 
clinical characteristics of the newborns. All diagnostic urine samples were stored 
at −80 °C in the Dutch participating laboratories until tested by real-time PCR at 
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that specific site (Leiden University Medical Center (LUMC, n = 61 urines), Erasmus 
Medical Center Rotterdam (Erasmus MC, n = 199 urines), and Academic Medical 
Center Amsterdam (AMC, n = 80 urines)). Because of ethical reasons, retrospective 
testing was performed anonymously. 
viral culture and real-time PCr 
Shell vial culture and CMV DNA extraction followed by amplification using seal 
herpesvirus (PhHV-1) as internal PCR control were performed as described 
previously.21–24 In short, extraction was performed on the MagnaPure LC station using 
the Total Nucleic Acid Isolation Kit – High Performance Kit (both Roche Diagnostics, 
Almere, The Netherlands) (all sites), and the PCR was carried out using a CFX96 TM 
real-time PCR detection system (BioRad, Veenendaal, The Netherlands) (LUMC)/a 
LightCycler480 PCR system (Roche Diagnostics, Almere, The Netherlands) (Erasmus 
MC, AMC). Amplified was a 126-bp fragment of the CMV immediate early antigen 
region (LUMC, AMC)/a 133-bp fragment of the CMV DNA polymerase gene (Erasmus 
MC). 
statistical analysis 
Sensitivity and specificity were calculated with both rapid CMV culture and real-time 
CMV PCR as reference. Kappa was calculated to assess test agreement. 
results 
In total 340 urine samples of newborns ≤3 weeks of age were included in the 
comparison and were retrospectively tested with CMV real-time PCR (Table 1). The 
proportion of newborns found to be congenitally infected by rapid culture was 7.4% 
(25/340, 95%CI 4.9–10.8%), and 8.2% (28/340, 95%CI 5.6–11.8%) by real-time CMV 
PCR. All culture positive samples were detected by CMV PCR. In contrast, three urine 
samples were detected by real-time PCR that were negative in rapid CMV culture. 
When considering rapid culture as reference, real-time PCR was highly sensitive 
(100%) and specific (99.1%). Sensitivity of rapid culture was 89.3% when considering 
real-time PCR as reference. The CMV DNA load of the three samples with discrepant 
results (median 64,000 copies/ml, range 24,000–210,000 copies/ml, Table 2) was 
lower than the load of the 25 culture-positive samples (median 260,000 copies/ml, 
range 4400–95,000,000 copies/ml). These three urines were sampled at day 10, 17 
and 17 of age, respectively, whereas the median time of sampling of the 25 culture-
positive samples was 3 days (range 0–11 days). Additional testing of the discrepant 
Real-time PCR versus viral culture on urine in the diagnosis of congenital CMV
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samples by repeated extraction and amplification of a different target (gB) gene (at a 
different participating center) yielded confirmatory positive PCR results.
table 1  Comparison of internally controlled real-time PCR with shell vial culture of urine 
samples from newborns (n = 340) in the diagnosis of congenital CMV infection. 
Real-time CMV PCR 
Positive Negative Total 
Rapid CMV culture 
Positive 25 0 25 (7.4%) 
Negative 3 312 315 
Total 28 (8.2%) 312 340 
Reference: real-time PCR 
Sensitivity culture (95% CI) 89.3% (70.6–97.2%) 
Specificity culture (95% CI) 100% (98.5–100%) 
Reference: rapid CMV culture 
Sensitivity PCR (95% CI) 100% (83.4–100%) 
Specificity PCR (95% CI) 99.1% (97.0–99.8%) 
Kappa (95% CI) 0.94 (0.87–1)
table 2  CMV DNA load and time of sampling of the urines with discrepant test results. 
Rapid CMV 
culture 
Real-time CMV PCR 
(copies CMV DNA/ml) 
Time of urine sampling 
(days after birth) 
Negative Positive (24,000) 17 
Negative Positive (64,000) 17
Negative Positive (210,000) 10
discussion 
In our multicenter comparison, CMV was more frequently detected in urine samples 
of newborns by real-time PCR than by rapid culture, which is still referred to as the 
reference method for diagnosing congenital CMV infection. These discrepant test 
results theoretically can be attributed to either false negative viral culture results, or 
false positive real-time PCR results. False negative viral culture results have been 
described both in experimental setting9 and in clinical setting, testing urine samples 
of (immunocompromised) patients.13–15,24 Loss of viable CMV particles implicated in 
false negative culture results may be caused by transport at room temperature25 and 
antiviral therapy. In our analysis, two of the three discrepant samples had transport 
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times of >1 day. Concerning potential false positive PCR results, the use of real-time 
PCR procedures (which are less prone to contamination than nested procedures), 
the use of negative controls and confirmatory testing of the discrepant samples, 
render false positive CMV DNA detection in our study highly unlikely. Hence, false 
negative results in the viral culture assays constitute the most likely explanation for 
the discrepant test results in our study. 
Previous studies comparing viral culture with CMV PCR on urine as initial or screening 
assay in the diagnosis of congenital CMV were reviewed, and sensitivity and specificity 
was calculated with both rapid CMV culture and real-time CMV PCR as reference 
(Table 3). Assuming PCR as reference, sensitivity of viral culture ranged from 61.5% 
to 100%. Negative CMV PCR results of culture positive urine samples were only 
described in earlier studies in which per report several gel-based PCR assays were 
compared while optimizing sensitivity.26,27 Internal controls for potential PCR inhibiting 
components present in urine28,29 were lacking in these studies. 
Two of the three samples with discrepant test results in our study were taken 17 
days after birth, and we cannot exclude that these were derived from postnatally 
acquired CMV infections. Postnatal CMV infection commonly occurs, because of 
frequent acquisition of CMV in the birth canal or from breast milk.6 The restriction 
of samples taken within the first 3 weeks of life is considered safe to demonstrate 
congenitally acquired CMV infection.5,6 However, literature contains mixed references 
to this time frame,4,5,18,20 which is based on viral culture techniques and might not 
necessarily be identical for more sensitive diagnostic methods. Previous data have 
shown that CMV replicates with a doubling time of approximately one day.30 Assuming 
that the analytical sensitivity of CMV PCR on urine is 100 times more sensitive than 
viral culture,9 PCR could theoretically detect CMV 6.6 days (100 log2) earlier than 
viral culture, hence on day 14 postpartum compared to day 21 when using viral 
culture. Unfortunately, partially because of ethical reasons, neither clinical data nor 
other materials (saliva, (dried) blood) could be retrieved from these three newborns 
to discriminate congenital and postnatal infection. Data from studies combining 
clinical data with real-time CMV PCR results should address the distinction between 
congenitally and postnatally acquired CMV infection. 
In conclusion, our results are supported by with analytical and clinical data on CMV 
DNA detection in neonatal urine and suggest enhanced sensitivity of recent PCR 
techniques. There is considerable rationale to favor real-time CMV PCR as a gold 
standard in the diagnosis of congenital CMV infection. A large-scale study combining 
laboratory and clinical data is required to determine the exact time frame for sampling 
of neonatal urine when using real-time PCR.
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This thesis addresses several aspects of congenital cytomegalovirus (CMV) infection 
in general and more specifically in the Netherlands, in order to determine the 
necessity and feasibility of newborn screening for congenital CMV. The major topics 
studied were 
I. the disease burden of congenital CMV infection in the Netherlands, 
II. postnatal screening tools for congenital CMV, and 
III. pros and cons of newborn screening for congenital CMV. 
In this chapter, the implications of our main findings are discussed, overall conclusions 
are formulated and recommendations for future studies are made.
Part i disease burden of Congenital Cmv infeCtion
imPliCations of this finding
In a cross-sectional study, a large sample of dried blood spots (DBS) from infants 
born in the Netherlands was retrospectively tested for CMV DNA. The birth prevalence 
of congenital CMV was estimated at 0.54% (95%CI 0.36–0.72%) (Chapter 2). This 
finding, combined with the total number of newborns in the Netherlands (182,765 
newborns/ year, 2007)1, implicated that annually about 1000 children are born with 
congenital CMV infection in the Netherlands. This annual number of congenitally 
infected newborns is higher than some other well-known congenital conditions 
(Figure 1), including Down syndrome and spina bifida, for which prenatal screening 
is standard care.2 Moreover, congenital CMV is at least 10 times more frequent than 
congenital hypothyroidism, and 100 times more frequent than homocystinuria, both 
disorders for which postnatal screening is standard care nowadays.3 Based on the 
current knowledge on the natural history of congenital CMV infection4, about 125 
of these 1000 congenitally infected cases are expected to be symptomatic at birth. 
Approximately 5 congenitally infected newborns are expected to die each year in the 
Netherlands because of severe CMV inclusion disease. About 18% (1 out of 5) of 
the newborns with congenital CMV will develop neurological sequelae.4 This implies 
that annually about 180 of these 1000 infected children born in the Netherlands will 
The birth prevalence of congenital CMV in the Netherlands was 0.54% 




eventually suffer from CMV-related sequelae, of whom 87%4 (157) were asymptomatic 
at birth. The most frequently encountered sequela related to congenital CMV 
infection is hearing loss, followed by mental retardation, developmental delay, visual 
impairment, seizures, and paresis/paralysis. These conditions are known to have 
































































































































































































































































































































figure 1 Annual number of newborns with congenital CMV in the Netherlands compared 
with several other congenital conditions (data from 2007).2 
recommendations for future studies
Our calculations of the number of infants with CMV-related sequelae and symptoms 
at birth were based on previous data on the natural history of congenital CMV infection 
in the United States.4 The frequency and severity of clinical symptoms at birth and 
the long-term sequelae are known to differ among primary and non-primary maternal 
infections.5 The proportion of primary and non-primary infections is associated with 
the seroprevalence in the underlying population (Chapter 4), and therefore varies 
among different countries. Thus, it would be interesting to study the prevalence of 
CMV-related symptoms and sequelae in the Netherlands, in a prospective study 
design. Follow-up of neurologic sequelae would be desirable for many years after 
birth because of the frequent late-onset and progressive nature of the hearing loss 
associated with congenital CMV.6,7 Since developmental disorders (e.g. IQ<70) and 
visual impairment are the second and third most frequently encountered sequelae 
of congenital CMV infection5,8, it would be interesting to address the prevalence of 
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congenital CMV-related mental retardation and more subtle mental, developmental 
and visual impairment in the Netherlands.     
It has been suggested that congenital CMV infection is associated with disorders 
belonging to the autism spectrum. However, evidence is limited to case reports 
and a small series of children diagnosed with both autism and congenital CMV.9 A 
large study would be necessary to rule out or confirm this speculative association of 
congenital CMV with autism. One of the major challenges of a retrospective analysis 
would be the age of diagnosis of autism, in combination with the limited time-frame 
to retrospectively diagnose congenital CMV using DBS (the storage duration of DBS 
in the Netherlands is 5 years).
implications of these findings
Analyzing a cohort of children in the Netherlands with bilateral hearing loss at a later 
age (3-5 years), we found that the hearing loss was associated with congenital CMV 
infection in 1 in 5 deaf children (Chapter 3). This would render CMV the leading cause 
of non-genetic congenital hearing loss. Importantly, 2 of the 8 (25%) infants with both 
congenital CMV and hearing loss had passed the newborn hearing screening test, 
probably because of delayed-onset or progressive hearing loss. One should be 
aware that, in the absence of universal screening for congenital CMV infection, up 
to half 6 of the children with congenital CMV associated hearing loss at later ages 
may be missed by newborn hearing screening. Consequently, the Joint Committee 
on Infant Hearing recommended additional hearing evaluations in children with 
congenital CMV.10 
About 1 out of 5 deaf children in the Netherlands was congenitally infected with 
CMV  
 
2 of the 8 (25%) congenitally infected children with hearing loss at later age had 




Furthermore, we found that children with both hearing loss and congenital CMV had 
a greater delay in language comprehension than uninfected infants with comparable 
degrees of hearing loss. This implies that the delay in language comprehension in 
the infected infants was the result of a factor additional to the hearing loss, possibly 
cerebral damage resulting from congenital CMV infection. 
 
recommendations for future studies
The delayed onset and progressive nature of the hearing loss associated with 
congenital CMV is remarkable and the pathological mechanisms involved are largely 
unknown. CMV DNA has been detected in inner ear fluids (perilymph) of congenitally 
infected children up the age of 7 years, undergoing cochlear implant surgery.11,12,13,14 
The presence of CMV genome in the cochlea up to several years after birth supports 
the hypothesis of ongoing replication of CMV in the inner ear.14 Moreover, this would 
be in line with data on long-term viral shedding in other body fluids of children with 
congenital CMV infection. The median duration of shedding of CMV in urine has 
been found to be approximately 4 years in both symptomatic and asymptomatic 
children.15 CMV detection in the inner ear is limited to few reports describing a small 
number of congenitally infected patients. It would be interesting to further unravel the 
pathological mechanism of hearing loss associated with congenital CMV infection by 
analyzing the inner ear fluid of a large number of children undergoing cochlear implant 
surgery. Such a study would also provide insight in the proportion of congenital CMV 
infections among children with cochlear implants in the Netherlands, and would 
enable more detailed estimates of the disease burden and costs involved. 
implications of this finding
Our region based case-control analysis showed that congenital CMV infection 
was most frequent in subpopulations with a high proportion of young children (a 6 
times higher risk), and non-Western immigrants (a 3 times higher risk) (Chapter 2). 
The proportions of young children and immigrants in a population can be seen as 
demographic markers for environmental factors and behaviors that facilitate CMV 
transmission. Young children shed CMV in their body fluids, and a CMV shedding child 
Subpopulations in the Netherlands with more young children, and with more non-
western immigrants, had a higher risk of congenital CMV infection (Chapter 2)
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is a known risk factor for maternal CMV infection.16 Similarly, CMV seroprevalence is 
reported to be higher among immigrant mothers than among native Dutch mothers17, 
implicating a more frequent exposure to CMV. Factors involved in increased exposure 
and potentially related to cultural differences include large household size, crowding, 
certain child care practices, and possibly sexual practices.8 Assessing subpopulations 
and indicating (behavioral) risk factors for congenital CMV infection in the Netherlands 
will provide insight in the transmission of CMV and potential preventive measures. 
While a vaccine is currently unavailable, prevention of congenital CMV infection is 
limited to hygiene practices. 
recommendations for future studies
In our study, risk factors were analyzed at a regional level. It would be interesting to 
assess risk factors for congenital CMV in the Netherlands at the individual level, in a 
prospective or retrospective design. Identification of risk factors is vital for proposing 
preventive measures. While there is evidence that hygiene counseling results in a 
reduced rate of CMV seroconversion among pregnant women18,19,20, further studies 
are required to determine whether these measures reduce the rate of congenital CMV 
infection and disease. 
implications of this finding
Applying the population-based prediction model we developed, we found that, for 
populations with CMV seroprevalence of 30% to 95%, non-primary maternal CMV 
infections accounted for the majority of congenital CMV infections (Chapter 4). The 
proportion of newborns with congenital CMV attributable to non-primary maternal 
infections was up to 96% in populations with seroprevalence of 95% (95%CI 88-99%). 
Additionally, the proportion of newborns with sequelae attributable to non-primary 
infections increased with CMV seroprevalence, and was up to 89% (95%CI 26-97%). 
These findings stressed the impact of non-primary infections on the disease burden 
of congenital CMV. 
Combining this prediction model (Chapter 4) with our findings on the birth prevalence 
of congenital CMV in the Netherlands (Chapter 2), additional estimates could 
be made on the proportion and number of congenitally infected children born 
Non-primary maternal CMV infections were estimated to account for the majority 




from seropositive mothers in the Netherlands (Figure 2). Data on maternal CMV 
seroprevalence in the Netherlands (50%17,21) were combined with the annual number 
of newborns with congenital CMV and CMV-related sequelae in the Netherlands (987 
and 177, respectively, Chapter 2). This resulted in an estimate of 681 congenitally 
infected children born from seropositive mothers in the Netherlands annually, of 
whom about 76 children eventually will be affected by sequelae. The birth prevalence 
of congenital CMV in the Netherlands as predicted by our model (based on 50% CMV 
seroprevalence) corresponded with the birth prevalence as detected in our cross-











































































































































































































































































































































figure 2 Annual number of children born in the Netherlands with congenital CMV infection 
and with CMV-related permanent neurological sequelae (at later ages) according 
to primary and non-primary maternal infection. Estimates were based on the 
population based predication model (Chapter 4) (50% CMV seroprevalence17,21) 
and the annual number of congenitally infected newborns based on the birth 
prevalence in the Netherlands (Chapter 2). 
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Similarly, additional calculations could be made when combining our model (Chapter 
4) with seroprevalence data of subpopulations in the Netherlands found to be at higher 
risk of congenital CMV (Chapter 3). CMV seroprevalence data of subpopulations of 
Dutch and Turkish/Moroccan origin in the Netherlands were used (35% and 96% 
seroprevalence17,21, respectively). Among mothers of Turkish/Moroccan origin, non-
primary maternal infections were estimated to account for 91% of the congenital 






















figure 3 Estimated proportion of children with congenital CMV and CMV-related sequelae in 
the Netherlands among subpopulations of Dutch and of Turkish/Moroccan origin, 
according to non-primary and primary maternal infection (seroprevalence of 35% 
and 96% 17, respectively). Estimates were based on the population based prediction 
model (Chapter 4). 
The apparent contradiction of maternal immunity as a risk factor for congenital 
CMV can be explained by the higher force of (re-)infection in highly seroprevalent 
(sub)populations.22 Additionally, maternal re-activations may play a role. Awareness 
of the risk of seroimmune pregnant women of having a congenitally infected and 
neurologically affected newborn will have significant consequences for preventive 
strategies to reduce the disease burden of congenital CMV. Preventive measures 
such as hygiene counseling should not be limited to seronegative pregnant women. 
In that case, prenatal maternal serological screening will be futile as long as no 




is only partially protective for congenital infection raises questions on the ratio of re-
infections with new strains versus reactivations of latent virus in seroimmune pregnant 
women. Passive and active immunization efforts should aim at provision of antibodies 
and vaccines for both seronegative and seropositive women, while, currently, an 
immunological correlate of full protection against congenital CMV infection and 
disease seems to be lacking. Recently, a CMV glycoprotein B vaccine has been 
shown to boost immunity in CMV seropositive women23, however future studies are 
needed to determine the capacity of this vaccine to reduce congenital CMV infection 
and disease. 
 
recommendations for future studies
Practical data are desired to confirm our theoretical estimates, which were derived 
from a model, based on data from previous reports. A prospective study with follow-
up of a large cohort of pregnant women would deliver data on the (re-)infection 
rate among pregnant women in the Netherlands. Preliminary data we obtained by 
means of an additional cross-sectional study in which sera from CMV seropositive 
pregnant women in the first trimester were assessed for CMV DNA, indicated that 
a very low proportion of these women was CMV viremic at the time of sampling 
(1/122, 0.8% of CMV IgG positive sera, data not shown). Furthermore, it would be 
interesting to distinguish re-infections with new strains from reactivations of latent 
virus in pregnant women. A recent serological study showed that re-infection with 
new strains was a major source of congenital infection, occurring in about 8% of 
seroimmune pregnancies in Brazil.24 However, the proportion of maternal re-infections 
versus reactivations resulting in congenital infection is not known and further studies 
distinguishing CMV strains by means of serology and/or genome analysis (see 
Chapter 8) would be helpful. Immunization studies addressing the capacity of CMV 
vaccines to reduce maternal-to-fetal transmission rates among both seronegative 
and seroimmune women are needed. A search for correlates of protection of fetal 
infection and disease is essential. 
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implications of this finding
A digital questionnaire sent to interns, residents, senior doctors, general practitioners 
and medical researchers involved in mother and child care in the Netherlands, 
suggested that the responding physicians (in training) had suboptimal knowledge 
concerning congenital CMV. About half of the responding obstetricians and 
gynecologists (in training) were not aware of the fact that CMV is not transmitted by 
air and can be transmitted by kissing young children on the mouth and changing 
diapers (Chapter 5). Furthermore, only the minority of the respondents in pediatrics 
realized that newborns with congenital CMV may be asymptomatic at birth and that 1 
out of 5 congenitally infected newborns will develop long-term sequelae. Our findings 
imply that congenital CMV infections may not be recognized by these physicians and 
therefore under-diagnosed with the risk of treatment delay or refrain. Furthermore, 
these physicians were not likely to be able to optimally advise on the risk of congenital 
CMV and how this risk may be reduced. 
recommendations for future work
Education of physicians on congenital CMV is expected to result in increased 
awareness, and awareness of physicians is essential for awareness of pregnant 
women and policy makers in health care. Increased knowledge and awareness of 
physicians and pregnant women is expected to improve recognition and care, to 
stimulate diagnostic investigations and audiological follow-up of infected newborns, 
and to enhance preventive measures. A two-fold reduction of the risk of seroconversion 
among pregnant women has been reported20 after advising mainly three hygiene 
measures, also promoted by the CDC: 1. hand washing after diaper changes, 2. 
avoiding kissing young children on the mouth, 3. avoiding sharing utensils. A large 
study is needed to determine the effect of hygiene measures on the number of 
(prevented) congenital CMV infections. Overall, it is recommended that educational 
efforts are increased employing all possible methods to reach all groups involved.
Knowlegde of the responding obstetricians and gynecologists (in training) on 




overall ConClusions of Part i
Combining insights provided by the findings presented in part I of this thesis as well as 
from other available data, it can be concluded that the disease burden of congenital 
CMV in the Netherlands is considerable. Congenital CMV infection is the most frequent 
congenital disorder and appears to be the leading cause of non-genetic congenital 
hearing loss. Congenital CMV disease affects all subpopulations in the Netherlands, 
and seronegative as well as seropositive pregnant women are at risk of having a 
newborn with congenital CMV-related disabilities. The disease burden is striking 
when one realizes that a non-negligible part of the congenitally infected newborns 
with late-onset hearing loss is not detected in the newborn hearing screening, with 
delayed intervention for hearing loss as a consequence. Uncorrected prelingual 
hearing loss has profound negative effects on speech and language development, 
communication and learning, and affects the socio-economic status of the affected 
children and their families. Though an extensive analysis of the exact costs involved 
in congenital CMV disease is currently underway, lifetime costs of prelingual bilateral 
hearing loss, irrespective of etiology, are impressive (>700,000 euros per disabled 
individual25,26,27,28). Moreover, additional to the postnatal disease burden of congenital 
CMV addressed in this thesis, congenital CMV has been associated with intra-uterine 
fetal death29,30,31,32, increasing its impact even further. 
Taken together, it can be concluded that congenital Cmv infection can be labeled 
as an important public health problem.
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Part ii Postnatal sCreening tools for Conge-
nital Cmv
imPliCations of this finding
Sensitivity and applicability of several DNA extraction methods for high-throughput 
usage were assessed by means of in vitro experiments using Guthrie cards spotted 
with CMV positive blood. Significant differences were found between the extraction 
methods with respect to the sensitivity. Sensitivities ranged up to about 86% for 
Guthrie cards spotted with CMV DNA loads around the reported33 median load of 3.4 
log10 copies/ml for symptomatic and asymptomatic congenitally infected newborns. 
When considering the usage of DBS for universal newborn screening for congenital 
CMV infection, an assay which is sensitive, specific, and applicable for 96-well format 
testing, while using only a very small amount of dried blood, is required. When 
evaluating screening assays, the predictive values of screening test results are even 
more important than sensitivity and specificity. Considering a national congenital 
CMV birth prevalence of 0.54% (Chapter 2), a screening test with a sensitivity of 75% 
would still result in a negative predictive value as high as 99.8%. Furthermore, the 
demonstrated association between viral load and outcome34,35,36,37 suggests that any 
cases missed would be those with the lowest viral loads and probably the lowest 
chance of developing severe permanent sequelae. Thus, the clinical sensitivity, 
based on the detection of children who will eventually develop sequelae, may well 
be acceptable.38,39,40 
recommendations for future studies
When considering universal newborn screening for congenital CMV infection, an 
assay which is sensitive, specific, and applicable for 96-well format testing is needed. 
In view of the existing route of the national metabolic screening program, DBS would 
be the most practical specimen of choice. Experience with DNA detection in newborn 
screening laboratories is accumulating, in particular in the postnatal screening for 
cystic fibrosis.41 Therefore, it is interesting to further optimize DBS DNA extraction 
protocols, PCR techniques, testing algorithms, and test procedures. Large scale 
Sensitivity of CMV DNA detection in dried blood spots (DBS) varied widely, 




prospective and retrospective studies have assessed several PCR-based assays 
for CMV detection in DBS and their results mainly correspond with our findings, 
reporting sensitivities of 71-100%.42,43,44,45 In contrast, the widely commented38,39 study 
by Boppana et al46 reported a sensitivity as low as 34% of the specific DBS assay 
used to screen 20,448 newborns. Exploratory studies in which optimized CMV DBS 
assays are used for large-scale newborn screening are needed to address remaining 
analytic and logistic issues.
While further exploring DBS PCR assays, alternative assays with potential for 
sensitive and high-throughput detection of CMV may be explored. Recently, the use 
of dried saliva for screening for congenital CMV has been tested and found to be very 
sensitive. Table 1 summarizes clinical pilot studies on PCR-based newborn screening 
assays for congenital CMV infection reported to date. Future studies are likely to 
address the logistic feasibility of materials other than DBS in more detail. Potentially, 
logistic issues may be more challenging in countries where a large proportion of the 
children are born and sampled in their home environment. 
Additionally, since current metabolic screening is mainly performed using mass 
spectrometric assays, it would be logistically advantageous to use mass spectrometric 
detection of CMV in DBS. While it may be difficult to detect relatively low amounts 
of CMV-specific proteins present in DBS, it would be worthwhile to explore mass 






























































































































































































































































































































































































































































































































































































































































































































































































































































implications of this finding
Detection of CMV DNA in DBS has been shown to be a challenge44,45,42,46 due to 
the small amount of dried blood available (Chapter 6). In spite of this, using our 
genotype assay, a genotype could be assigned to approximately 75-80% of the 
CMV DNA positive DBS of congenitally infected newborns. Others have shown that 
genotyping of CMV has supported the discrimination of reactivation of latent virus 
from re-infection with new CMV strains in plasma from transplant patients, allowing 
a better definition of donor-to-recipient transmission patterns.58 As described in 
Chapter 4, congenital CMV infections mainly result from recurrent maternal infections, 
comprising re-infections and possibly reactivations. Our genotyping tool might 
support the discrimination of maternal reactivation from re-infection, reveal mother-
to-fetus transmission patterns and the clinical outcome of congenital infection after 
reactivation versus re-infection. Increased insight into transmission risks of latent 
and new strains may have significant implications for preventive and therapeutic 
strategies, including CMV vaccine research.
recommendations for future studies
Future studies, analyzing a large number of newborns and their mothers should 
address the frequency of re-infections and reactivations, mother-to-fetus 
transmission patterns, and the potential role of congenital infections with multiple 
CMV genotypes. Additionally, it would be of interest to study the presence of genomic 
variants longitudinally within one human host. Recent genome-wide next-generation 
sequencing of CMV in urine of congenitally infected newborns suggested that the 
genomic intra-host variability of CMV (0.2% nucleotide diversity per sample) may be 
comparable to that of many RNA viruses.59
The multiplex real-time CMV glycoproteins B and H genotyping assays developed, 
were efficient, sensitive for detecting mixed infections in plasma, and applicable 
for usage on DBS (Chapter 8)
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implications of this finding
A retrospective analysis of a large series of neonatal urine samples received for 
congenital CMV diagnostics, showed that CMV was more frequently detected by real-
time PCR than by viral culture. False negative CMV urine culture results have been 
reported, both in experimental setting60 and in clinical setting61,62,63,64, and therefore 
seem the most likely explanation for our discrepant test results. Loss of viable CMV 
particles implicated in false negative culture results may be caused by transport at 
room temperature65, and/or antiviral therapy. Our results, supported by analytical and 
clinical data on CMV DNA detection in neonatal urine, suggested enhanced sensitivity 
of recent PCR techniques when compared to viral culture. These combined findings 
provide considerable rationale to favor real-time CMV PCR as a gold standard in the 
diagnosis of congenital CMV infection. 
recommendations for future studies
Data from large-scale studies combining clinical data from newborns with diagnostic 
inhibition-controlled real-time CMV PCR procedures should address the differentiation 
between congenitally and postnatally acquired CMV infection, and should determine 
the exact time-frame for sampling of neonatal urine when using real-time PCR.
CMV was more frequently detected by real-time PCR than by viral culture of 




overall ConClusions of Part ii: sCreening tools
Combining the findings presented in part II of this thesis with data from the literature, 
the overall conclusion would be that, now that several newborn screening tools for 
congenital CMV have been studied, PCR-based screening assays using DBS, saliva, 
and urine appear to be the most attractive tools currently available for newborn 
screening for congenital CMV. Whereas saliva and urine samples have the advantage 
of containing high viral loads53 and potentially high test sensitivity, DBS have the 
major logistic advantage of being suitable for use in Guthrie card-based metabolic 
screening. The wide range of sensitivities of DBS PCR assays reported in (clinical 
pilot) studies including our own, provides the insight that sensitivity data of specific 
DBS PCR assays cannot be generalized. It appears that a sub-selection of DBS PCR 
assays with high DNA extraction capacity has the potential to achieve sensitivity and 
specificity levels approaching those of assays currently used in metabolic screening 
in the Netherlands (about 100% sensitivity and ≥99.97% specificity66). It must be 
noted that a lower analytical sensitivity may well be acceptable, since the previously 
demonstrated association between viral load and clinical outcome34,35,36,37 suggests 
that any cases missed, would be those with the lowest viral loads and probably the 
lowest chance of developing severe permanent sequelae. 
The use of dried urine samples collected on filter paper placed in diapers has 
been described as feasible for mass screening and should be explored.51 When 
considering the use of (dried) urine samples for newborn screening for congenital 
CMV, a narrow time-frame for sampling must be taken into account, in order to 
differentiate congenital from postnatal infection.
Taken together, while currently available screening tools are being optimized and 




Part iii Pros and Cons of newborn sCreening for 
Congenital Cmv
Despite previous appeals for preventive measures for congenital CMV infection67,68, 
newborn screening for congenital CMV has only recently begun to be considered 
seriously. The potential for newborn screening for CMV lies in the identification of 
the large proportion of asymptomatic congenitally infected newborns at risk for 
developing late-onset hearing loss or other sequelae. There is growing support for 
two primary ideas: the benefit of hearing preservation in symptomatic newborns by 
means of antiviral treatment, and the benefit of early identification of late-onset 
hearing loss by means of extensive audiological follow-up in congenitally infected 
infants. It appears that, after many years of research, congenital CMV infection now 
satisfies most screening criteria of Wilson and Jungner.40,69 Pros and cons for newborn 
screening for congenital CMV are addressed in detail in the following Chapters 11 
and 12. 
From these discussions and combining insights, as provided by the studies presented 
in this thesis as well as from other available data, the overall conclusion is that a large-
scale study on the safety and efficacy of combined newborn screening and antiviral 
therapy is the necessary next step to take in the long-lasting fight against the damage 
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Congenital cytomegalovirus (CMV) infection is an important public health problem 
with approximately 7 in 1,000 newborns infected and consequently at risk for hearing 
impairment. Newborn hearing screening will fail to detect this hearing impairment in 
approximately half of the cases because late onset hearing loss is frequent. Hearing 
impairment has profound impact on cognitive and social development of children 
and their families, determining most of the disease burden of congenital CMV 
infection. The potential value of newborn screening for congenital CMV is increasingly 
discussed. To date, many experts acknowledge the benefit of antiviral treatment in 
the prevention of hearing deterioration in newborns with neurological symptoms, 
and the benefit of early identification of late-onset hearing impairment by means of 
extensive audiological follow up of infected infants. These opinions imply that the 
potential of newborn screening for CMV would lie in the identification of the large 
proportion of asymptomatic congenitally infected newborns at risk for developing 
late-onset hearing loss. Experience with postnatal antiviral treatment of symptomatic 
newborns is encouraging, but has not been studied in asymptomatic congenitally 
infected newborns. A large-scale study on the safety and effectiveness of combined 
screening and antiviral therapy for congenital CMV infection is the necessary next 
step to take and should not be delayed. 




Despite the appeals for preventive measures for congenital cytomegalovirus (CMV) 
infection by Yow and Demmler in 1992 ‘‘Congenital CMV disease—20 years is long 
enough’’ 1 and the statement by Adler that, in 2005, ‘‘there is considerable rationale 
for implementing neonatal screening now’’ 2, newborn screening for congenital CMV 
has only recently begun to be explored. Indeed, in the last year, several original 
articles, editorials and reviews have been published on this subject.3–11 In a recent 
review, Dollard et al.8 showed that, after many years of research, congenital CMV 
infection now satisfies most screening criteria of Wilson and Jungner.12 There is 
growing support3,6,8,9,11 for two primary conceptions: the benefit of prevention of 
hearing deterioration in symptomatic newborns by means of antiviral treatment, 
and the benefit of early identification of late-onset hearing impairment by means of 
extensive audiological follow-up in congenitally infected infants. So now, after again 
almost 20 years, the stage appears to be set for neonatal screening. 
the wilson and Jungner criteria and newborn screening on congenital cmv 
The Wilson and Jungner12 criteria for newborn screening include the requirements 
that the disease has to be an important public health problem with a well understood 
history, that an early diagnosis can be made with a suitable screening test, and 
that the benefits outweigh the risks and costs of early intervention. The overall birth 
prevalence of congenital CMV is approximately 0.7%, and an estimated 18% of the 
congenitally infected newborns will develop permanent neurological sequelae.13–16 
Hence, congenital CMV is responsible for affecting approximately 126 in 100,000 
newborns causing permanent neurologic sequelae, most prominently sensorineural 
hearing loss (SNHL), but also neurodevelopmental disabilities. In the 27 countries 
of the European Union (EU-27), every year 37,800 congenital CMV-infected babies 
are born, of which 6807 will eventually suffer from permanent sequelae (Figure 1). 
Among children with bilateral profound SNHL, the hearing disability is attributable to 
congenital CMV infection in one in five patients, making CMV the leading cause of 
non-genetic congenital hearing impairment.14,17 Due to the frequently occurring late 
onset character of the hearing loss caused by congenital CMV, approximately half of 
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figure 1  Congenital CMV disease burden in the EU-27. 
Compared to several other diseases for which newborn screening has already been 
implemented, the prevalence of congenital CMV infections is notably high (Table 1). 
For example, sequelae caused by congenital CMV are more than 100 times more 
prevalent than homocystinuria, a partially untreatable disorder for which postnatal 
screening is standard care in most developed countries nowadays.19 
One of the Wilson and Jungner criteria for newborn screening concerns the availability 
of an acceptable screening test, suitable for diagnosis in an early stage of the disease. 
Newborn screening for congenital CMV infection would indeed identify newborns 
at risk for developing late-onset hearing loss at an early stage. Dollard et al.8 have 
reviewed several laboratory aspects of newborn screening for congenital CMV. In 
view of the existing routes of national metabolic screening programmes, dried blood 
spots (DBS) would be the most practical specimen of choice. CMV DNA detection in 
DBS is technically feasible and has become routine practice in an increasing number 
of clinical microbiological laboratories.20 Experience with DNA detection in newborn 
screening laboratories is accumulating, in particular in the postnatal screening for 
cystic fibrosis.19 Specificity of CMV PCR assays on DBS has been reported to range 
between 99.3% and 100%21–23, with a specificity approaching 100% as a prerequisite 
for an acceptable positive predictive value.











































































































































































































































































































































































































































































































Additional confirmatory testing of newborns with CMV positive DBS, using urine 
sampled within the first 2–3 weeks after birth, the current gold standard, would 
increase specificity to 100% (positive predictive value of 100%). 
The issue has been raised whether the sensitivity of DBS testing for CMV DNA is 
adequate for screening purposes.4,5,7,9 Previously reported analytical and clinical 
sensitivities of CMV DNA detection using DBS vary within a wide range from 34% by 
Boppana et al.4 up to 100%.10,20,23–31 The wide range in reported sensitivities can be 
explained by the population of newborns tested (proportion of asymptomatic and 
symptomatic cases), and the testing method used. A small number of prospective 
studies have tested sensitivity of CMV DNA detection in DBS in a large population of 
unselected newborns in comparison with the gold standard, i.e. urine CMV culture 
or PCR at 2–3 weeks after birth. Soetens et al.30 reported sensitivities up to 83% 
testing DBS from 55 CMV-infected newborns detected with a large urine screening 
program in an unselected population. Yamamoto et al.32 reported a sensitivity of 71% 
testing 332 DBS from urine screened unselected newborns of whom seven with 
congenital CMV infection. Johansson et al.28 described a sensitivity of 81% testing 
DBS from 16 congenitally infected newborns identified by means of urine screening. 
In contrast, the annotated5,7 study by Boppana et al.4 reported a sensitivity as low as 
34% of the DBS assay used to screen 20,448 newborns compared to saliva testing. 
However, the most recent report on sensitivity of DBS testing by Kharrazi et al.,10 
screening 3972 newborns using DBS, measured a prevalence similar to reports 
using established methods for diagnosing congenital CMV infection, suggesting an 
adequate sensitivity. The major factor responsible for these considerable differences 
in reported sensitivities of DBS assays, even when assessing an unselected 
population of newborns in comparison with the gold standard, is the testing method 
used.5,7 Widely different DBS test protocols have been used, including variations in 
DNA extraction methods. It has been demonstrated that these differences in DBS test 
protocols result in major divergences in sensitivity.25 Thus, sensitivity results obtained 
using one specific DBS testing protocol cannot be generalised to other DBS testing 
methods. Optimising DNA extraction protocols, PCRs, and testing algorithms, e.g. 
by means of performing independent triplicate testing, have been shown to increase 
analytical sensitivity significantly.25,27,30 Recently, Gohring et al.27 calculated a detection 
limit as low as 200 copies CMV-DNA per millilitre using a highly sensitive protocol. 
More important than the sensitivity when evaluating screening assays is the negative 
predictive value. Considering an international birth prevalence of 0.64%, a screening 
test with a sensitivity of 75% would still result in a negative predictive value as high 
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as 99.84%. It appears that a perceived lack of analytical sensitivity need not be a 
diagnostic limitation. Furthermore, the previously demonstrated association between 
viral load and clinical outcome33–36 suggests that any cases missed would be those 
with the lowest viral loads and probably the lowest chance of developing severe 
permanent sequelae. Thus, as Dollard et al. also mentioned, the clinical sensitivity, 
based on the detection of children that will eventually develop sequelae, may well 
be acceptable.5,7,8 Obviously, high-throughput testing should be optimised before 
implementing universal neonatal screening.25 It appears that with optimal quality 
assurance, a high specificity and a sufficient clinical sensitivity can be achieved, 
enabling exploratory regional trials for large-scale newborn screening. 
Postnatal interventional options 
As described by Wilson and Jungner12, the benefits of newborn screening and 
intervention should outweigh potential physical and psychological disadvantages. 
The major benefit of newborn screening for congenital CMV would be early 
identification of newborns at risk for developing late-onset hearing loss. The current 
universal newborn hearing screening fails to detect approximately half of all SNHL 
caused by congenital CMV infection18 and presently, the median age of detection of 
hearing impairment caused by congenital CMV infection is approximately 2 years.37 
Hearing impairment in the first 3 years of life has detrimental effects on speech and 
language development.38,39 Correction of hearing impairment with hearing aids or 
cochlear implantation is most effective prior to the age of 6 months.38,39 At that early 
stage, correction of hearing can result in communicative and linguistic skills very 
similar to those of their normally hearing peers.38,39 Newborn screening for congenital 
CMV would enable the identification of the 0.7% of newborns at risk for developing 
hearing impairment due to congenital CMV, potentially followed by intensive follow-up 
of audiological performance in this selected group. Audiological follow-up of up of all 
newborns without screening for congenital CMV is not an attractive alternative due 
the enormous numbers of newborns involved with the logistic, psychological, and 
financial consequences attached. 
The ultimate benefit of newborn screening would come from the prevention of both 
early and late-onset hearing deterioration. Any reduction in the number of children 
with severe to profound hearing loss will have great impact on the burden of disease, 
influencing both the quality of life of the patients and the economic burden of 
disease. One randomised controlled trial with intravenous ganciclovir therapy for 6 
weeks significantly reduced hearing deterioration in a selected group of symptomatic 
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newborns with congenital CMV infection involving the central nervous system 
(microcephaly, intracranial calcifications, abnormal CSF, chorioretinitis, and/or hearing 
deficits).40 Sixty-eight % of the untreated infants in the trial had hearing deterioration 
at the age of 1 year versus 21% of the ganciclovir-treated infants, resulting in an 
efficacy of 69%. Additionally, ganciclovir had a beneficial effect on the neurological 
development (personal/social and motor development) of these infants.41 Although 
this study had some major drawbacks, such as the high number of cases lost to 
follow-up and the lack of the usage of a placebo in the untreated group, these results 
have led to the general opinion that this subgroup of congenitally infected children 
with neurological symptoms should be treated with at least 6 weeks of (val)ganciclovir. 
Subsequent trials with this particular group of symptomatic children have actually not 
included a placebo-group (www.clinicaltrials.gov, accessed December 2010). 
Despite the encouraging results in symptomatic children, the benefit of antiviral therapy 
in asymptomatic newborns with congenital CMV infection has not yet been proven 
to date. For this reason, this intervention is not included in current guidelines.42,43 To 
our knowledge, only one randomised controlled trial with asymptomatic congenitally 
infected newborns without hearing loss has been reported studying the effect of 3 
weeks intravenous ganciclovir on hearing.44 During 4 to 10 years of follow-up, none of 
10 treated infants developed hearing loss, compared with two out of eight untreated 
infants. Unfortunately, this study lacked statistical power to draw firm conclusions 
about the efficacy of the antiviral treatment in this group. In addition, Yilmaz-Ciftdogan 
et al.45 reported the improvement of bilateral hearing impairment in an otherwise 
asymptomatic congenitally infected newborn treated with intravenous ganciclovir for 
1 week followed by oral valganciclovir for five additional weeks. 
Valganciclovir, which can be administered as a convenient oral solution, is now 
considered an adequate and practical substitute of the previously applied intravenous 
formulation of ganciclovir.46–48 In many other (pediatric) settings, both ganciclovir and 
valganciclovir have increasingly been tested and used, also for prolonged periods. 
(Val)ganciclovir has side-effects, with neutropenia being the most common one. A 
moderate to severe neutropenia is seen in approximately one out of five untreated 
newborns with congenital CMV infection and in an additional two out of five 
ganciclovir treated newborns.40,45 This neutropenia is transient and reversible within 
a few days upon dose reduction or discontinuation of the drug. Human data on the 
potential long-term side effects of the active substance of valganciclovir, ganciclovir 
are lacking. The only data come from a small number of animal studies in which 
carcinogenic and aspermatogenec effects have been observed.49,50 Ganciclovir was 
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carcinogenic in mice at doses that produced concentrations of 0.1 and 1.4 times the 
mean drug exposure in humans.49 Additionally, ganciclovir decreased fertility in mice 
at concentrations comparable to human usage, whereas embryotoxicity in pregnant 
rabbits and mice have only been observed at twice the drug concentrations obtained 
in humans.49 It is unclear to what extent these limited data can be extrapolated to 
humans. Future data from a lifetime of human usage will position these long-term 
side effects in the proper perspective. To date, no reports have been published on 
documented or suspected carcinogenic or teratogenic effects due to (val)ganciclovir, 
despite its extended usage in adults and its growing usage in the paediatric 
publication since the first publication on ganciclovir in 1982.51 
Though randomised controlled-trials should provide further evidence, there are data 
that support the hypothesis that antiviral therapy has a role in preventing hearing loss 
in asymptomatic newborns. Several findings suggest that ongoing viral replication 
is responsible for CMV-associated SNHL. First, CMV-induced labyrinthitis has been 
demonstrated in human cases and animal model studies.52–56 Viral DNA has indeed 
been detected in the perilymph of children with congenital CMV infection at ages 
ranging from one to 19 years.57–60 Finally, indirect evidence of a viral replication-
associated pathogenesis can be found in the previously published relationship 
between CMV viral load in the newborn and the occurrence of SNHL33–36,61–63, the late-
onset character of the hearing loss18,64 and the beneficial effect of antiviral treatment 
in reducing the development or deterioration of SNHL.40,41 On the other hand it has 
been shown that treatment with intravenous ganciclovir or oral valganciclovir will 
reduce CMV viral load in a predictable pattern as shown by Emery et al.65 Since the 
majority of children with congenital CMV infection are asymptomatic at birth, studies 
are required to define their baseline viral load and determine if this can be efficiently 
reduced to an undetectable and safe level. 
To initiate postnatal antiviral treatment in initial asymptomatic children is a difficult 
decision, due to the fact that about 82% of the children with congenital CMV infection 
will not develop any sequelae13 but will be treated with an antiviral drug with potential 
side-effects. However, the potential lifelong benefit for those that will have severe 
hearing loss and possibly neurodevelopmental delay has to be balanced against 
this disadvantage of a preemptive strategy. To achieve a benefit ratio of 10 newborns 
needed to treat to obtain benefit for one child, the efficacy of antiviral treatment of 
approximately 70% is needed, based on the natural history of development of hearing 
loss as described by Fowler et al.64 To date, no data are available on the efficacy of 
antiviral therapy in initially asymptomatic newborns, and therefore, a well-considered 
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appraisal cannot be made at this moment. Considering that potential harm would be 
mild and temporary whereas potential benefit would be substantial and permanent, 
the preventive measure of combined neonatal screening and antiviral treatment is 
certainly worth to be studied in a randomised controlled trial. Ongoing research will 
lead to insight into the optimal treatment strategy and duration and should reveal both 
viral and host factors involved in clinical outcome, potentially leading to a defined risk 
group that would benefit most from antiviral treatment.
Cost-effectiveness
No data are available published on the cost-effectiveness of newborn screening for 
congenital CMV infection followed by intervention as compared to refraining from any 
screening or intervention. However, reliable data exist on the disease burden due 
to congenital CMV infection and the number of children with permanent sequelae. 
On the EU-27 scale, implementing a congenital CMV newborn screening program 
would detect approximately 37,800 newborns (Figure 1) with congenital CMV. The 
current lack of efficacy data on early antiviral treatment is hampering a detailed cost-
effectiveness analysis at this moment. However, data on lifetime costs of hearing 
impairment, irrespective of the etiology, are available.66–69
Lifetime costs include assistive devices, medical costs, special education and lost 
productivity, and (in 2007) were estimated to be over € 700,000 per person with 
prelingual bilateral hearing loss.66–69 The costs of prevention of hearing deterioration 
of partially unilateral and bilateral hearing impairment as caused by congenital 
CMV (cost-of illness) are not exactly reported and differentiated. However, it would 
be worthwhile to weigh the costs and benefits of newborn screening followed by 
intervention when insight in efficacy of treat-ment of initially asymptomatic newborns 
is expanded. Given the enormous costs of hearing impairment contracted in early 
childhood, there is potential for substantial cost reduction. 
Conclusion 
Now that an increasing number of the Wilson and Jungner criteria for newborn 
screening have been met, a large-scale study on the effectiveness of newborn 
screening for congenital CMV infection is the necessary next step to take. Further 
delay should be considered undesirable and unjustifiable. Policy makers in healthcare 
should take action now, as the infected infants deserve the benefit of the doubt. 
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to the editor: 
Dr Boppana and colleagues1 concluded that dried blood spot (DBS) real-time PCR 
assays are not suitable for screening newborns for congenital CMV infection due to 
their insufficient sensitivity. 
[Boppana et al. published in JAMA (2010) results of a multicenter study in which 
20 448 newborns were screened for congenital CMV infection by means of rapid 
culture of saliva specimens and 2 different in-house DBS real-time PCR assays. 
Congenital infection was confirmed by means of rapid culture of saliva or urine in 
92 infants. Sensitivity and specificity of these PCR assays were at most 34.4% and 
99.9%, respectively. Negative and positive predictive values were 99.8% and 91.7%, 
respectively. The authors stated that, DBS real-time PCR assays have limited value for 
screening newborns for congenital CMV infection because of insufficient sensitivity.] 
We believe that this is a premature conclusion, based on a number of considerations 
that were not sufficiently discussed in this article. 
First, the sensitivity of DBS testing is highly variable, largely depending on the nucleic 
acid extraction methodology used,2 so conclusions cannot be generalized. It appears 
that this problem can be reduced by using optimized techniques that differ from those 
applied in the study by Boppana et al [Qiagen M48 robot (MagAtract) extraction using 
two 3-mm disks of dried blood].1 In addition, performing independent triplicate testing 
to increase sensitivity has been advocated,2 an approach not used in this study. 
Second, it should be clear what the clinical relevance is of the cases that were missed. 
These cases will likely involve the samples with the lowest or even absent viral loads, 
and there is evidence that such cases are associated with lower risks of late-onset 
sequelae, including hearing loss.3 Sensitivity should be judged by patients in whom 
hearing loss is eventually caused by CMV. The intended follow-up of the infants with 
congenital CMV infection in this study will reveal the clinical outcome, and these data 
should be awaited before discarding the screening test that was used. 
Third, we are concerned about the possible inclusion of very common but generally 
harmless postnatal CMV infections. Oropharyngeal contamination during vaginal 
delivery might cause positive saliva samples soon after birth, as has been shown 
for herpes simplex virus.4 Sampling in this study was mainly performed on the day of 
birth. Confirmation of the presumed congenital infections was carried out at a mean 
age of more than 6 weeks, although it is commonly accepted that only CMV infections 
diagnosed within the first 2 or 3 weeks can be considered proof of congenital CMV 
infection.5 If postnatally infected neonates were indeed included, this would falsely 
suggest a lower sensitivity of DBS testing.




 1.  Boppana SB, Ross SA, Novak Z, et al; National Institute on Deafness and Other Communication 
DisordersCMVand Hearing Multicenter Screening (CHIMES) Study. Dried blood spot real-time 
polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. 
JAMA. 2010;303(14):1375-1382.
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Virussen bestaan slechts uit een hoeveelheid erfelijk materiaal ingesloten in een 
omhulsel van eiwit met eventueel vet en hebben daarom een gastheercel nodig om 
zich te vermenigvuldigen, in tegenstelling tot bacteriën. Het cytomegalovirus (CMV) 
behoort tot de Herpesvirus familie, zoals ook het Epstein-Barr virus (de verwekker 
van de ziekte van Pfeiffer), het herpes simplex virus (de verwekker van de koortslip), 
en het varicella-zoster virus (de verwekker van waterpokken en gordelroos). CMV 
komt wereldwijd veel voor en wordt van persoon tot persoon overgedragen via direct 
contact met lichaamsvloeistoffen waarin het virus wordt uitgescheiden. Met name 
urine en speeksel van jonge kinderen kunnen grote hoeveelheden CMV bevatten en 
spelen daarom een grote rol bij overdracht van het virus. CMV wordt niet door hoesten 
overgedragen. Infectie met CMV bij gezonde volwassenen en kinderen verloopt 
meestal zonder klachten. In sommige gevallen ontstaat er echter een ziektebeeld 
vergelijkbaar met Pfeiffer, bestaand uit keelpijn, koorts, en vergrote klieren in de hals. 
Na infectie blijft CMV (net als alle virussen van de Herpesvirus familie) levenslang in het 
lichaam aanwezig, maar meestal zonder dat het klachten veroorzaakt. Bij personen 
met een slechte afweer (patiënten met HIV, kanker, of na een transplantatie) kan CMV 
zich opnieuw gaan vermenigvuldigen en schade veroorzaken aan het darmstelsel, de 
lever, de longen, en/of de ogen.
In Nederland is ongeveer de helft van de volwassenen ooit geïnfecteerd geraakt 
met CMV en heeft als gevolg daarvan afweer tegen het virus. Onder bepaalde 
bevolkingsgroepen buiten en binnen Nederland heerst er meer CMV, met name als 
gevolg van frequenter contact met jonge kinderen (bijvoorbeeld in (sub)culturen met 
grote gezinnen, crèches, en minder hygiënische omstandigheden).
aangeboren (congenitale) infectie met Cmv
Overdracht van CMV van moeder naar ongeboren kind vindt plaats via de placenta. 
In tegenstelling tot bijvoorbeeld rodehond kan CMV ook worden overgedragen op het 
ongeboren kind als de zwangere al vóór de zwangerschap geïnfecteerd is geweest 
met CMV en afweer heeft tegen het virus. Ongeveer 1 op de 10 pasgeborenen met een 
in de baarmoeder verworven (ofwel congenitale) infectie met CMV heeft bij geboorte 
geelzucht, bloedafwijkingen, vergrote lever, en/of schade aan het zenuwstelsel 
(onderontwikkelde hersenen, slechthorendheid en/of oogontsteking). Ongeveer de 
helft van de pasgeborenen met afwijkingen bij geboorte zal levenslang beperkingen 
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ondervinden. Van de congenitaal geïnfecteerde pasgeborenen zonder afwijkingen bij 
geboorte, zal ongeveer 1 op de 10 in de eerste levensjaren alsnog afwijkingen krijgen 
(geduid als ‘late-onset’). Het meest voorkomend is slechthorendheid, daarnaast kan 
het mentale achterstand, vertraagde ontwikkeling, slecht zien, en/of epileptische 
aanvallen betreffen. Pasgeborenen met een moeder die reeds voor de zwangerschap 
afweer tegen CMV had, zijn meestal minder ernstig ziek. Een congenitale CMV infectie 
kan worden aangetoond met behulp van urine, speeksel en/of de hielprikkaart van de 
pasgeborene. In Nederland wordt bij alle pasgeborenen een paar druppels bloed uit de 
hiel afgenomen en opgevangen op een kaart (de hielprikkaart) voor routine screening 
op 18 erfelijke (stofwisselings)ziekten. De hielprikkaart wordt niet routinematig getest 
op CMV. Een pasgeborene met afwijkingen veroorzaakt door congenitale CMV kan 
worden behandeld met een antiviraal medicijn. Recent onderzoek laat zien dat deze 
behandeling tevens op de lange termijn slechthorendheid kan voorkomen. Het is nog 
niet onderzocht of antivirale behandeling ook slechthorendheid kan voorkomen bij 
congenitaal geïnfecteerde pasgeborenen zonder afwijkingen bij geboorte. 
dit proefschrift
Het doel van dit proefschrift was om zowel de noodzaak als de haalbaarheid van 
screening van pasgeborenen op congenitale CMV in Nederland te onderzoeken. 
Hiervoor werd respectievelijk de ziektelast van congenitale CMV in Nederland in 
kaart gebracht en een groot aantal beschikbare testen voor detectie van CMV bij 
pasgeborenen onderzocht.
ziektelast 
In dit proefschrift werd de ziektelast van congenitale CMV in Nederland bestudeerd op 
verschillende manieren. Het vóórkomen van congenitale CMV infecties in Nederland 
werd onderzocht met behulp van een grote steekproef van hielprikkaarten, welke 
getest werden op aanwezigheid van CMV. In totaal 5 op de 1000 pasgeborenen 
in Nederland bleek congenitaal geïnfecteerd te zijn met CMV. Dit betekent dat er in 
Nederland jaarlijks ongeveer 1000 kinderen geboren worden met congenitale CMV 
infectie, waarvan ongeveer 180 kinderen lange termijn gevolgen zullen ondervinden, 
met name slechthorendheid. Een aanvullende analyse van risicofactoren toonde aan 
dat congenitale CMV infecties vaker voorkomen in regio’s met meer jonge kinderen 
en in regio’s met meer immigranten. 
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De ziektelast van congenitale CMV in Nederland werd tevens bestudeerd door de 
proportie congenitale CMV infecties onder slechthorende kinderen te bepalen (met 
behulp van hielprikkaarten). In totaal 8% van de slechthorende kleuters, en maar 
liefst 1 op de 5 dove kleuters in Nederland bleek congenitaal geïnfecteerd te zijn 
met CMV. De slechthorendheid op kleuterleeftijd was bij een belangrijk deel (25%) 
van de kinderen met CMV niet geconstateerd bij de routine gehoorscreening van 
pasgeborenen. 
Tevens werd een schatting gemaakt van het aandeel congenitale CMV infecties onder 
zwangere vrouwen met reeds voor de zwangerschap afweer tegen CMV, met behulp 
van een theoretisch model. Paradoxaal genoeg bleek het aandeel congenitaal 
geïnfecteerde pasgeborenen onder moeders met afweer tegen CMV groter dan het 
aandeel onder moeders zonder afweer tegen CMV. Waarschijnlijk hebben moeders 
die al ooit een infectie met CMV hebben opgelopen een groter risico om opnieuw 
geïnfecteerd te worden door CMV (re-infectie), waarbij leefomstandigheden een rol 
spelen.  
Geconcludeerd kan worden dat de ziektelast van congenitale CMV infecties in 
Nederland aanzienlijk is. Congenitale CMV is de belangrijkste oorzaak van niet-
genetisch bepaald, aangeboren gehoorverlies. Congenitale CMV infecties komen 
frequenter voor dan het syndroom van Down, open ruggetje, en diverse erfelijke 
(stofwisselings)ziekten waarop hedendaags gescreend wordt bij zwangeren dan 
wel pasgeborenen. De restverschijnselen van congenitale CMV infectie zoals 
slechthorendheid en mentale retardatie zijn ingrijpend en hebben levenslang 
negatieve gevolgen voor taalontwikkeling, spraakontwikkeling, communicatie en 
leervermogen, en beïnvloeden de sociale en economische status van de getroffen 
kinderen en hun families. Kortom, congenitale CMV infecties zijn een belangrijk 
maatschappelijk gezondheidsprobleem. 
screeningstest 
Diverse potentiële screeningstesten voor het aantonen van congenitale CMV bij 
pasgeborenen met behulp van de hielprikkaart werden bestudeerd in dit proefschrift. 
De capaciteit van deze testen varieerde aanzienlijk afhankelijk van de testmethode. 
Optimalisatie van de techniek resulteerde in verbeterde capaciteit waarbij ongeveer 
80% van alle pasgeborenen met congenitale CMV zouden kunnen worden opgespoord. 
Andere onderzoekers laten zien dat met behulp van urine en speeksel mogelijk nog 
meer gevallen opgespoord zouden kunnen worden. Echter, testen gebaseerd op de 
hielprikkaart hebben als voordeel dat gebruik gemaakt zou kunnen worden van de 
huidige logistiek van de pasgeborenen screening op erfelijke (stofwisselings)ziekten. 
Samenvatting voor de niet medisch onderlegde lezer
186
Samengevat lijkt screening van pasgeborenen op congenitale CMV technisch steeds 
meer haalbaar nu potentiële screeningstesten worden geoptimaliseerd. 
discussie: screening van pasgeborenen
De optie van screening van pasgeborenen op congenitale CMV wordt in toenemende 
mate serieus overwogen in de medische wereld. De toegevoegde waarde zou liggen 
in de identificatie van geïnfecteerde pasgeborenen die niet anderszins (klinische 
presentatie, gehoorscreening) opgespoord zouden worden, maar wel risico lopen 
op gehoorschade en andere restverschijnselen in de eerste levensjaren. In de 
medische wereld wordt het belang ingezien van zowel het beschermend effect van 
vroege antivirale behandeling op het gehoor van geïnfecteerde pasgeborenen met 
afwijkingen, als het voordeel van vroege identificatie (en correctie) van gehoorverlies 
d.m.v. frequente controle van het gehoor van geïnfecteerde kinderen. Congenitale 
CMV lijkt momenteel te voldoen aan de meeste criteria die zijn opgesteld voor 
screening. Terwijl de ervaring met antivirale behandeling van geïnfecteerde 
pasgeborenen bemoedigend is, is het nut van deze behandeling bij geïnfecteerde 
pasgeborenen zonder verschijnselen nog niet bestudeerd.
Daarom is een grootschalige studie naar de veiligheid en effectiviteit van screening 
en behandeling van pasgeborenen de eerstvolgende te nemen stap in de langdurige 
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